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Introduction
According to the Dutch Kidney Foundation (Nierstichting) 1 in 10 inhabitants of 
The Netherlands suffer from impaired renal function (1). Chronic kidney disease 
(CKD) is a life threatening condition that is associated with an increased risk of 
cardiovascular disease. Patients with stage 5 CKD, end stage renal disease 
(ESRD), require renal replacement therapy (RRT). In The Netherlands the 
number of patients undergoing RRT is growing (Figure 1). At the start of 2016 
16,727 patients were on RRT, that is 0.1% of the Dutch population (2). The 
increase of patients on RRT may be caused by an increase in CKD patients, an 
increase in the number of patients accepted for RRT, and an improvement of 
survival of patients on RRT.
Figure 1. Number of patients on renal replacement therapy on January 1 in the Netherlands per year. 
Source: Renine 1-1-2016, Nefrovisie (2).
Compared to dialysis and deceased donor kidney transplantation, living donor 
kidney transplantation (LDKT) is the best treatment for patients with ESRD 
resulting in higher life expectancy and better quality of life (3-5). However, 
comparison of mere treatment options for patients with ESRD is complex, 
because of wide variation in patient characteristics and the lack of randomized 
controlled studies. Patients accepted for kidney transplantation are a selected 
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group of end stage renal disease patients. They are selected on physical 
condition and on an acceptable peri-transplant death risk.
Ideally, all patients with ESRD should be transplanted if their condition allows 
this. However, some patients choose to start or remain on dialysis, whereas 
others experience contraindications to transplantation. Acceptance criteria for 
kidney transplantation have been subject to change over time. While age above 
40 years used to be an absolute contraindication in the early years of 
transplantation, currently even old age is only a relative contraindication. 
Nowadays, absolute contraindications are metastatic solid tumor, active 
infections, severe liver disease, and serious heart conditions. Though without 
absolute contraindications, patients with relative contraindications are less often 
referred for transplantation than patients without any contraindication (6).
These patients with relative contraindications are often elderly, have 
comorbidities, or have incomplete management of the language. It is 
questionable whether these patients should be rejected for transplantation. It is 
not known if they are doing worse after transplantation.
Once patients have been accepted for transplantation, the next challenge is to 
find them a kidney with the best possible outcome. A living donor kidney 
transplantation is not attainable for all patients accepted for transplantation, as 
not all ESRD patients succeed in finding a suitable living donor. Patients without 
a living donor, will be placed on the deceased donor waiting list for kidney 
transplantation. However, placement on the waiting list does not guarantee that 
patients receive a kidney offer. Waiting times vary between patients, dependent 
on ABO blood types and human leukocyte antigen (HLA) typing, between 0 and 
5 years. For patients with high titers of HLA antibodies waiting times may reach 
up to 10 years.
Factors influencing access to kidney transplantation
Inequality in access to kidney transplantation results from several factors. 
Medical factors, such as ABO blood type and sensitization, may complicate 
finding a match (7). For highly sensitized patients and patients that are 
incompatible with their donor in terms of ABO blood type or a positive 
crossmatch, the acceptable mismatch program and the Dutch national living 
donor kidney exchange program were developed (8, 9). Alternatively, ABO 
incompatible donor-recipient pairs can participate in ABO-incompatible 
transplantation programs, in which recipients are pretreated to lower the 
concentration of isoagglutinins anti-A or anti-B before transplantation (10).
Likewise, desensitization of highly sensitized patients and recipients of HLA 
incompatible transplants increases transplant chances for this patient population 
(11, 12). Though age is not a factor used in deceased donor kidney allocation 
programs, recipient age is associated with reduced access to kidney 
transplantation, because elderly patients are less likely to be referred (6, 13, 
14).
The presence of comorbidity may also reduce accessibility to transplantation (6, 
15). Important factors reducing access are cardiovascular disease, diabetes, 
obesity, HIV, and other infections. The cause of ESRD influences access as well, 
as patients with diabetic ESRD have been demonstrated to have reduced access 
(14, 16).
Several studies showed that patients living in socially deprived areas had a lower 
chance to be considered for transplantation. Socioeconomic factors influencing 
access were ethnicity, education level, income, substance abuse, marital status, 
and socioeconomic status (6, 14, 15, 17-20).
More specifically, access to LDKT was influenced by recipient age, ethnicity, 
socioeconomic status, ABO blood type, and panel reactive antibody (21-24).
Modifiable factors such as knowledge, communication, and early transplant 
awareness were found to be associated with the ethnic inequalities in access 
(22, 25).
Factors influencing patient and graft survival
Various recipient, donor, donor-recipient combination, and transplant factors 
influence patient and graft survival. Throughout the years survival improved 
considerably, because of better immunosuppressive medication and improved 
surgical and diagnostic techniques, while the increasing number of LDKT played 
a role as well (Figure 2).
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Figure 2. Kaplan-Meier survival curve comparing overall graft survival per decade in the population 
transplanted in Rotterdam between 1971 and 2015 with a living or deceased donor kidney.
The scope of research in transplantation broadened from mainly immunological 
and surgical factors in the early years to non-immunological and social factors in 
recent years. Most studies on the influence of socioeconomic variables on the 
influence on survival have been performed in the USA, showing that they have 
an influence on graft and patient survival (20, 26, 27). Would that also hold true 
for a socially organized country as the Netherlands with an adequate health 
system with equal chances for everyone?
The influence of HLA mismatches has been studied in various ways and though 
unmistakably important, it raises questions (11, 28-35). How important is HLA 
matching compared to other variables influencing graft survival? Should we 
reject a completely HLA mismatched living donor kidney in order to wait for a 
better HLA matched deceased donor kidney? The same question holds for donor 
age. Should we reject an older living donor in order to hope and wait for a 
younger deceased donor kidney?
The influence of comorbidity on the results of renal transplantation can only be 
properly studied in a population with a high proportion of comorbidities. As 
patients with comorbidity have limited access to transplantation, literature is 
hampered by relatively low numbers (36, 37). Besides, the effect of comorbidity 
on survival after kidney transplantation has mostly been studied using a general 
score from which applicability to the transplant population can be questioned 
(38). A new study in a population with a high number of patients with 
comorbidities, using a customized score, is warranted.
Aims and outline of this thesis
The aim of this thesis is twofold: first, to find out which factors influence access 
to living or deceased donor kidney transplantation. The other aim is to find out 
which factors influence graft and patient survival once transplantation is 
performed. All studies were performed using large samples from a single center 
cohort.
In chapter 2 we describe what happens to patients that are being placed on the 
waiting list for kidney transplantation. Outflow patterns for patients on the 
waiting list are visualized. The influence of age on these patterns is described. In 
chapter 3 both clinical and socioeconomic factors influencing access to living 
donor kidney transplantation are studied. The effect of these factors on graft 
and patient survival is described in chapter 4. In chapter 5 we study the 
influence of donor age on graft survival censored for death in a multivariable 
model. In chapter 6 the influence of HLA mismatches on graft survival censored 
for death is studied, corrected for various other factors. In chapter 7 the 
influence of comorbidity on graft and patient survival is studied. We describe the 
development of a new score, the RoCKeT score, to measure the degree of 
comorbidity in transplant patients. Finally, in chapter 8 a general discussion of 
the results obtained in this thesis is provided.
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Abstract
Age criteria for kidney transplantation have been liberalized throughout the 
years resulting in more waitlisted elderly patients. In this retrospective cohort 
study we analyzed how age influenced the chance to become transplanted.
Between 2000-2013, 2643 patients were placed on our regional waiting list. 
Waiting time was defined as the period between start dialysis and being delisted. 
Patients were categorized according to age at inflow. In February 2016, 1907
(72%) patients had been transplanted, 290 (11%) had been delisted without a 
transplantation, 256 (10%) had died, and 190 (7%) were still waiting. When 
comparing the age groups, outflow patterns were completely different. Within 6 
years 93% of the population <25 years had received a transplant, the vast 
majority from a living donor. In the population >64 years 55% had been 
transplanted, slightly more than half of the recipients with a living donor kidney. 
In the population >54 years without a living donor approximately 50% had died 
or had been delisted without a transplant and will never become transplanted. In 
order to improve the survival of patients over 54, living donor kidney 
transplantation should be promoted in this population.
Introduction
Over the years, acceptance criteria for kidney transplantation have been eased. 
For instance, strict age criteria for transplantation have been liberalized (1-3),
resulting in an increase in the representation of elderly patients on the waiting 
list. In most studies, elderly was defined as 65 years and older. Although 
recipient age is known to be an important independent variable determining the 
all-over outcome of kidney transplantation, patient survival is better in the 
elderly population that received a kidney transplantation, compared to dialysis 
(2-4). However, age is still an important factor for non-referral (5, 6).
Patients are preferentially transplanted with a living donor kidney, because the 
outcomes of living donor transplantation are superior compared with those of 
deceased donor transplantation (7). Besides, living donor transplantation can be 
performed without the delay of waiting time. When no living donor is available, 
patients accepted for transplantation are placed on the waiting list for a 
deceased donor transplant. In our center a liberal policy regarding acceptance of 
donation after cardiac death (DCD) and donation after brain death (DBD) 
kidneys for transplantation is applied. Our center participates in Eurotransplant 
Senior Program (ESP). In the Netherlands the availability of deceased donor 
organs has been stable throughout the years. In the Eurotransplant area, 
waiting time starts when dialysis is started. Unfortunately, waiting times may be 
up to several years, while both age and waiting time are important risk factors 
for death on the waiting list (8, 9).
In many countries living donor transplantation is performed on a large scale or 
even outnumbers deceased donor transplantation. However, patients that do not 
find a willing or suitable living donor remain dependent on the waiting list for a 
deceased donor kidney. How are the chances for a kidney transplant of patients 
on the waiting list and what is the influence of age on these chances?
To answer these questions, we studied whether outflow reasons differed 
between age groups.
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Materials and methods
Study sample
Between January 1, 2000 and December 31, 2013 2663 patients had been 
placed on the regional waiting list for kidney transplantation. Twenty patients 
were removed from the waiting list; 6 due to wrong listing and 14 since they 
had recovered from their disease. Consequently, 2643 patients were included in 
this retrospective cohort study (see Figure 1). Waiting time was defined as time 
between first dialysis date and being removed from the waiting list. For enlisted 
transplant patients whose transplant failed within 90 days, waiting time for the 
previous transplant was added to current waiting time.
The waiting list was retrieved from Eurotransplant. For patients for whom no 
start dialysis date was present in the Eurotransplant database, patient files of 
our hospital system were checked. This resulted in 147 corrections. In 56 cases 
(2.1%) information on dialysis could not be retrieved from the patient file. In 
these cases Eurotransplant data were used which means that for these patients 
waiting time was zero as dialysis was supposed not to have been initiated.
Patients were categorized according to age at inflow on the waiting list: group 1: 
<25 (n=122), group 2: 25-44 (n=603), group 3: 45-54 (n=591), group 4: 55-
64 (n=757), and group 5: >64 years (n=570). In the oldest age group 58 
patients were above 74 years and 7 patients were 80 years or older. Reasons of 
outflow from the waiting list were: 1) died or delisted, 2) still on the waiting list, 
3) deceased donor kidney transplantation (DDKT), and 4) living donor kidney 
transplantation (LDKT). Patients transplanted outside Eurotransplant received a 
living donor kidney and thus were included in LDKT. Observation was until 
February 9, 2016.
Statistical analyses
Chi-square tests were performed to test the difference in outflow reasons 
between the age groups and ABO blood types. For transplanted patients, patient 
survival with functioning graft was studied using Kaplan-Meier survival analysis. 
Survival curves were generated to test the influence of age. Follow-up was until 
graft failure, death, or end of observation (February 9, 2016). Cases with 
missing values were excluded. SPSS version 21 (IBM Corporation, Armonk, NY) 
was used to perform all statistical analyses. P-values <0.05 were considered 
significant.
Figure 1. Flowchart of outflow of patients enlisted between January 2000 and December 2013. End of 
observation was February 9, 2016.
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Results
Out of the 2643 waitlisted patients 1907 (72%) had been transplanted before 
February 2016: 649 patients had received a DDKT, 1249 a LDKT, and 9 had 
been transplanted outside Eurotransplant (Figure 1). Out of the 736 (28%) 
patients that had not been transplanted 290 had been delisted without a kidney 
transplantation and 256 had died while on the waiting list. The remaining 190 
(7%) patients were still waiting in February 2016.
In Figure 2 the reasons of outflow per year for the total population and per age 
group are shown. The X-axis shows waiting time in years after dialysis was 
started, the Y-axis shows the percentage of patients. White represents the 
patients still waiting. In none of the age groups 100% was waiting at time point 
0 which means that patients were preemptively removed from the list because 
of transplantation or because of death or illness. Figure 2 shows that preemptive 
transplantation (time point 0) decreased with age group, while the percentage of 
patients that had died or had been delisted before start of dialysis increased with 
age.
After 6 years on the waiting list 93% of patients in the youngest group had been 
transplanted, the vast majority (75% of total outflow) with a LDKT (Figure 2; 
light blue). Both the percentage of patients transplanted after 6 years and the 
proportion of LDKT decreased with increasing age. In group 55-64 years 66% 
and in group >64 only 55% had been transplanted, the latter slightly more than 
half (30% of total outflow) with a LDKT. The differences between the age groups 
occurred within the first few years. In all age groups most LDKTs had been 
performed within 2 years after start dialysis. However, this accounted for the 
majority (70%) of younger patients but only for a minority (25%) of older 
patients. From 2 years onwards, LDKT leveled off, while the proportion of DDKT 
(middle blue) gradually increased over time. In the first few years the proportion 
of patients that had died or had been delisted without a transplant (dark blue) 
increased with age. After 2 years 23% of patients in the oldest age group had 
died or had been delisted. The percentage leveled off after 4 years. In the oldest 
two age groups yearly more patients had died or had been delisted compared 
with those that had received a DDKT.
Figure 2. Percentage of patients that died/were delisted (dark blue), still waiting (white), or underwent 
deceased donor (DD; middle blue) or living donor (LD; light blue) kidney transplantation per year for 
the total population and for each age category. Patients that were not still waiting on time point 0 had 
been pre-emptively transplanted, had died or had been delisted before dialysis had started.
In Figure 3 the reasons of outflow at the end of observation are shown per age 
group. Reasons of outflow significantly differed between the age groups 
(P<0.001). In the youngest age group at the end of observation the majority 
had received a LDKT (light blue) and 96% had been transplanted with either a 
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LDKT or DDKT. In the population from 55 years and older a minority had 
received a LDKT; for patients >64 years even less than a third.
Figure 3 also shows the outflow percentages after exclusion of LDKT. In the 
population <25 years without a living donor by far most patients (83%) had 
received a DDKT. Conversely, in the oldest two age groups a minority had 
received a DDKT whereas almost half of these patients had died or had been 
delisted without a kidney transplantation.
In the population above 54 years without a living donor, ABO blood type did not 
have a significant influence on outflow (P=0.436). The percentages that had 
died or had been delisted at the end of observation were: Blood type A: 49%, 
AB: 44%, B: 48%, and blood type O: 48% (data not shown).
Kaplan-Meier analysis was used to study survival of transplanted patients. Out of 
1907 patients 67 (3.5%) cases had missing values. Consequently, 1840 cases 
were included in the analysis (614 DDKT and 1226 LDKT). There were 562 
events; 322 graft failures (140 DDKT and 182 LDKT) and 240 deaths (105 DDKT 
and 135 LDKT). Recipient age had a significant influence on patient survival with 
functioning graft (P<0.001; Figure 4). In the oldest age group after 10 years 
37% of patients were still alive with functioning graft. After 2 and 6 years 
survival was 81% and 61% respectively.
Figure 3. Number of patients that had died/had been delisted (dark blue), were still waiting (white), or 
had received a deceased donor (DD; middle blue) or a living donor (LD; light blue) kidney 
transplantation at the end of observation (February 9, 2016) per age category. Percentages given are 
after exclusion of living donor kidney transplantation.
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Figure 4. Kaplan-Meier survival curve comparing patient survival with functioning graft (P<0.001) for 
WKHYDULRXVDJHJURXSV$IWHU%RQIHUURQLFRUUHFWLRQIRUPXOWLSOHFRPSDULVRQVĮ WKHGLIIHUHQFHV
between <25 and >64 years (P=0.002), between 25-44 and 55-64 years (P=0.002), between 25-44
and >64 years (P<0.001), and between 45-54 and >64 years (P<0.001) were significant.
Discussion
For patients that are being placed on the waiting list for DDKT the most relevant 
question is how long they will have to wait for a kidney offer. To answer that 
question, the median waiting time can be given. However, that does not take 
into account other reasons for delisting; LDKT, death, or a worsened condition. 
Thus, an additional question that should be answered is whether or not they will 
survive the waiting time and stay in adequate condition until transplantation. To 
date, only a few papers were published in which all reasons of outflow from the 
waiting list were taken into account (10-12). In 2009 Schold and colleagues 
found that nearly half of elderly (above 60 years) waitlisted patients were 
estimated to die before DDKT (10). However, results were not compared with 
those of younger patients as they were not included in the study. Moreover, the 
Kaplan-Meier analysis that was used is known to overestimate outcomes. In this 
study competing events were not accounted for. Kaplan-Meier analysis provides 
"conditional" probabilities only, for instance the probability of receiving a DDKT 
after 5 years if nothing else happens (i.e. death, delisting, LDKT). To overcome 
the problem of overestimation, the competing risk method can be used to 
analyze outcomes of patients on the waiting list (11-13). Sapir-Pichhadze et al. 
recently described the difference in risk estimation by conventional and 
competing risk analysis (13). The competing risk method predicts individual 
chances to become transplanted based on specific characteristics/patient 
profiles. Variables that were found to significantly influence the chance of 
becoming transplanted were age, ABO blood type, PRA, and HLA frequency (11, 
12). However, such individual predictions should be communicated with caution 
as these chances are no guarantee for an individual. The purpose of the present 
study was to show what happened to patients of various age groups that had 
been placed on our waiting list. It is not a risk estimation, but a straightforward 
method that clearly visualizes outflow patterns for groups of patients. 
Overestimation is prevented as all outflow reasons were present in the same 
analysis, excluding competition between events.
In the current study large differences in outflow from the waiting list between 
the age groups were found. In the highest age categories respectively 25% and 
35% of patients on the waiting list were not transplanted because they had died 
or their condition had worsened. For patients that presented without a living 
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method that clearly visualizes outflow patterns for groups of patients. 
Overestimation is prevented as all outflow reasons were present in the same 
analysis, excluding competition between events.
In the current study large differences in outflow from the waiting list between 
the age groups were found. In the highest age categories respectively 25% and 
35% of patients on the waiting list were not transplanted because they had died 
or their condition had worsened. For patients that presented without a living 
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donor, percentages were even worse. At least half of patients aged >54 years 
without a living donor will never be transplanted compared with a quarter of 
patients aged 54 years or younger (Figure 3). As was shown, the number of 
elderly patients that had died or had been delisted increased profoundly in the 
first years after start dialysis. As the mean waiting time for DDKT is 3 to 4 
years, they cannot afford waiting for a deceased donor kidney. The chance of 
receiving a DDKT is also influenced by ABO blood type and PRA. In a previous 
study we found that patients with ABO blood type O and patients with a PRA 
>85 have a significantly longer waiting time (14). In the present population 
above 54 years without a living donor and thus dependent on the waiting list for 
a kidney transplantation, ABO blood type did not have a significant influence on 
final outflow. Therefore, for all elderly potential recipients on the waiting list, it is 
important to find a living donor, independent of ABO blood type. However, in the 
elderly population LDKT lags behind. Their network of contemporaries is small 
while recipients’ adult children are less likely to donate (15). This means that for 
transplantation elderly are more dependent on deceased donors through the 
waiting list. It is known that there is a high burden of comorbidity in the 
population with renal disease that negatively influences survival. When waiting 
time for a deceased donor kidney transplantation exceeds survival of these 
elderly patients they wait in vain and will never be transplanted.
A reduction of racial disparity in access to LDKT has been attained by including 
patients’ social networks in education on renal replacement therapies using 
house call interventions (16, 17). Such interventions may be useful in the 
elderly population as well. They could try to find peers, relatives, or other 
persons from their social network to donate to them.
As expected, patient survival was found to be worse for elderly transplant 
patients. However, their survival was good considering that some had already 
spent several years on dialysis. It should be kept in mind that transplanted 
patients are a selection of the population and that only the influence of age on 
survival was studied. The analyses were uncorrected for donor type, waiting 
time, comorbidity etc. In previous studies age was shown to be an independent 
factor influencing both graft and patient survival (18, 19). As uncensored patient 
survival was studied, Kaplan-Meier analysis was not influenced by competing 
events.
The strength of this study is that it includes a relatively large patient sample 
with a low number of missing values. Besides, our study is a plain and 
comprehensible method to compare outflow patterns in various groups of 
patients. It surpasses the limitations of Kaplan-Meier analysis, that studies only 
a single outflow reason at a time, and the complexity of competing risk analysis, 
that only shows individual effects and no group effects. 
In the Eurotransplant area waiting time is calculated from start dialysis onwards. 
With this uniform definition waiting time depends on patient disease status and 
not on subjective factors. Patients can be put on the waiting list before dialysis 
was initiated but their chances are low as long as they are not on dialysis. The 
definition of waiting time may be different in other allocation systems, where 
waiting time starts at placement on the waiting list and is independent of start 
dialysis. This could distort outflow patterns.
A possible limitation of single center studies in general may be generalizability. 
In our center there is a relatively large population of LDKT recipients. In the 
population that received a LDKT, younger patients and patients without 
comorbidity are overrepresented (19). However, still a large percentage of the 
elderly received a LDKT. Although patient selection on medical reasons cannot 
be completely ruled out, DDKT allocation is independent of the presence of a 
LDKT program. After exclusion of the LDKT population it is obvious that the 
elderly population that is dependent on DDKT lags behind and half of them are 
removed from the waiting list without a transplant. In centers without a LDKT 
program, percentages of elderly patients delisted without a transplant may even 
be worse.
In Eurotransplant deceased donor allocation, apart from ESP and pediatric 
status, age is not a selection criterion for matching. Allocation policy of 
Eurotransplant is comparable to policies in for instance the USA, UK, 
Scandinavia, and Australia and New Zealand (20-24). Generally, the most 
important matching criteria in all allocation systems are ABO blood type, HLA-
matching, waiting time, and distance from donor hospital.
Another limitation is that no information on transplantable urgency was 
available. The proportion of (temporarily) not transplantable elderly patients 
could be higher than the proportion of (temporarily) not transplantable younger 
patients. This may have led to longer waiting times, less transplants, and more 
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survival was studied, Kaplan-Meier analysis was not influenced by competing 
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The strength of this study is that it includes a relatively large patient sample 
with a low number of missing values. Besides, our study is a plain and 
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patients. It surpasses the limitations of Kaplan-Meier analysis, that studies only 
a single outflow reason at a time, and the complexity of competing risk analysis, 
that only shows individual effects and no group effects. 
In the Eurotransplant area waiting time is calculated from start dialysis onwards. 
With this uniform definition waiting time depends on patient disease status and 
not on subjective factors. Patients can be put on the waiting list before dialysis 
was initiated but their chances are low as long as they are not on dialysis. The 
definition of waiting time may be different in other allocation systems, where 
waiting time starts at placement on the waiting list and is independent of start 
dialysis. This could distort outflow patterns.
A possible limitation of single center studies in general may be generalizability. 
In our center there is a relatively large population of LDKT recipients. In the 
population that received a LDKT, younger patients and patients without 
comorbidity are overrepresented (19). However, still a large percentage of the 
elderly received a LDKT. Although patient selection on medical reasons cannot 
be completely ruled out, DDKT allocation is independent of the presence of a 
LDKT program. After exclusion of the LDKT population it is obvious that the 
elderly population that is dependent on DDKT lags behind and half of them are 
removed from the waiting list without a transplant. In centers without a LDKT 
program, percentages of elderly patients delisted without a transplant may even 
be worse.
In Eurotransplant deceased donor allocation, apart from ESP and pediatric 
status, age is not a selection criterion for matching. Allocation policy of 
Eurotransplant is comparable to policies in for instance the USA, UK, 
Scandinavia, and Australia and New Zealand (20-24). Generally, the most 
important matching criteria in all allocation systems are ABO blood type, HLA-
matching, waiting time, and distance from donor hospital.
Another limitation is that no information on transplantable urgency was 
available. The proportion of (temporarily) not transplantable elderly patients 
could be higher than the proportion of (temporarily) not transplantable younger 
patients. This may have led to longer waiting times, less transplants, and more 
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delisting/deaths in the older age groups. In the future transplantable urgency 
should be registered so that in follow-up studies this information can be taken 
into account to verify the outflow patterns. Ideally, all periods of being 
temporarily not transplantable should be taken into account, as it may reflect 
the less fit patients.
In conclusion, the chances for kidney transplantation of patients aged >64 years 
on the waiting list are low. This holds true for patients aged 55-64 years as well. 
Thus, the disadvantages of aging start at 55 years in the population with renal 
disease. For elderly patients without a living donor the chance of receiving a 
DDKT is relatively small as well. They cannot afford waiting for a DDKT. In order 
to improve their survival LDKT should be promoted in elderly renal disease 
patients.
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Abstract
Background. In the past 30 years, the number of living donor kidney 
transplantations has increased considerably and nowadays outnumbers the 
deceased donor transplantations in our center. We investigated which 
socioeconomic and clinical factors influence who undergoes living or deceased 
donor kidney transplantation.
Methods. This retrospective study included all 1338 patients who received a 
kidney transplant between 2000 and 2011 in the Erasmus MC Rotterdam. 
Clinical and socioeconomic variables were combined in our study. Clinical 
variables were recipient age, gender, ethnicity, primary renal disease, 
retransplants, ABO blood type, panel-reactive antibody, pretreatment, and 
transplantation year. Each recipient’s postcode was linked to a postcode area 
information data base, to extract demographic information on urbanization level, 
percentage non-Europeans in the area, income, and housing value. Chi-square, 
analysis of variance, and univariable and multivariable logistic regression 
analyses were performed. 
Results. There were significant differences between the recipients of a living 
versus deceased donor kidney transplantation. In multivariable logistic 
regression analyses, 10 variables had a significant influence on the chance of 
receiving living donor kidney transplantation. Clinical and socioeconomic factors 
had an independent influence on this chance. Patients with ABO blood type O 
and B have smaller chances. Highly sensitized and elderly patients have smaller 
chances especially when combined with a collection of other unfavorable factors. 
Accumulation of unfavorable factors in non-Europeans prevents their 
participation in living donation programs.
Conclusion. Both clinical and socioeconomic factors are associated with 
participation in living or deceased donor kidney transplantation. This study 
highlights the populations that would benefit from educational intervention 
regarding living donor transplantation.
Introduction
In our center, the number of living donor kidney transplantations (LDKT) has 
increased considerably during the past 30 years, but LDKT does not seem to be 
equally accessible for all populations.
A number of clinical factors are known to influence the chance of living donor 
transplantation, for example, ABO blood type and panel-reactive antibody (PRA). 
In a previous study, we found that, although 44% of patients on our waiting list 
have a non-European background, only 15% of actual living donors have a non-
European background (1). There are far less living kidney donors in all non-
European populations in comparison with the European population, and there 
are differences in characteristics between European and non-European living 
kidney donors. However, differences between various non-European populations 
were not significant. The non-European populations studied immigrated to The 
Netherlands after the Second World War. Indonesians arrived in the 1950s; 
Moroccans and Turkish in the 1960s; and Surinamese, Antilleans, and Africans in 
the 1970s. For many, socioeconomic factors were the driving force behind their 
immigration. The non-European population that has resided the longest in The 
Netherlands is the most integrated in Dutch society and has the highest level of 
LDKT (1). This suggests that although ethnicity is likely to contribute, 
socioeconomic factors may also play a role in willingness to donate a kidney.
These findings led to the following questions: What is the influence of clinical 
and socioeconomic factors on participation in living versus deceased donor 
transplantation programs? Is there interaction between these factors and 
ethnicity in their influence on the chance of living donor transplantation?
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Materials and methods
This retrospective study includes all adult renal transplant recipients with a 
transplantation performed in the Erasmus MC Rotterdam between January 1, 
2000, and December 31, 2010. Every potential kidney recipient visits our 
pretransplant outpatient department once a year. When a patient is suitable for 
transplantation, LDKT is discussed. Most non-Europeans with incomplete 
knowledge of the Dutch language bring family members or friends to translate. 
If not, an independent interpreter can be arranged for their visit. All patients are 
provided with a booklet and DVD on LDKT available in seven languages. 
Transplantation-related information is also available on our website in seven 
languages.
The Central Bureau for Statistics in the Netherlands collects data per postcode 
area regarding population composition and various demographic variables. A 
postcode consists of two numbers that represent the region, another two 
numbers represent the neighborhood, and the last two letters represent the 
street. The postcode in combination with the number of the house is unique and 
suffices for delivery of the post. This unique code is also used for other 
applications. For our study, the numerical part of each recipient’s postcode was 
linked to the Central Bureau for Statistics 2004 postcode area information 
database to extract demographic information.
Variables studied
The first category is the reference category for that particular variable (between 
brackets). When no reference category is mentioned, the variable is entered as 
a continuous variable.
Clinical variables
Age, gender (male), ethnicity (European), primary renal disease in seven 
categories (glomerulonephritis vs. congenital/hereditary disease, diabetes 
mellitus, hypertension/renovascular disease, tubulointerstitial 
disease/obstruction, systemic diseases, and other), year of renal 
transplantation, ABO blood type (A), previous transplantations (0), previous 
renal replacement therapy (continuous ambulatory peritoneal dialysis), and 
maximum PRA.
Postcode-related variables
Urbanization level (high: more than 1500 addresses per km2 vs. low), 
percentage non-Europeans in the area (low: less than 10% vs. high), income, 
and housing value.
Statistics
Statistical analysis was conducted using Statistical Package for the Social 
Sciences, version 16.0. The chi-square test was used to test the associations 
between two categorical nominal or ordinal variables. Patient characteristics 
were compared with a one-way analysis of variance when they were continuous 
variables. A P value less than 0.05 was considered significant. To predict 
transplantation with a living donor in comparison with deceased donor kidney, 
univariable and multivariable binary logistic regression analyses were 
performed.
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Materials and methods
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Statistics
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were compared with a one-way analysis of variance when they were continuous 
variables. A P value less than 0.05 was considered significant. To predict 
transplantation with a living donor in comparison with deceased donor kidney, 
univariable and multivariable binary logistic regression analyses were 
performed.
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Results
In the period studied, 513 patients (38%) received deceased donor 
transplantation and 825 (62%) received living donor transplantation. Four 
percent of patients had one or more missing values.
When clinical and socioeconomic variables were compared between recipients of 
a deceased versus LDKT, there were vast differences (Table 1). When clinical 
and socioeconomic variables were compared between European and non-
European recipients, there were also significant differences between these 
populations (Table 2).
Table 1. Patient characteristics, comparison of renal transplant recipient populations that received a 
deceased (N=513) versus living (N=825) donor transplant
Deceased donor Living donor P
Recipient age in years, mean (SD) 52 (14) 48 (15) <0.001a
Gender (male), % 61 64 nsb
Ethnicity (non-European), % 41 18 <0.001b
primary renal disease, %
   Diabetes mellitus 16 10 0.001b
   All other nsb
Transplant year, median 2005 2007 <0.001c
ABO blood type, %
   A 35 45 <0.001b
   AB 7 4 0.003b
   B 17 12 0.007b
   O 41 39 nsb
Retransplants, % 25 15 <0.001b
Pretreatment, %
   CAPD 30 31 nsb
   Hemodialysis 67 38 <0.001b
   None 3 31 <0.001b
Maximum PRA, mean (SD), % 25 (33) 9 (19) <0.001a
Postcode-related variables
   Urbanization (high), % 72 63 0.001b
   Housing value x €1000, mean (SD) 100 (49) 129 (78) <0.001a
   % Non-Europeans (high), % 61 43 <0.001b
   Income in € per month, mean (SD) 1770 (514) 2001 (647) <0.001a
a ANOVA to test significance between recipients of deceased and living donor kidneys.
b ǒ2 test to test significance between recipients of deceased and living donor kidneys.
c Mann-Whitney U to test significance between recipients of deceased and living donor kidneys.
ANOVA, analysis of variance; CAPD, continuous ambulatory peritoneal dialysis; ns, not significant; PRA, 
panel reactive antibodies; SD, standard deviation.
Table 2. Patient characteristics, comparison of European (N=977) and non-European (N=361) renal 
transplant recipient populations
European Non-European P
Donor type (living donor), % 68 39 <0.001b
Recipient age in years, mean (SD) 50 (15) 48 (14) 0.021a
Gender (male), % 64 57 0.014b
primary renal disease, %
   Congenital hereditary 20 6 <0.001b
   Diabetes mellitus 8 24 <0.001b
Transplant year 2006 2006 nsc
ABO blood type, %
   A 45 33 <0.001b
   AB 4 9 <0.001b
   B 10 24 <0.001b
   O 41 34 0.007b
Retransplants, % 19 18 nsb
Pretreatment, %
   CAPD 34 25 0.002b
   Hemodialysis 43 67 <0.001b
   None 23 8 <0.001b
Maximum PRA, mean (SD), % 15 (26) 20 (28) 0.003a
Postcode-related variables
   Urbanization (high), % 55 90 <0.001b
   Housing value x €1000, mean (SD) 128 (74) 80 (33) <0.001a
   % Non-Europeans (high), % 36 85 <0.001b
   Income in € per month, mean (SD) 2044 (638) 1609 (403) <0.001a
a ANOVA to test significance between European and non-European patients.
b ǒ2 test to test significance between European and non-European patients.
c Mann-Whitney U to test significance between European and non-European patients.
ANOVA, analysis of variance; CAPD, continuous ambulatory peritoneal dialysis; ns, not significant; PRA, 
panel reactive antibodies; SD, standard deviation.
In univariable analysis, all variables studied exerted a significant influence on 
the chance of receiving LDKT (data not shown).
In multivariable analysis, 10 of 13 variables contributed significantly to the 
chance of receiving LDKT (Table 3). Recipients who were transplanted more 
recently were more likely to have received a living donor transplant. Europeans 
were more likely to receive living donor transplantation than non-Europeans. 
ABO blood type A had the best chances. Patients on hemodialysis had a smaller 
chance in comparison with patients on continuous ambulatory peritoneal 
dialysis. The chance of living donor transplantation is related to recipient age: 
the younger, the higher the chances (Figure 1). After correction for all variables 
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included in the regression analysis, the chance of living donor transplantation in 
the eldest population turned out to be only 10% of the chances of the youngest 
population (Figure 1). However, in reality, 87%, of recipients between ages 17 
and 20 years (n=45) received a living donor transplantation, and in the 
population transplanted above 70 years of age (n=82), 42% received a living 
donor transplantation (Figure 2). So, in reality, elderly patients received LDKT 
more often than expected based on the results of the regression analysis. A 
higher maximum PRA was also associated with a lower chance. In multivariable 
logistic regression analysis, highly sensitized patients are shown to have only 
10% the chance of unsensitized patients of receiving living donor 
transplantation. In reality, 78% of unsensitized patients (PRA 0%) received 
living donor transplantation, and 11% of highly sensitized patients (PRA above 
85%) received living donor transplantation. With regard to postcode-related 
variables, higher housing value, and living in an urbanized area was associated 
with a better chance. Living in an area with a high percentage of non-Europeans 
decreased the chance. The influence of ethnicity was independent of the 
influence of the postcode-related variables and of pretreatment as there was no 
interaction between these variables.
Table 3. Results of the multivariable binary logistic regression analysis on the chance of receiving a 
LDKT
Variable (reference category) Exp(B) 95% CI P
Recipient age (per year) 0.962 0.952 – 0.972 <0.001
Gender (male) 1.398 1.044 – 1.873 0.025
Transplant year (per year) 1.146 1.095 – 1.199 <0.001
ABO blood type (A) <0.001
   AB 0.275 0.144 – 0.525 <0.001
   B 0.515 0.337 – 0.787 0.002
   O 0.616 0.455 – 0.833 0.002
Maximum PRA 0.975 0.969 – 0.980 <0.001
Pretreatment (CAPD) <0.001
   None 7.105 3.991–12.650 <0.001
   Hemodialysis 0.682 0.507 – 0.916 0.011
Ethnicity (European) 0.494 0.350 – 0.695 <0.001
Postcode-related variables
   % Non-Europeans (low) 0.592 0.426 – 0.824 0.002
   Urbanization (high) 0.672 0.483 – 0.935 0.018
   Housing value 1.004 1.002 – 1.007 0.002
LDKT, living donor kidney transplantations; CAPD, continuous ambulatory peritoneal dialysis.
Figure 1. Result of multivariable binary regression analysis. Influence of recipient age on the chance of 
receiving a living donor kidney transplantation (LDKT) after correction for all other variables present in 
the analysis. In comparison to patients aged 20 years, patients aged 40 years have 50% chance to get 
a LDKT.
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Figure 2. Distribution of living and deceased donor kidney transplantations per age category.
Discussion
This study is a comparison of the populations for whom transplantation became 
available and shows that the population that made it to LDKT is different from 
the population that made it to deceased donor kidney transplantation. In this 
study, only transplanted patients were analyzed. Patients on the waiting list and 
those delisted from the waiting list were not included.
This study shows that beside clinical factors, socioeconomic factors play an 
important and independent role in access to LDKT; unfavorable clinical factors 
are ABO blood type O, high PRA, and high age. These factors have also been 
shown to be important in other studies (2–5). In direct living donation 
programs, recipients with blood type O and highly sensitized patients are known 
to have smaller chances of transplantation (4, 6). With alternative living and 
deceased donation programs, their chances increase (2, 6). Despite these 
programs, the chance of receiving a living donor renal transplantation of a 
patient with a PRA of 27% is only half that of an unsensitized patient, and highly 
sensitized patients have only 10% chance of living donor transplantation when 
other variables are the same. The perceived discrepancy with the actual 
situation in our center where 78% of unsensitized patients and 11% of highly 
sensitized patients received living donor transplantation means that the highly 
sensitized patient population that made it to living donor transplantation is a 
selection of recipients with favorable factors other than PRA. This means that 
highly sensitized patients with a collection of other unfavorable factors on top of 
that are even less likely to receive living donor transplantation. Figure 2 shows 
that the chance for living donor renal transplantation decreases with increasing 
age. A 40-year-old patient has only half the chance of a 20-year-old patient of
receiving living donor transplantation, while for those above 70 years, the 
chance decreases to only 10%. In this study, the discrepancy with the actual 
situation where 87% of the population younger than 20 years and 45% of the 
population between 70 and 80 years received living donor transplantation shows 
that the elderly population that made it to living donor transplantation is 
selected on favorable variables other than age. Elderly transplant patients with a 
collection of unfavorable factors other than age received a transplant through 
the deceased donor transplantation program.
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In The Netherlands, minorities consist of immigrants rather than indigenous 
people as in some other countries. Minorities are known to have a twofold to 
threefold higher prevalence of end-stage kidney disease, and they have a 
smaller chance to be waitlisted and receive kidney transplantation (7–17). The 
proportion of transplants from living donors is also lower among indigenous than 
among white transplant recipients in Australia, New Zealand, and the United 
States (15).
The chance of receiving LDKT is not only related to ethnicity but also to 
socioeconomic factors (18–22). Socioeconomic deprivation has also been 
associated with a decreased likelihood of placement on the deceased donor 
transplant waiting list in the United States and United Kingdom (12, 19, 23–25). 
Lower socioeconomic status correlates with later referral for dialysis among 
patients with end-stage kidney disease, later referral for transplant registration, 
which confounds their ability to get listed for transplantation, and a decreased 
likelihood of undergoing transplantation either from a living or from a deceased 
donor (3, 26).
To disentangle the influences of socioeconomic factors and ethnicity, these 
factors were included in our multivariable analysis. Both socioeconomic factors 
and ethnicity exerted a significant influence on the chance of receiving a LDKT, 
and these effects were independent of each other. Non-European patients 
received living donor transplantation significantly less often than European 
patients. The socioeconomic factors that significantly and negatively influenced 
the chance of living donor transplantation were low housing value, low 
urbanization grade, and high percentage non-Europeans living in the area. In 
our study, income did not influence the chance for living donor transplantation. 
It is likely that housing value estimated by postcode is a more accurate 
reflection of a person’s socioeconomic situation than income estimated by 
postcode.
Unfortunately, unfavorable factors tend to accumulate in the non-European 
population. An explanation might be that the non-European population studied 
has been in the Netherlands for a maximum of 60 years. The first generation 
primarily immigrated for economic reasons and had limited education: there are 
still 500,000 non-Europeans in The Netherlands who are illiterate. The majority 
of patients are the first generation living in The Netherlands. This means that 
many non-Europeans did not yet achieve the socioeconomic standards that are 
common in the European population. When European and non-European 
populations are compared on the variables that influence the chance of living 
donor renal transplantation (Tables 1 and 2), there are significant differences in 
PRA, previous treatment, percentage of non-Europeans living in the area, and 
housing value. The most prevalent European patient has a mean PRA 15%, is 
not on hemodialysis, and lives in an area with a low percentage of non-
Europeans in a house with a mean value of €128,000 (Table 2). In comparison 
with the reference category, the chance for a living donor renal transplantation 
of this most prevalent European population is 1 (for European) x 0.69 (for PRA) 
x 1 (for not on hemodialysis) x 1 (for area) x 1 (for housing value)=0.69 (Table 
3). This means 69% chance of receiving a living donor renal transplantation 
compared with the reference category. However, the most prevalent non-
European patient has PRA 20%, is on hemodialysis, lives in a house of €80,000, 
and lives in an area with a high percentage of non-Europeans. In comparison 
with the reference category, the chance of a living donor renal transplantation of 
the most prevalent non-European population is 0.494 (for non-European) x
0.682 (for hemodialysis) x 0.606 (for PRA) x 0.825 (for housing value) x 0.592 
(for area)=0.10. The chance dramatically decreases to only 10% in comparison 
with the reference category, partly caused by unexplained ethnic factors, and 
partly caused by clinical and socioeconomic factors.
We showed that also in the Netherlands, the chance of LDKT in comparison with 
deceased donor kidney transplantation is significantly and independently 
influenced by ethnicity and socioeconomic factors. It is remarkable that 
socioeconomic factors still exert such an important influence on the chance of 
receiving living donor transplantation as the medical health system in the 
Netherlands assures equal health care for all inhabitants, largely excluding 
economic circumstances as an important factor for decreased access to living 
donor transplantation. Moreover, all donor costs are paid by the recipient’s 
health company. To explore psychosocial factors that may influence LDKT 
among patients of diverse ethnic backgrounds, a qualitative study was 
conducted in our center (27). Focus group discussions and in-depth interviews 
were conducted among 50, mostly hemodialysis, patients on the deceased donor 
transplant waiting list. Most patients preferred LDKT (96%), but a living donor 
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was not available for them. Religion was not perceived as an obstacle to living 
kidney donation but was felt to promote helping and saving the life of a person. 
However, individual Faith leader’s opinion was felt to be influential and may be 
negative. The majority of non-Europeans reported they did not comprehend the 
information given in the hospital, did not actively seek information, and had 
fears and anxieties and misconceptions regarding the process of organ donation. 
Our focus group study also showed that our patients had a positive attitude 
toward home-based education on living do-nor transplantation (28). The 
effectiveness of this program is currently being tested in a randomized 
controlled trial. In conclusion, both clinical and socioeconomic factors are 
independently associated with participation in living or deceased donor kidney 
transplantation. This study highlights the populations that would benefit from 
additional educational intervention regarding living donor transplantation.
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independently associated with participation in living or deceased donor kidney 
transplantation. This study highlights the populations that would benefit from 
additional educational intervention regarding living donor transplantation.
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Abstract
Background. Studies on the influence of socioeconomic factors and ethnicity on 
the results of kidney transplantation have led to various outcomes. In this study, 
we analyzed the influence of a combination of these factors on graft and patient 
survival in a population of kidney transplant recipients.
Methods. This retrospective study included all 1,338 patients who received a 
kidney transplant between 2000 and 2011 (825 living, 513 deceased donor 
transplantations). Both clinical and socioeconomic variables were studied. 
Clinical variables were recipient age, gender, ethnicity, primary renal disease, 
maximum and current panel reactive antibodies, ABO blood type, retransplants, 
pretreatment, time on dialysis, comorbidity, transplant year, total number of 
HLA mismatches, donor type (living or deceased), age and gender, and 
calcineurin inhibitor treatment. Each recipient’s postal code was linked to a 
postal code area information database to extract information on housing value, 
income, percentage non-Europeans in the area, and urbanization level.
Results. In multivariable analysis, graft survival censored for death was 
significantly influenced by recipient age, maximum panel reactive antibodies, 
HLA mismatches, donor type, donor age, and calcineurin inhibitor treatment. 
Patient survival was significantly influenced by recipient age, comorbidity,
transplant year, and donor type. Socioeconomic factors and ethnicity did not 
have a significant influence on graft and patient survival.
Conclusions. Though ethnicity and socioeconomic factors do not influence 
survival after kidney transplantation, the favorable influence of living donor type 
is of paramount importance. As non-Europeans and patients with unfavorable 
socioeconomic variables less often receive a living donor kidney transplant, their 
survival may be unfavorable after all.
Introduction
The literature on the combined influence of socioeconomic factors and ethnicity 
on the results of kidney transplantation is inconclusive as a multitude of studies 
led to various outcomes. Four explanations could cause this inconsistency. The 
first possible explanation is that there is a difference in ethnicity of the 
population studied, for example, African versus Asian versus European (1-23). 
Mostly, results of Caucasians are better than results of Africans or African 
Americans (1-8, 20-23). Secondly, the influence of a range of socioeconomic 
variables has been studied, for example, education, employment status, income, 
and insurance coverage. Different combinations of parameters have been 
studied. Results range from a negative effect of socioeconomic factors on graft 
survival to no effect at all (13-25). A third explanation for the inconsistency in 
the literature could be a difference in access to living donor kidney 
transplantation for patients with favorable and unfavorable socioeconomic 
factors and for patients with different ethnicities (26-28). As survival after living 
donor kidney transplantation is better than after deceased donor kidney 
transplantation, this could influence the outcome of these studies. Finally, the 
difference in health care systems between countries could be influencing results 
(22, 23). If access to health care depends on socioeconomic status, patients 
with unfavorable social factors could be disadvantaged.
Our transplant program does not only serve the indigenous population of the 
Netherlands but also immigrants from other countries in Europe and other 
continents, for example, a Dutch black population native to the Caribbean, 
Northern part of South America and sub-Saharan Africa, and Northern Africa 
(from where there is large-scale immigration to the Netherlands). All patients 
who permanently reside in the Netherlands are eligible to receive a kidney 
transplant. In the Rotterdam area, socioeconomic factors vary considerably 
between neighborhoods. In a national database, demographic variables are 
available for each neighborhood in the Netherlands, for example, housing value, 
income, percentage of non-Europeans living in the area, and urbanization level. 
Non-European patients and recipients of a deceased donor kidney more often 
live in socioeconomically deprived areas. Access to living donor kidney 
transplantation is lower in groups of certain ethnicities and socioeconomic 
status. As living donor kidney transplantation leads to better graft and patient 
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survival than deceased donor kidney transplantation, this could have a negative 
influence on the results of these groups. The National Health system in the 
Netherlands assures equal care for all inhabitants. We studied the influence of 
ethnicity and socioeconomic factors on graft and patient survival in our system 
of equal health care.
Materials and methods
Study Sample
In this retrospective cohort study, all 1,338 kidney transplantations performed in 
our center from January 1, 2000 until December 31, 2010 were included. 
Informed consent to use data was obtained from all patients. The 
immunosuppressive regimen for patients and screening procedure for potential 
living kidney donors have been described previously (29, 30).
The Central Bureau for Statistics in the Netherlands collects demographic data 
per postal code area (31). A postal code consists of four numbers and two 
letters. The first two numbers represent the region, the last two numbers the 
neighborhood, and the two letters represent the street. For the present study, 
each recipient’s postal code was linked to the Central Bureau for Statistics 2004 
postal code area information database to extract demographic information.
Statistical Analysis
We studied both graft failure censored for death and patient death. Follow-up 
was until February 2013 or until graft failure, death, or lost to follow-up. 
Differences between European and non-European patients were analyzed using 
two-tailed independent-samples t tests, chi-square tests, and Mann-Whitney U
tests. Variables that were studied are mentioned in Table 1. In two separate Cox 
proportional hazards analyses, the influence of these variables was studied: on 
graft failure censored for death, respectively on patient death. Univariable Cox 
was used to determine variables to include in the initial multivariable model. 
Subsequently, variables with non-significant influence were excluded through 
backward elimination. Initially excluded variables were added to the model to 
verify whether their influence was significant in multivariable analysis.
Patients were classified into five ethnicities: African (n=112), Arabian (n=48), 
Asian (n=132), European (n=977), and Turkish (n=69). Socioeconomic factors 
were housing value, income, percentage non-Europeans in the area (high: more 
than 10% vs. low), and urbanization level (high: more than 1,500 
addresses/km2 vs. low). Comorbidity was defined as the previous experience 
with or presence of one or more of the following conditions in addition to the 
primary kidney disease: cardiac events, cerebrovascular accident, vascular 
disease, and diabetes mellitus.
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The proportional hazards assumption was tested for categorical variables with 
log-minus-log plots. Statistical Package for the Social Sciences (SPSS) 20.0.0.1 
(IBM Corporation, Armonk, NY, USA) was used to perform all analyses. P values 
less than 0.05 were considered significant. Cases with missing values were 
excluded from the analyses.
Table 1. Transplantation characteristics for European and non-European patients.
European N=977 Non-European N=361 P
Recipient age in years, mean (SD) 50.3 (14.9) 48.3 (13.6) 0.020a
Recipient gender (male), % 65 58 0.014b
primary renal disease, % <0.001b
   Diabetes mellitus 8 24
   Other 92 76
Maximum PRA, median (%>5%) 4 (29) 4 (39) <0.001c
Current PRA, median (%>5%) 0 (12) 0 (17) 0.436c
ABO blood type, % <0.001b
   A 44 33
   AB 4 9
   B 10 24
   O 42 34
Retransplants, % 19 18 0.819b
Pretreatment, % 78 91 <0.001b
Time on dialysis in days, median (IQR) 475 (7-941) 960 (456.5-1595.5) <0.001c
Comorbidity, % 34 44 0.001b
Transplant year, median (IQR) 2006 (2003-2009) 2006 (2003-2008) 0.769c
HLA mismatches, mean (SD) 3.1 (1.7) 3.2 (1.5) 0.255a
Donor type (living donor), % 69 42 <0.001b
Donor age in years, mean (SD) 51.6 (13.3) 48.5 (13.4) <0.001a
Donor gender (male), % 45 48 0.300b
CNI as initial immunosuppression, % 95 97 0.133b
Housing value x €1000, median (IQR) 115 (86-151) 75 (58-101.75) <0.001c
Income in € per month, median (IQR) 1900 (1600-2300) 1500 (1400-1700) <0.001c
% Non-Europeans (high), % 36 85 <0.001b
Urbanization (high), % 57 91 <0.001b
a Independent-samples t test.
b Chi-square test.
c Mann-Whitney U to test significance between European and non-European patients.
CNI, calcineurin inhibitor; IQR, interquartile range; PRA, panel reactive antibodies; SD, standard 
deviation.
Results
In the study period, 513 patients received a deceased donor kidney and 825 
patients received a living donor kidney. Patients were included in this study 
between January 2000 and December 2010. Observation was until February 
2013 so that at least 2 years of follow-up could be obtained. Median follow-up 
was 4.5 years (54 months). In total, 32 patients were lost to follow-up with 
median time after transplantation of 25.5 months (range 0-110). Observation of 
these patients was until they were lost to follow-up. The variables maximum and 
current panel reactive antibodies (PRA) had five missing values, housing value 
22, income 39, and percentage non-Europeans in the area 7.
Table 1 shows transplantation characteristics. Compared to European patients, 
non-European patients live in neighborhoods with lower housing value, lower 
income, more non-Europeans, and more urbanization. Significant clinical 
differences emerged in recipient age and gender, primary renal disease, 
maximum PRA, ABO blood type, pretreatment, time on dialysis, comorbidity, 
and donor type and age. There were no significant differences between 
Europeans and non-Europeans regarding current PRA, retransplants, transplant 
year, total number of HLA mismatches, donor gender, and calcineurin inhibitor 
(CNI) treatment.
There were 271 graft failures. In univariable Cox proportional hazards analysis, 
recipient age, maximum and current PRA, retransplants, pretreatment, time on 
dialysis, transplant year, donor type, donor age, and CNI treatment had a 
significant influence on the risk of graft failure censored for death, whereas the 
influence of ethnicity and socioeconomic factors was not significant (data not 
shown). Multivariable Cox proportional hazards analysis showed that recipient 
age, maximum PRA, total number of HLA mismatches, donor type, donor age, 
and CNI treatment had a significant influence on the risk of graft failure 
censored for death (Table 2a). The influence of pretreatment and time on 
dialysis was not significant. Other variables were excluded through backward 
elimination, including ethnicity and socioeconomic factors.
One hundred seventy-seven patients died. In univariable Cox proportional 
hazards analysis, recipient age, primary renal disease, time on dialysis, 
comorbidity, total number of HLA mismatches, and donor type, age, and gender 
significantly influenced the risk of patient death. Ethnicity and socioeconomic 
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median time after transplantation of 25.5 months (range 0-110). Observation of 
these patients was until they were lost to follow-up. The variables maximum and 
current panel reactive antibodies (PRA) had five missing values, housing value 
22, income 39, and percentage non-Europeans in the area 7.
Table 1 shows transplantation characteristics. Compared to European patients, 
non-European patients live in neighborhoods with lower housing value, lower 
income, more non-Europeans, and more urbanization. Significant clinical 
differences emerged in recipient age and gender, primary renal disease, 
maximum PRA, ABO blood type, pretreatment, time on dialysis, comorbidity, 
and donor type and age. There were no significant differences between 
Europeans and non-Europeans regarding current PRA, retransplants, transplant 
year, total number of HLA mismatches, donor gender, and calcineurin inhibitor 
(CNI) treatment.
There were 271 graft failures. In univariable Cox proportional hazards analysis, 
recipient age, maximum and current PRA, retransplants, pretreatment, time on 
dialysis, transplant year, donor type, donor age, and CNI treatment had a 
significant influence on the risk of graft failure censored for death, whereas the 
influence of ethnicity and socioeconomic factors was not significant (data not 
shown). Multivariable Cox proportional hazards analysis showed that recipient 
age, maximum PRA, total number of HLA mismatches, donor type, donor age, 
and CNI treatment had a significant influence on the risk of graft failure 
censored for death (Table 2a). The influence of pretreatment and time on 
dialysis was not significant. Other variables were excluded through backward 
elimination, including ethnicity and socioeconomic factors.
One hundred seventy-seven patients died. In univariable Cox proportional 
hazards analysis, recipient age, primary renal disease, time on dialysis, 
comorbidity, total number of HLA mismatches, and donor type, age, and gender 
significantly influenced the risk of patient death. Ethnicity and socioeconomic 
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factors did not significantly influence this risk. In multivariable analysis, recipient 
age, comorbidity, transplant year, and donor type had a significant influence on 
the risk of patient death (Table 2b). Ethnicity and socioeconomic factors were 
excluded through backward elimination.
The proportional hazards assumption was not violated.
Table 2. Results of the multivariable Cox Proportional Hazards Analysis. Failure event is (a) graft 
failure censored for death, (b) patient death.
Variable (reference category) Exp(B) 95% CI P
(a) 271 eventsa
   Recipient age (per year) 0.979 0.970 - 0.987 <0.001
   Maximum PRA (per %) 1.006 1.002 - 1.010 0.004
   Pretreatment (no) 1.415 0.937 - 2.138 0.099
   Time on dialysis (per day) 1.000 1.000 - 1.000 0.065
   HLA mismatches (per HLA mismatch) 1.105 1.020 - 1.198 0.015
   Donor type (deceased donor) 0.443 0.330 - 0.595 <0.001
   Donor age (per year) 1.028 1.018 - 1.039 <0.001
   CNI as initial immunosuppression (no) 0.296 0.185 - 0.472 <0.001
(b) 177 eventsb
   Recipient age (per year) 1.061 1.047 - 1.076 <0.001
   Comorbidity (no) 1.935 1.408 - 2.657 <0.001
   Transplant year (per year) 0.944 0.894 - 0.998 0.041
   Donor type (deceased donor) 0.656 0.487 - 0.885 0.006
a Event is graft failure censored for death. Final model after backward elimination of the following 
covariates: recipient gender, ethnicity, primary renal disease, current PRA, ABO blood type, 
retransplants, comorbidity, transplant year, donor gender, housing value, income, non-Europeans, and 
urbanization level.
b Event is patient death. Final model after backward elimination of the following covariates: recipient 
gender, ethnicity, primary renal disease, maximum PRA, current PRA, ABO blood type, retransplants, 
pretreatment, time on dialysis, HLA mismatches, donor age, donor gender, CNI as initial 
immunosuppression, housing value, income, non-Europeans, and urbanization level.
CNI, calcineurin inhibitor; PRA, panel reactive antibodies
Discussion
The influence of socioeconomic factors and ethnicity on the results of kidney 
transplantation has been studied in various ways, and these studies led to 
various outcomes. As different combinations of variables are studied in the 
literature, it is hard to get a clear overview of those variables that really matter. 
In some studies, ethnicity was the only variable studied (1-12). In other studies, 
combinations of various socioeconomic factors were the only variables studied 
(24, 25). There were also studies that corrected for the influence of ethnicity or 
socioeconomic factors while the main focus was on the other variable (13-23).
Ethnicity without correction for socioeconomic factors
In most studies on the influence of ethnicity, a negative influence of African 
ethnicity on graft survival was found (1-8). Eckhoff et al. showed that the effect 
of ethnicity on the graft failure risk was not constant in the population studied 
(1). Early graft survival did not display a racial disparity. However, in the 
constant phase of graft loss, a racial disparity emerged, with African Americans 
experiencing a higher rate of graft loss over time than non-African Americans. 
The influence of high immune responder status and CYP3A5 responder status 
was studied in two different studies (2, 3). The effect of ethnicity on graft 
survival remained significant in both studies. Finally, in 1999, compared to 
European ethnicity, a negative influence of African and Arabian ethnicity on the 
graft failure risk was found in our own population (P=0.023, respectively 
P=0.019) (4). In a health system providing free post-transplant medication, the 
negative effect of ethnicity on graft survival disappeared after the introduction of 
thymoglobulin induction therapy (9).
In one European study, the influence of African ethnicity on graft survival was 
not significant in univariable analysis (10). In other European studies comparing 
Asian and Caucasian ethnicity, no difference in graft survival was found between 
these ethnicities (11, 12).
Socioeconomic factors without correction for ethnicity
In a few studies, socioeconomic factors were tested without correcting for 
ethnicity (24, 25). They found that less education (24) and income deprivation 
(25) were predictors of graft loss.
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age, comorbidity, transplant year, and donor type had a significant influence on 
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a Event is graft failure censored for death. Final model after backward elimination of the following 
covariates: recipient gender, ethnicity, primary renal disease, current PRA, ABO blood type, 
retransplants, comorbidity, transplant year, donor gender, housing value, income, non-Europeans, and 
urbanization level.
b Event is patient death. Final model after backward elimination of the following covariates: recipient 
gender, ethnicity, primary renal disease, maximum PRA, current PRA, ABO blood type, retransplants, 
pretreatment, time on dialysis, HLA mismatches, donor age, donor gender, CNI as initial 
immunosuppression, housing value, income, non-Europeans, and urbanization level.
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various outcomes. As different combinations of variables are studied in the 
literature, it is hard to get a clear overview of those variables that really matter. 
In some studies, ethnicity was the only variable studied (1-12). In other studies, 
combinations of various socioeconomic factors were the only variables studied 
(24, 25). There were also studies that corrected for the influence of ethnicity or 
socioeconomic factors while the main focus was on the other variable (13-23).
Ethnicity without correction for socioeconomic factors
In most studies on the influence of ethnicity, a negative influence of African 
ethnicity on graft survival was found (1-8). Eckhoff et al. showed that the effect 
of ethnicity on the graft failure risk was not constant in the population studied 
(1). Early graft survival did not display a racial disparity. However, in the 
constant phase of graft loss, a racial disparity emerged, with African Americans 
experiencing a higher rate of graft loss over time than non-African Americans. 
The influence of high immune responder status and CYP3A5 responder status 
was studied in two different studies (2, 3). The effect of ethnicity on graft 
survival remained significant in both studies. Finally, in 1999, compared to 
European ethnicity, a negative influence of African and Arabian ethnicity on the 
graft failure risk was found in our own population (P=0.023, respectively 
P=0.019) (4). In a health system providing free post-transplant medication, the 
negative effect of ethnicity on graft survival disappeared after the introduction of 
thymoglobulin induction therapy (9).
In one European study, the influence of African ethnicity on graft survival was 
not significant in univariable analysis (10). In other European studies comparing 
Asian and Caucasian ethnicity, no difference in graft survival was found between 
these ethnicities (11, 12).
Socioeconomic factors without correction for ethnicity
In a few studies, socioeconomic factors were tested without correcting for 
ethnicity (24, 25). They found that less education (24) and income deprivation 
(25) were predictors of graft loss.
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Socioeconomic factors with correction for ethnicity
After correction for ethnicity, Begaj et al. showed a negative influence of a 
combination score of socioeconomic factors on overall and patient survival (13), 
whereas in another study recipients with higher education level, resident aliens 
(as compared with U.S. citizens), and patients with private insurance were found 
to have a lower risk of graft and recipient failure (14). On the other hand, 
Petersen found an effect of pre- and post-transplant employment status on graft 
and patient survival (15).
Ethnicity with correction for socioeconomic factors
After correction for various socioeconomic factors, some authors did not find an 
effect of ethnicity on graft survival (16-19). Although a negative influence of 
African (American) ethnicity on graft survival was shown by Butkus in 
univariable analysis, ethnicity was not significant in multivariable analysis 
including recipient age, HLA mismatches, and insurance coverage (16). In this 
study, type of insurance coverage had a significant influence in both univariable 
and multivariable analyses. In another study from this author, post-transplant 
compliance was the only variable related to graft survival in multivariable 
analysis, whereas African (American) ethnicity was not associated with reduced 
graft survival (17). These findings had been shown before in a small study that 
included a low percentage of non-whites (18). In this study, the only significant 
variables were income and compliance whereas ethnicity did not reach 
significance.
A significant and negative effect of ethnicity on graft failure risk was found in 
other studies on the influence of ethnicity that included socioeconomic factors 
(20-23). College education and employment did not, but ethnicity and insurance 
coverage did influence the graft failure risk in a population that received their 
first kidney transplantation (20). After adjustment for poverty, employment 
status, and clinical covariates, African Americans and Hispanics had higher rates 
of graft failure compared to whites (21). Though Medicare’s lifetime coverage of 
immunosuppressive medication claims to have offset the income-related 
disparities in graft survival, income and ethnicity still significantly influenced the 
graft failure risk in 2008 (22).
After correction for a large number of categories of variables (e.g., 
socioeconomic variables), Asian and Hispanic or Latino recipients demonstrated 
consistently superior long-term deceased donor and living donor graft and 
patient survival compared to white recipients (23). African-American recipients 
had consistently inferior long-term living donor and deceased donor graft 
survival relative to the other ethnic groups. These findings suggest that access 
to care (including immunosuppressive agent coverage) does not seem to 
completely explain the observed large racial disparities in kidney transplant 
outcomes.
In the present study, we found that socioeconomic factors and ethnicity do not 
have a significant influence on death-censored graft survival or patient survival. 
This holds true for both univariable and multivariable analysis. Though the 
access to living donor kidney transplantation is influenced by ethnicity and 
socioeconomic factors, these factors do not influence the prognosis once 
transplantation has been performed. However, we showed that donor type is an 
important factor in graft survival, which causes an indirect disadvantage for 
patients with unfavorable socioeconomic variables.
The strength of our findings is that access to living donor kidney transplantation 
and graft survival are studied in the same population. Access to living donor 
kidney transplantation is impaired probably because of a lack of adequately 
informed living donors in the population with unfavorable socioeconomic factors 
and non-European ethnicity. On the other hand, the Dutch health system 
assures equal availability of immunosuppressive medication, securing graft 
survival. In the United States, health care is dependent on socioeconomic status. 
This means that immunosuppressive medication is not equally available for all 
inhabitants, theoretically leading to decreased graft survival for some. An 
exception to this system is made for veterans and active-duty personnel and 
their dependents. Although Oliver et al.’s findings are in line with this theory (9), 
Chakkera et al.’s findings refuted it (20).
Though significance was low, a negative influence of ethnicity on the risk of graft 
failure was found in our own center without correction for socioeconomic factors 
in 1999 (4). The negative effect of ethnicity on graft survival that we found in 
1999 had disappeared in the present study. The medical health system did not 
change between then and the present time, undermining the hypothesis that the 
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socioeconomic factors, these factors do not influence the prognosis once 
transplantation has been performed. However, we showed that donor type is an 
important factor in graft survival, which causes an indirect disadvantage for 
patients with unfavorable socioeconomic variables.
The strength of our findings is that access to living donor kidney transplantation 
and graft survival are studied in the same population. Access to living donor 
kidney transplantation is impaired probably because of a lack of adequately 
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assures equal availability of immunosuppressive medication, securing graft 
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This means that immunosuppressive medication is not equally available for all 
inhabitants, theoretically leading to decreased graft survival for some. An 
exception to this system is made for veterans and active-duty personnel and 
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1999 had disappeared in the present study. The medical health system did not 
change between then and the present time, undermining the hypothesis that the 
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availability of the health system is indispensable for graft survival. The only 
change between these periods was the population of non-Europeans themselves. 
Most non-Europeans immigrated between the fifties and seventies of the 
previous century, whereas the numbers of new immigrants decreased 
considerably after that time. The present non-European population is made up of 
first-, second-, and third-generation immigrants. They are better integrated and 
educated than 10 years ago, and their employment status is higher (31).
The influence of ethnicity on graft survival and its relation with various 
socioeconomic factors has been studied in different settings and populations. 
When a subject is studied this intensively and outcomes differ considerably, the 
explanation most probably is that the influence of ethnicity is multifactorial and 
context dependent. The influence of ethnicity on graft survival probably depends 
on many factors, for example, HLA matching, poverty, education, employment, 
degree of integration, a health system with a controlling function, and access to 
medication. If all these factors are negative, a negative influence of ethnicity on 
graft survival will be found. However, if these factors are positive, ethnicity may 
not have any influence on outcome of kidney transplantation at all.
In conclusion, in our study cohort, neither ethnicity nor socioeconomic factors 
had an important influence on graft and patient survival. Nevertheless, the low 
prevalence of living donor kidney transplantation in ethnic minorities and 
socioeconomically deprived patients does influence the ultimate prognosis of this 
population.
Research shows that fear and a lack of knowledge play a major role in the 
absence of living donors in this population (32). Active education and 
information for these patients and potential donors is very important to improve 
results (33-36).
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Abstract
,QGHFHDVHGGRQRUNLGQH\WUDQVSODQWDWLRQGRQRUDJHLVNQRZQWRLQÀXHQFHJUDIW
VXUYLYDO7KHLQÀXHQFHRIOLYLQJGRQRUDJHRQJUDIWVXUYLYDOLVTXHVWLRQHG:H
FRPSDUHGWKHLQÀXHQFHRIOLYLQJDQGGHFHDVHGGRQRUDJHRQWKHRXWFRPHRI
renal transplantation. All 1821 transplants performed in our center between 
1990 and 2009 were included in the analysis. Observation was until April 2012. 
A total of 941 patients received a deceased donor kidney and 880 a living donor 
kidney. In multivariable Cox analysis, recipient age, maximum and current panel 
reactive antibodies, transplant year, HLA mismatches, donor age, donor gender, 
donor type, delayed graft function, and calcineurin inhibitor (CNI) and 
SUHGQLVRQHDVLQLWLDOLPPXQRVXSSUHVVLRQZHUHIRXQGWRKDYHDVLJQL¿FDQW
LQÀXHQFHRQGHDWK-FHQVRUHGJUDIWIDLOXUH7KHLQÀXHQFHRIERWKOLYLQJDQG
deceased donor age followed a J-shaped curve, above 30 years the risk 
increased with increasing age. Donor type and donor age had an independent 
LQÀXHQFH7KHJUDIWIDLOXUHULVNRIGHFHDVHGGRQRUWUDQVSODQWDWLRQLVDOPRVWWZLFH
that of living donor transplantation so that a 60-year-old living donor kidney has 
the same graft failure risk as a 20-year-old deceased donor kidney.
Introduction
To keep pace with the waiting list, more kidney donations are accepted from 
living extended criteria donors (ECD). Although donor hypertension and obesity 
play a role, the most prominent characteristic of both living and deceased ECDs 
is that they are older than standard criteria donors (SCD) (1–5).
,QGHFHDVHGGRQRUNLGQH\WUDQVSODQWDWLRQGRQRUDJHLVNQRZQWRLQÀXHQFHJUDIW
VXUYLYDOLQOLYLQJGRQRUNLGQH\WUDQVSODQWDWLRQWKLVLQÀXHQFHLVOHVVFOHDU The 
composition of living and deceased donor recipient populations is different in 
many respects; this probably explains part of the difference in graft survival in 
these populations.
8QWLOQRZWKHLQÀXHQFHRIGRQRUDJHKDVEHHQVWXGLHGLQGHFHDVHGRUOLYing 
donor kidney transplantation populations separately, ruling out comparison 
because of heterogeneity of the populations (2, 6–13). Besides, in many studies 
age was categorized resulting in small elderly populations (3, 9–11, 14). In most 
living donor populations donor age range is narrow because of donor selection, 
VRWKHLQÀXHQFHRIDJHFDQQRWEHVWXGLHGSURSHUO\
Deceased donor kidney transplantations have been performed in our center 
since 1971 and living donor kidney transplantations since 1981. Only in the very 
beginning were high recipient and deceased donor age exclusion criteria. The 
wide distributions in recipient and donor age in our population allowed us to 
VWXG\WKHLQÀXHQFHRIDJHDVDFRQWLQXRXVYDULDEOHRQWKHULVNRIJUDIWIDLOXUH
both in deceased and living donor kidney transplantation. How important is 
living donor age and how does it compare to deceased donor age?
67
Relative importance of donor age in kidney transplantation
Abstract
,QGHFHDVHGGRQRUNLGQH\WUDQVSODQWDWLRQGRQRUDJHLVNQRZQWRLQÀXHQFHJUDIW
VXUYLYDO7KHLQÀXHQFHRIOLYLQJGRQRUDJHRQJUDIWVXUYLYDOLVTXHVWLRQHG:H
FRPSDUHGWKHLQÀXHQFHRIOLYLQJDQGGHFHDVHGGRQRUDJHRQWKHRXWFRPHRI
renal transplantation. All 1821 transplants performed in our center between 
1990 and 2009 were included in the analysis. Observation was until April 2012. 
A total of 941 patients received a deceased donor kidney and 880 a living donor 
kidney. In multivariable Cox analysis, recipient age, maximum and current panel 
reactive antibodies, transplant year, HLA mismatches, donor age, donor gender, 
donor type, delayed graft function, and calcineurin inhibitor (CNI) and 
SUHGQLVRQHDVLQLWLDOLPPXQRVXSSUHVVLRQZHUHIRXQGWRKDYHDVLJQL¿FDQW
LQÀXHQFHRQGHDWK-FHQVRUHGJUDIWIDLOXUH7KHLQÀXHQFHRIERWKOLYLQJDQG
deceased donor age followed a J-shaped curve, above 30 years the risk 
increased with increasing age. Donor type and donor age had an independent 
LQÀXHQFH7KHJUDIWIDLOXUHULVNRIGHFHDVHGGRQRUWUDQVSODQWDWLRQLVDOPRVWWZLFH
that of living donor transplantation so that a 60-year-old living donor kidney has 
the same graft failure risk as a 20-year-old deceased donor kidney.
Introduction
To keep pace with the waiting list, more kidney donations are accepted from 
living extended criteria donors (ECD). Although donor hypertension and obesity 
play a role, the most prominent characteristic of both living and deceased ECDs 
is that they are older than standard criteria donors (SCD) (1–5).
,QGHFHDVHGGRQRUNLGQH\WUDQVSODQWDWLRQGRQRUDJHLVNQRZQWRLQÀXHQFHJUDIW
VXUYLYDOLQOLYLQJGRQRUNLGQH\WUDQVSODQWDWLRQWKLVLQÀXHQFHLVOHVVFOHDU The 
composition of living and deceased donor recipient populations is different in 
many respects; this probably explains part of the difference in graft survival in 
these populations.
8QWLOQRZWKHLQÀXHQFHRIGRQRUDJHKDVEHHQVWXGLHGLQGHFHDVHGRUOLYing 
donor kidney transplantation populations separately, ruling out comparison 
because of heterogeneity of the populations (2, 6–13). Besides, in many studies 
age was categorized resulting in small elderly populations (3, 9–11, 14). In most 
living donor populations donor age range is narrow because of donor selection, 
VRWKHLQÀXHQFHRIDJHFDQQRWEHVWXGLHGSURSHUO\
Deceased donor kidney transplantations have been performed in our center 
since 1971 and living donor kidney transplantations since 1981. Only in the very 
beginning were high recipient and deceased donor age exclusion criteria. The 
wide distributions in recipient and donor age in our population allowed us to 
VWXG\WKHLQÀXHQFHRIDJHDVDFRQWLQXRXVYDULDEOHRQWKHULVNRIJUDIWIDLOXUH
both in deceased and living donor kidney transplantation. How important is 
living donor age and how does it compare to deceased donor age?
68
Chapter 5
Methods
All 1821 transplants performed in our center between January 1990 and 
December 2009 were included in the analysis. Observation was until April 2012 
or until graft failure, death, or lost to follow-up. 27 patients were lost to follow-
up with a median time after transplantation of 31 months (0–160). Standard 
immunosuppression was cyclosporine, prednisone in 1990, but was changed to 
prednisone, cyclosporine, and mycofenolate mofetil (MMF) in 1996, whereas 
tacrolimus was introduced in 1998 as substitute for cyclosporine. In patients 
that started on triple therapy, prednisone was tapered and discontinued at 4 
months after transplantation.
Screening of our potential living kidney donors has been described thoroughly 
(15). Absolute contra-indications for donation are body mass index >35 kg/m2, 
GFR <80 ml/min, hypertension with end-organ damage, history of invasive 
malignancies, diabetes mellitus, pregnancy, intravenous drug abuse, major 
FDUGLRUHVSLUDWRU\GLVHDVHKXPDQLPPXQRGH¿FLHQF\YLUXVSRVLWLYLW\KHSDWLWLV%
or C infection, psychiatric disorders, and systemic disease. Living donor age 
itself has never been a contraindication for donation.
In our center deceased donor kidneys are accepted from donation after brain 
death (DBD) donors and donation after cardiac death (DCD) donors. We 
primarily accept donors after controlled cardiac death (Maastricht category III). 
Uncontrolled Maastricht category II donors are accepted under strict conditions 
only.
We studied graft failure censored for death, uncensored graft failure, and patient 
death. anova and chi-square tests were performed to test the difference 
between living and deceased donor populations and between donor age 
categories. Kaplan–Meier analysis was performed, including donor age and type 
(living vs. deceased). For Kaplan–Meier analysis, donor age was subdivided into 
the categories 0–39, 40–59, and 60 years and older. Univariable and 
multivariable Cox proportional hazard analyses were performed, including all 
variables mentioned in Table 1 and donor type, which was included as a 
categorical variable (DBD, DCD, living). Backward elimination was chosen as the 
method of variable selection. Transplantation year was included to correct for 
time related changes in diagnostics, treatment options, and experience. Donor 
and recipient age were included as continuous variables. Initial 
immunosuppression was included as six binary variables consisting of any 
combination of immunosuppressants with or without: (i) CNI (tacrolimus, 
cyclosporine), (ii) induction therapy (rATG, IL2-blocker, OKT3),(iii) mTOR 
inhibitor (rapamycin, everolimus), (iv) MMF,(v) prednisone, and (vi) other 
(azathioprine, trial medication). The proportional hazards assumption was tested 
for donor type with a log-minus-log plot. The analyses were performed using 
Statistical Package for the Social Sciences (SPSS) PASW 17.0.2 for Windows 
(IBM Corporation, Armonk, NY, USA). P-values < 0.05 were considered 
VLJQL¿FDQW
Table 1. Characteristics for deceased donor (DD) and living donor (LD) kidney recipients.
All N=1821 DD N=941 LD N=880 P
Recipient age (mean ± SD) 47.8±14.2 49.4±13.5 46.1±14.8 <0.001a
Male recipients (%) 62 61 63 nsb
Maximum PRA (median; %>5%) 5; 44 9; 58 4; 28 <0.001a
Current PRA (median; %>5%) 0; 17 0; 24 0; 10 <0.001a
Transplant year (median) 2002 1999 2005 <0.001a
Previous transplants (%) <0.001b
   0 81 76 86
   1 15 18 11
   2+ 5 6 3
Pretreatment (%) <0.001b
   Hemodialysis 55 70 39
   Peritoneal dialysis 29 27 31
   Pre/Trans 16 3 30
HLA mismatches (mean ± SD) 2.8±1.6 2.6±1.5 3.0±1.7 <0.001a
DR mismatches (mean ± SD) 0.8±0.7 0.7±0.7 1.0±0.7 <0.001a
Donor age (mean ± SD) 47.6±14.7 45.7±16.1 49.6±12.7 <0.001a
Male donors (%) 50 55 44 <0.001b
Delayed graft function (%) 24 42 5 <0.001b
CNI as initial immunosuppression (%) 95 94 95 nsb
Induction therapy (%) 13 14 11 nsb
mTOR inhibitor (%) 6 3 10 <0.001b
MMF (%) 66 57 75 <0.001b
Prednisone (%) 94 93 96 0.005b
Other immunosuppression (%) 8 5 10 <0.001b
a ANOVA to test significance between DD and LD.
b Chi-square to test significance between DD and LD.
CNI, calcineurin inhibitor; MMF, mycofenolate mofetil; PRA, panel reactive antibodies; SD, standard 
deviation.
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Results
A total of 941 patients received a deceased donor kidney and 880 a living donor 
kidney. There were 94 donors after cardiac death (Maastricht category III n = 
91, Maastricht category II n = 3). In Table 1 transplantation characteristics are 
shown. There were missing values in 15 cases (0.8%). Recipients of a living 
GRQRUNLGQH\ZHUHVLJQL¿FDQWO\\RXQJHUWKDQUHFLSLHQWVRIDGHFHDVHGGRQRU
NLGQH\ZKHUHDVOLYLQJGRQRUVZHUHVLJQL¿FDQWO\ROGHUWKDQGHFHDVHGGRQRUV
The distribution of donor and recipient age was also different between the living 
and deceased donor populations (Figure 1a and 1b). Very young donors were 
present in the deceased donor population but absent in the living donor 
population. Age in the living donor population was shifted to the right (older 
donors) in comparison to the deceased donor population. In addition to recipient 
DQGGRQRUDJHWKHUHZHUHVLJQL¿FDQWGLIIHUHQFHVEHWZHHQWKHOLYLQJDQG
deceased donor populations (Table 1).
Figure 1. (a) Donor and (b) recipient age distributions in deceased (DD) versus living donor (LD) 
kidney transplantation.
There were 507 graft failures; 341 in recipients of deceased donor kidneys and 
166 in recipients of living donor kidneys. In Table 2 numbers and causes of graft 
failuUHDUHVKRZQIRUDJHFDWHJRULHVDQGGRQRUW\SHV7KHUHZDVQRVLJQL¿FDQW
difference between the age groups regarding numbers of graft failures (Table 
2a). However, in the eldest donor age group never functioning grafts occurred 
VLJQL¿FDQWO\PRUHRIWHQDQGleast in the youngest donor age group. When 
comparing recipients of kidneys from DBD, DCD, and living donors, there was a 
VLJQL¿FDQWGLIIHUHQFHLQWKHQXPEHURIJUDIWIDLOXUHV7DEOHE/LYLQJGRQRU
kidneys failed less often than DBD kidneys. The incidences of chronic rejection 
and recurrence of primary renal disease was also different between the 
populations.
Table 2. Numbers and causes of graft failure per (a) donor age category and (b) donor type.
Donor age (years)
(a)  40-59  Pa
N 492 926 402
Numbers of failures 134 242 130 0.064
Failure causes (n)
   Chronic rejection 68 121 58 0.534
   Acute rejection 18 27 14 0.753
   Technical problems 17 33 10 0.226
   Recurrence primary renal disease 11 15 7 0.624
   Never functioning graft 3 23 27 <0.001
   Other 17 23 14 0.632
Donor type
(b) DBD DCD Living Pa
N 847 94 880
Numbers of failures 317 24 166 <0.001
Failure causes (n)
   Chronic rejection 149 5 93 0.003
   Acute rejection 41 1 17 0.344
   Technical problems 46 3 11 0.039
   Recurrence primary renal disease 11 2 20 0.001
   Never functioning graft 40 11 3 <0.001
   Other 30 2 22 0.409
a Chi-square to test significance between all three groups.
DBD, donation after brain death; DCD, donation after cardiac death.
In Kaplan–Meier analysisJUDIWVXUYLYDOFHQVRUHGIRUGHDWKZDVVLJQL¿FDQWO\
different in the three donor age categories in the deceased donor population (P
< 0.001), but not in the living donor population (P = 0.08) (Figure 2). Graft 
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   Recurrence primary renal disease 11 2 20 0.001
   Never functioning graft 40 11 3 <0.001
   Other 30 2 22 0.409
a Chi-square to test significance between all three groups.
DBD, donation after brain death; DCD, donation after cardiac death.
In Kaplan–Meier analysisJUDIWVXUYLYDOFHQVRUHGIRUGHDWKZDVVLJQL¿FDQWO\
different in the three donor age categories in the deceased donor population (P
< 0.001), but not in the living donor population (P = 0.08) (Figure 2). Graft 
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survival censored for death after living donor transplantation was better than 
after deceased donor transplantation for all donor age categories, P = 0.008 for 
0–39 years, P < 0.001 for 40–59 years, and P < 0.001 for 60 years and older, 
respectively.
 
Figure 2. Kaplan-Meier curve comparing death-censored graft survival after (a) deceased donor 
transplantation (P < 0.001) and (b) living donor transplantation (ns) for three donor age categories.
7KHLQÀXHQFHRIDOOYDULDEOHVVKRZQLQ7DEOHDQGWKHLQÀXHQFHRIGRQRUW\SH
on graft failure risk were studied in the Cox proportional hazards analysis. In 
univariable Cox analysis, recipient age, maximum panel reactive antibodies 
(PRA), current PRA, transplant year, previous transplants, pretreatment, total 
number of HLA mismatches, donor age, donor type, delayed graft function, and 
CNI treatment, induction therapy, MMF treatment, and prednisone as initial 
LPPXQRVXSSUHVVLRQKDGDVLJQL¿FDQWLQÀXHQFHRQWhe risk of graft failure, 
FHQVRUHGIRUGHDWK7KHLQÀXHQFHRIGRQRUDJHZDVQRWOLQHDUEXWH[SRQHQWLDO
GDWDQRWVKRZQ7KHRWKHUYDULDEOHVGHVFULEHGLQ7DEOHGLGQRWVLJQL¿FDQWO\
LQÀXHQFHWKLVULVN,QWKH¿QDOPXOWLYDULDEOH&R[PRGHODQXPEHURIIDFtors 
ZHUHIRXQGWRKDYHDVLJQL¿FDQWLQÀXHQFHRQWKHUHODWLYHULVN55RU([S%RI
graft failure, censored for death (Table 3a). All variables not present in Table 3a 
KDGEHHQH[FOXGHGYLDEDFNZDUGHOLPLQDWLRQLQSUHYLRXVUXQV7KHLQÀXHQFHRI
DCD was noWVLJQL¿FDQWO\GLIIHUHQWIURP'%'ZKHUHDVWKHULVNRIOLYLQJGRQDWLRQ
ZDVVLJQL¿FDQWO\ORZHUWKDQWKDWRI'%''RQRUDJHKDGDTXDGUDWLFLQÀXHQFHRQ
the risk of graft failure (Figure 3a). Between the ages of 20 and 40 years graft 
failure risk hardly changed (relative risk, respectively, 0.60 and 0.63 in 
comparison to 20-year-old deceased donor). However, between living donor 
ages of 40 and 60 years the relative risk of graft failure increased from 0.63 to 
1.01 in comparison to 20-year-old deceased donor. The interaction terms 
between donor type and either HLA mismatches, current PRA, maximum PRA, 
UHFLSLHQWDJHDQGGRQRUDJHZHUHQRWVLJQL¿FDQW7KHUHZDVQHLWKHULQWHUDFWLRQ
between donor and recipient age nor between donor age and transplant year.
Table 3b shows the results of the multivariable Cox analysis with death and/or 
graft failure as the event studied (univariable results not shown). As the square 
RIGRQRUDJHZDVDOVRVLJQL¿FDQWWKHLQÀXHQFHRIGRQRUDJHIROORZHGD--shaped 
curve (Figure 3b).
Table 3c shows the results of the multivariable Cox analysis with patient death 
as the event studied (univariable results not shown). The proportional hazards 
assumption was not violated.
Figure 3. Calculated relative risk (RR) of (a) graft failure censored for death and (b) uncensored graft 
failure with increasing donor age for donation after brain death (DBD) and living donor transplantation. 
The reference value is a 20 year old DBD donor. The dotted lines demonstrate the comparison of the 
risk between recipients of a living donor kidney and a DBD kidney. 
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survival censored for death after living donor transplantation was better than 
after deceased donor transplantation for all donor age categories, P = 0.008 for 
0–39 years, P < 0.001 for 40–59 years, and P < 0.001 for 60 years and older, 
respectively.
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the risk of graft failure (Figure 3a). Between the ages of 20 and 40 years graft 
failure risk hardly changed (relative risk, respectively, 0.60 and 0.63 in 
comparison to 20-year-old deceased donor). However, between living donor 
ages of 40 and 60 years the relative risk of graft failure increased from 0.63 to 
1.01 in comparison to 20-year-old deceased donor. The interaction terms 
between donor type and either HLA mismatches, current PRA, maximum PRA, 
UHFLSLHQWDJHDQGGRQRUDJHZHUHQRWVLJQL¿FDQW7KHUHZDVQHLWKHULQWHUDFWLRQ
between donor and recipient age nor between donor age and transplant year.
Table 3b shows the results of the multivariable Cox analysis with death and/or 
graft failure as the event studied (univariable results not shown). As the square 
RIGRQRUDJHZDVDOVRVLJQL¿FDQWWKHLQÀXHQFHRIGRQRUDJHIROORZHGD--shaped 
curve (Figure 3b).
Table 3c shows the results of the multivariable Cox analysis with patient death 
as the event studied (univariable results not shown). The proportional hazards 
assumption was not violated.
Figure 3. Calculated relative risk (RR) of (a) graft failure censored for death and (b) uncensored graft 
failure with increasing donor age for donation after brain death (DBD) and living donor transplantation. 
The reference value is a 20 year old DBD donor. The dotted lines demonstrate the comparison of the 
risk between recipients of a living donor kidney and a DBD kidney. 
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Table 3. Results of the multivariable Cox proportional hazards analysis. Failure event is (a) censored 
for death, (b) uncensored, and (c) censored for graft failure.
Variable (reference category) Exp(B) 95% CI P
(a) N=1821, 502 events
   Recipient age (per year) 0.984 0.977-0.990 <0.001
   Maximum PRA (per %) 0.995 0.990-1.000 0.045
   Current PRA (per %) 1.015 1.008-1.021 <0.001
   Transplant year (per year) 0.974 0.954-0.993 0.008
   HLA mismatches (per HLA mismatch) 1.107 1.040-1.178 0.001
   Donor age (per year) 0.970 0.943-0.998 0.033
   Donor age2 (per year2) 1.001 1.000-1.001 0.001
   Donor gender (female) 0.835 0.699-0.998 0.047
   Donor type (DBD) <0.001
         DCD 1.056 0.669-1.667 0.816
         Living 0.603 0.478-0.760 <0.001
   Delayed graft function (no) 2.006 1.629-2.471 <0.001
   CNI as initial immunosuppression (no) 0.236 0.174-0.321 <0.001
   Prednisone as initial immunosuppression (no) 0.710 0.514-0.980 0.037
(b) N=1821, 832 events
   Recipient age (per year) 1.013 1.007-1.019 <0.001
   Maximum PRA (per %) 0.996 0.992-1.000 0.028
   Current PRA (per %) 1.011 1.006-1.016 <0.001
   Transplant year (per year) 0.978 0.958-0.999 0.037
   HLA mismatches (per HLA mismatch) 1.057 1.009-1.108 0.021
   Donor age (per year) 0.977 0.957-0.998 0.033
   Donor age2 (per year2) 1.000 1.000-1.001 0.003
   Donor type (DBD) <0.001
         DCD 1.200 0.844-1.706 0.309
         Living 0.651 0.543-0.781 <0.001
   Delayed graft function (no) 1.770 1.499-2.091 <0.001
   CNI as initial immunosuppression (no) 0.282 0.214-0.371 <0.001
   MMF as initial immunosuppression (no) 0.812 0.662-0.997 0.047
   Prednisone as initial immunosuppression (no) 0.630 0.486-0.817 <0.001
(c) N=1821, 330 events
   Recipient age (per year) 1.071 1.060-1.082 <0.001
   Transplant year (per year) 0.941 0.918-0.965 <0.001
   Donor type (DBD) 0.012
         DCD 1.777 1.027-3.075 0.040
         Living 0.783 0.591-1.036 0.087
   Delayed graft function (no) 1.341 1.022-1.759 0.034
   CNI as initial immunosuppression (no) 0.366 0.208-0.645 <0.001
   Prednisone as initial immunosuppression (no) 0.609 0.406-0.915 0.017
CNI, calcineurin inhibitor; DBD, donation after brain death; DCD, donation after cardiac death; MMF, 
mycofenolate mofetil; PRA, panel reactive antibodies.
Discussion
The present study shows that in Kaplan–Meier analysis living donor age appears 
QRWWRKDYHDVLJQL¿FDQWLQÀXHQFHRQJUDIWVXUYLYDOFHQVRUHGIRUGHDWK+RZHYHU
WKLVODFNRILQÀXHQFHRIGRQRUDJHLQ.DSODQ–Meier analysis could be caused by 
WKHIDFWWKDWWKLVDQDO\VLVGRHVQRWWDNHWKHLQÀXHQFHRIRWKHUYDULDEOHVLQWR
account. Moreover, the continuous variable age had to be distributed into 
arbitrary categories to be suitable for Kaplan–Meier analysis. As shown in Figure 
1 age distribution in the deceased and living donor populations is not 
comparable which means that the results of these separate Kaplan–Meier 
analyses cannot be compared.
,Q&R[DQDO\VLVGRQRUDJHWXUQVRXWWRKDYHDVLJQL¿FDQWLQÀXHQFHRQWKHULVNRI
graft failure censored for death and the risk of uncensored graft failure 
independent of donor type. This means tKDWGRQRUDJHLQÀXHQFHVJUDIWVXUYLYDO
in both living and deceased donor transplantation. The risk of graft failure in 
recipients of a kidney transplantation increases with increasing donor age 
according to a quadratic equation. However, the risk in deceased donor 
transplantation is almost twice that of living donor transplantation so that the 
graft failure risk for a recipient of a 60-year-old living donor kidney is the same 
as that of a recipient of a 20-year-old deceased donor kidney. As there is no 
interaction between donor and recipient age regarding graft failure risk it is not 
necessary to take age difference between donor and recipient into consideration.
,QWKHOLWHUDWXUHWKHLQÀXHQFHRILQFUHDVLQJGRQRUDJHRQWKHULVNRIJUDIWIDLOXUH
KDVEHHQVWXGLHGLQGLIIHUHQWZD\V,QVRPHVWXGLHVWKHLQÀXHQFHRIDJHZDV
studied in Kaplan–Meier analysis where age had to be categorized (16, 17). In 
other studies age was studied in a Cox analysis, either as a categorical (3, 6, 9–
11, 13, 14, 18) or as a continuous covariate (7, 8, 11). Subdivision in categories 
LVDUELWUDU\DQGQRWDOOVWXGLHVXVHWKHVDPHGH¿QLWLRQVIRUµHOGHUO\¶DQGµROG¶2Q
top of that, most studies included donor age as a dichotomous variable: old 
versus young (3, 9–11, 13, 16–18). As aging is a continuous process, its effect 
PRVWSUREDEO\IROORZVDFRQWLQXRXVOLQH&DWHJRUL]DWLRQSUREDEO\GRHVQRWUHÀHFW
WKHQDWXUDODJLQJSURFHVVDQGWKXVWKHLQÀXence on graft failure risk.
In deceased donor transplantation, donor age is known to have a negative effect 
on overall graft survival (6) and death-censored graft survival (7). In 1999, we 
GHVFULEHGWKHLQÀXHQFHRIGHFHDVHGGRQRUDJHDVDFRQWLQXRXVYDULDEle on 
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Table 3. Results of the multivariable Cox proportional hazards analysis. Failure event is (a) censored 
for death, (b) uncensored, and (c) censored for graft failure.
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   Current PRA (per %) 1.015 1.008-1.021 <0.001
   Transplant year (per year) 0.974 0.954-0.993 0.008
   HLA mismatches (per HLA mismatch) 1.107 1.040-1.178 0.001
   Donor age (per year) 0.970 0.943-0.998 0.033
   Donor age2 (per year2) 1.001 1.000-1.001 0.001
   Donor gender (female) 0.835 0.699-0.998 0.047
   Donor type (DBD) <0.001
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         Living 0.603 0.478-0.760 <0.001
   Delayed graft function (no) 2.006 1.629-2.471 <0.001
   CNI as initial immunosuppression (no) 0.236 0.174-0.321 <0.001
   Prednisone as initial immunosuppression (no) 0.710 0.514-0.980 0.037
(b) N=1821, 832 events
   Recipient age (per year) 1.013 1.007-1.019 <0.001
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   Donor age2 (per year2) 1.000 1.000-1.001 0.003
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         DCD 1.200 0.844-1.706 0.309
         Living 0.651 0.543-0.781 <0.001
   Delayed graft function (no) 1.770 1.499-2.091 <0.001
   CNI as initial immunosuppression (no) 0.282 0.214-0.371 <0.001
   MMF as initial immunosuppression (no) 0.812 0.662-0.997 0.047
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   Prednisone as initial immunosuppression (no) 0.609 0.406-0.915 0.017
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overall and death-censored graft survival in multivariable Cox analysis as a J-
shaped curve (8). The risk of graft failure was highest for recipients of older and 
extremely young donor kidneys. The risk was lowest for the age categories 
between 20 and 40 years.
7KHUHDUHIHZVWXGLHVWKDWGHVFULEHWKHLQÀXHQFHRIGRQRUDJHRQJUDIWVXUYLYDO
in populations that received either living or deceased donor kidney 
transplantation. In all these studies, donor age was included as a categorical 
variable. In Cox proportional hazards analysis with age as a categorical variable, 
0DWDVDQGFROOHDJXHVIRXQGDQXQIDYRUDEOHHIIHFWRIGRQRUDJHRQ
overall and death-censored graft survival in the population with deceased donor 
transplantation, but no effect in living donor transplantation population. Kerr and 
colleagues (10) reported the same results with donors aged 55 years or older. 
However, both groups performed separate analyses for deceased and living 
donor transplantation populations. In both studies, the cut-off age for elderly 
donors was relatively low as was the number of elderly donors included. As we 
showed, probably as a result of selection, living and deceased donor recipient 
populations are not comparable (Table 1). This means that the results of 
separate analyses in two different populations cannot be compared. Although 
the results of both analyses are different it does not mean that the results of 
both programs are different.
,Q8126GDWDEDVH*LOOHWDOVWXGLHGWKHLQÀXHQFHRIGRQRUDJHRQJUDIWVXUYLYDO
RIUHFLSLHQWVRIOLYLQJRUGHFHDVHGGRQRUNLGQH\V$JHZDVGH¿QHGDVD
categorical variable with four elderly groups above 55 years of age (9.7% of the 
population) compared with one young population below 55 years (90.3%). An 
increasing risk of graft failure was found with increasing age independent of 
GRQRUW\SH$OWKRXJKWKHLQÀXHQFHRI\RXQJHUGRQRUDJHFDWHJRULHVZDVQRW
separately analyzed in this study, results for the elderly population showed the 
same trend we found in our study. In another study, Gill et al. performed a 
multivariable analysis restricted to elderly recipients aged 60 years or older. 
They found superior graft survival results with older (>55) living donor kidneys 
compared to extended criteria deceased donor kidneys, but results were inferior 
to results from young living donor kidneys (3). Young et al. found no difference 
for (death-censored) graft loss between older living donor transplantation and 
deceased SCD in adult recipient transplantation (11).
In living donor transplantation, donor age analyzed in multivariable Cox 
SURSRUWLRQDOKD]DUGVDQDO\VLVDVDFRQWLQXRXVYDULDEOHGLGQRWVKRZDVLJQL¿FDQW
LQÀXHQFHRQJUDIWORVV+RZHYHULQWKLVVWXGy only 73 (5.8%) elderly 
donors aged 60 years or older were included. Dols et al. (12) studied donor age 
DVDGLFKRWRPRXV\HDUVYV\HDUVYDULDEOH,QPXOWLYDULDEOHDQDO\VLV
they found no difference in death-censored graft survival between recipient 
populations transplanted with an older living donor kidney and a young living 
donor kidney. In a population of living donor kidney recipients Toma and 
FROOHDJXHVVWXGLHGWKHLQÀXHQFHRIOLYLQJGRQRUDJHDVDWLPH-dependent 
variable. They found thaWOLYLQJGRQRUDJHKLJK\HDUVYVORZ\HDUV
was the most important risk factor for long-term overall graft failure. A meta-
analysis on the impact of transplantation of kidneys from extended criteria living 
donors on transplantation outcome revealed that recipients of kidneys from 
younger living donors had better outcomes than kidney recipients from older 
OLYLQJGRQRUV(OGHUO\GRQRUDJHZDVGH¿QHGDVDERYH\HDUVRIDJH
The meta-DQDO\VLVDOVRVKRZHGWKDWWKHQHJDWLYHLQÀXHQFHRILQFUHDVLQJdonor 
DJHDSSHDUHGWRGLPLQLVKLQWLPH7KLVLVLQOLQHZLWKRXU¿QGLQJVGXULQJWKH
period 1983–1997 where transplant results improved over time (8). The current 
VWXG\FRQ¿UPVWKLVHIIHFWRIWUDQVSODQW\HDURQWKHJUDIWIDLOXUHULVN$SUREDEOH
explanation is growing experience, improved medical care for concomitant 
disease, and improvements in diagnostics.
Our study also shows that initial use of CNI and of prednisone is associated with 
a decreased graft failure and patient death risk, whereas other 
imPXQRVXSSUHVVDQWVKDYHQRVLJQL¿FDQWLQÀXHQFH
In the present study we showed that in our population, a kidney from any living 
donor below age 60 has better graft survival than a 20-year-old deceased donor 
kidney. Between the ages of 20 and 40 years living donor graft failure risk 
hardly changes whereas over the age of 40 the relative risk of graft failure 
increases. This means that awaiting a deceased donor kidney is not an option 
when a living donor is available. Older living donor kidney transplantation 
certainly is better than remaining on the waiting list (19).
In conclusion, elderly living donors should not be rejected on the basis of their 
age only. Although there is an advantage for patients receiving a young living 
donor kidney (below age 40), even transplantation with an older living donor 
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overall and death-censored graft survival in multivariable Cox analysis as a J-
shaped curve (8). The risk of graft failure was highest for recipients of older and 
extremely young donor kidneys. The risk was lowest for the age categories 
between 20 and 40 years.
7KHUHDUHIHZVWXGLHVWKDWGHVFULEHWKHLQÀXHQFHRIGRQRUDJHRQJUDIWVXUYLYDO
in populations that received either living or deceased donor kidney 
transplantation. In all these studies, donor age was included as a categorical 
variable. In Cox proportional hazards analysis with age as a categorical variable, 
0DWDVDQGFROOHDJXHVIRXQGDQXQIDYRUDEOHHIIHFWRIGRQRUDJHRQ
overall and death-censored graft survival in the population with deceased donor 
transplantation, but no effect in living donor transplantation population. Kerr and 
colleagues (10) reported the same results with donors aged 55 years or older. 
However, both groups performed separate analyses for deceased and living 
donor transplantation populations. In both studies, the cut-off age for elderly 
donors was relatively low as was the number of elderly donors included. As we 
showed, probably as a result of selection, living and deceased donor recipient 
populations are not comparable (Table 1). This means that the results of 
separate analyses in two different populations cannot be compared. Although 
the results of both analyses are different it does not mean that the results of 
both programs are different.
,Q8126GDWDEDVH*LOOHWDOVWXGLHGWKHLQÀXHQFHRIGRQRUDJHRQJUDIWVXUYLYDO
RIUHFLSLHQWVRIOLYLQJRUGHFHDVHGGRQRUNLGQH\V$JHZDVGH¿QHGDVD
categorical variable with four elderly groups above 55 years of age (9.7% of the 
population) compared with one young population below 55 years (90.3%). An 
increasing risk of graft failure was found with increasing age independent of 
GRQRUW\SH$OWKRXJKWKHLQÀXHQFHRI\RXQJHUGRQRUDJHFDWHJRULHVZDVQRW
separately analyzed in this study, results for the elderly population showed the 
same trend we found in our study. In another study, Gill et al. performed a 
multivariable analysis restricted to elderly recipients aged 60 years or older. 
They found superior graft survival results with older (>55) living donor kidneys 
compared to extended criteria deceased donor kidneys, but results were inferior 
to results from young living donor kidneys (3). Young et al. found no difference 
for (death-censored) graft loss between older living donor transplantation and 
deceased SCD in adult recipient transplantation (11).
In living donor transplantation, donor age analyzed in multivariable Cox 
SURSRUWLRQDOKD]DUGVDQDO\VLVDVDFRQWLQXRXVYDULDEOHGLGQRWVKRZDVLJQL¿FDQW
LQÀXHQFHRQJUDIWORVV+RZHYHULQWKLVVWXGy only 73 (5.8%) elderly 
donors aged 60 years or older were included. Dols et al. (12) studied donor age 
DVDGLFKRWRPRXV\HDUVYV\HDUVYDULDEOH,QPXOWLYDULDEOHDQDO\VLV
they found no difference in death-censored graft survival between recipient 
populations transplanted with an older living donor kidney and a young living 
donor kidney. In a population of living donor kidney recipients Toma and 
FROOHDJXHVVWXGLHGWKHLQÀXHQFHRIOLYLQJGRQRUDJHDVDWLPH-dependent 
variable. They found thaWOLYLQJGRQRUDJHKLJK\HDUVYVORZ\HDUV
was the most important risk factor for long-term overall graft failure. A meta-
analysis on the impact of transplantation of kidneys from extended criteria living 
donors on transplantation outcome revealed that recipients of kidneys from 
younger living donors had better outcomes than kidney recipients from older 
OLYLQJGRQRUV(OGHUO\GRQRUDJHZDVGH¿QHGDVDERYH\HDUVRIDJH
The meta-DQDO\VLVDOVRVKRZHGWKDWWKHQHJDWLYHLQÀXHQFHRILQFUHDVLQJdonor 
DJHDSSHDUHGWRGLPLQLVKLQWLPH7KLVLVLQOLQHZLWKRXU¿QGLQJVGXULQJWKH
period 1983–1997 where transplant results improved over time (8). The current 
VWXG\FRQ¿UPVWKLVHIIHFWRIWUDQVSODQW\HDURQWKHJUDIWIDLOXUHULVN$SUREDEOH
explanation is growing experience, improved medical care for concomitant 
disease, and improvements in diagnostics.
Our study also shows that initial use of CNI and of prednisone is associated with 
a decreased graft failure and patient death risk, whereas other 
imPXQRVXSSUHVVDQWVKDYHQRVLJQL¿FDQWLQÀXHQFH
In the present study we showed that in our population, a kidney from any living 
donor below age 60 has better graft survival than a 20-year-old deceased donor 
kidney. Between the ages of 20 and 40 years living donor graft failure risk 
hardly changes whereas over the age of 40 the relative risk of graft failure 
increases. This means that awaiting a deceased donor kidney is not an option 
when a living donor is available. Older living donor kidney transplantation 
certainly is better than remaining on the waiting list (19).
In conclusion, elderly living donors should not be rejected on the basis of their 
age only. Although there is an advantage for patients receiving a young living 
donor kidney (below age 40), even transplantation with an older living donor 
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kidney provides comparable or better graft survival outcomes than with a 
deceased donor kidney.
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Abstract
Background. Human leukocyte antigen (HLA) mismatches are known to 
influence graft survival in deceased donor kidney transplantation. We studied 
the effect of HLA mismatches in a population of recipients of deceased donor or 
living donor kidney transplantations.
Methods. All 1998 transplantations performed in our center between 1990 and 
2011 were included in this retrospective cohort study. Four different 
multivariable Cox proportional hazard analyses were performed with HLA 
mismatches as continuous variable, as categorical variable (total number of HLA 
mismatches), as binary variable (zero vs. nonzero HLA mismatches), and HLA-A, 
-B, and -DR mismatches included separately.
Results. Nine hundred ninety-one patients received a deceased donor kidney 
and 1007 received a living donor kidney. In multivariable Cox analysis, HLA 
mismatches, recipient age, current panel-reactive antibodies, transplant year, 
donor age, calcineurin inhibitor treatment, and donor type were found to have a 
significant and independent influence on the risk of graft failure, censored for 
death. Variables representing the total number of HLA-A, -B, and -DR 
mismatches had a significant and comparable influence in all analyses.
Conclusions. The influence of HLA mismatches on death-censored graft survival 
holds true for both deceased and living donor kidney transplantation. However, 
the relative risk of death-censored graft failure of a 2-2-2 mismatched living 
donor kidney is comparable with that of a 0-0-0 mismatched deceased donor 
kidney.
Introduction
Since the very start in 1954, there has been a substantial improvement in both 
graft and patient survival among those undergoing renal transplantation. In 
deceased donor kidney transplantation, the importance of human leukocyte 
antigen (HLA) matching has been controversial. In the 1980s, the influence of 
HLA matching was found to be very important for graft survival (1, 2). In the 
1990s, the importance was put into perspective, as progressive increases in the 
number of mismatches above zero appeared to have only a relatively small 
effect on survival compared to the large benefits afforded by the use of kidneys 
with no mismatches (3). When the effect of HLA-A, -B, and -DR mismatches on 
the risk of graft failure was studied separately, HLA-DR was the only HLA 
variable found to be important (4). In the beginning of the 21st century, the 
positive effect of HLA matching in deceased donor kidney transplantation was 
confirmed with HLA mismatches as a binary variable: completely HLA-A, -B, and 
-DR matched versus not completely matched (5). The significance of HLA 
matching appeared to diminish in time as immunosuppressants improved (6). 
However, these results were not confirmed in another study (7).
In allocation algorithms for exchange organizations, HLA matching is an 
important factor. However, the number of studies on the influence of HLA 
matching in living donor kidney transplantation is low, except for those 
comparing HLA identical siblings with parents and deceased donors (8). We 
studied the influence of HLA matching on living donor kidney transplantation 
results: How does it compare to the influence of HLA on deceased donor kidney 
transplantation results? What is the influence of different immunosuppressive 
strategies? What is the influence of other improvements in medical diagnostics 
and therapies over time?
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the relative risk of death-censored graft failure of a 2-2-2 mismatched living 
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antigen (HLA) matching has been controversial. In the 1980s, the influence of 
HLA matching was found to be very important for graft survival (1, 2). In the 
1990s, the importance was put into perspective, as progressive increases in the 
number of mismatches above zero appeared to have only a relatively small 
effect on survival compared to the large benefits afforded by the use of kidneys 
with no mismatches (3). When the effect of HLA-A, -B, and -DR mismatches on 
the risk of graft failure was studied separately, HLA-DR was the only HLA 
variable found to be important (4). In the beginning of the 21st century, the 
positive effect of HLA matching in deceased donor kidney transplantation was 
confirmed with HLA mismatches as a binary variable: completely HLA-A, -B, and 
-DR matched versus not completely matched (5). The significance of HLA 
matching appeared to diminish in time as immunosuppressants improved (6). 
However, these results were not confirmed in another study (7).
In allocation algorithms for exchange organizations, HLA matching is an 
important factor. However, the number of studies on the influence of HLA 
matching in living donor kidney transplantation is low, except for those 
comparing HLA identical siblings with parents and deceased donors (8). We 
studied the influence of HLA matching on living donor kidney transplantation 
results: How does it compare to the influence of HLA on deceased donor kidney 
transplantation results? What is the influence of different immunosuppressive 
strategies? What is the influence of other improvements in medical diagnostics 
and therapies over time?
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Materials and methods
Study sample
All 1998 kidney transplantations performed in our center between January 1, 
1990 and December 31, 2010 were analyzed. Standard immunosuppressive 
regimen was cyclosporine combined with prednisone in 1990 but was changed to 
prednisone, cyclosporine, and mycophenolate mofetil (MMF) in 1996, whereas 
tacrolimus was introduced in 1998 as a substitute for cyclosporine. Patients were 
initially treated with triple therapy, but prednisone was tapered and discontinued 
at 4 months after transplantation.
The screening procedure of potential living kidney donors has been described 
thoroughly (9). All transplantations were performed after a negative 
complement-dependent cytotoxicity crossmatch with historical and current sera 
(10). From 1990 to 2000, HLA-A, -B, and -DR typing was performed 
serologically on split level at the National Reference Laboratory. In 2000, 
molecular HLA-A, -B and -DR typing was introduced using sequence-specific 
oligonucleotides. In recipients and in living donors, HLA typing was performed 
twice in different blood samples. For 109 transplantations, donor HLA typing was 
not performed in the reference laboratory. In those cases, local donor and/or 
recipient HLA typing was used. HLA mismatches were calculated on the serologic 
split level, both in deceased and living donor kidney transplantation, except for 
A28, B14, and DR3 (n=218) in accordance with Eurotransplant practice. In 53 
other cases, only broad antigens were available. These cases were excluded 
from the analyses. In living donor transplantation, a high number of HLA 
mismatches are not an exclusion criterion when the crossmatch is negative. 
However, in deceased donor transplantation, HLA matching is an allocation 
criterion in Eurotransplant, aiming at a low number of mismatches.
Statistical analysis
Graft failure censored for death was studied in this retrospective cohort study. 
Observation was until August 2012 or until graft failure, death, or lost to follow-
up. We performed two-tailed independent-samples t test, chi-square test, and 
Mann-Whitney U test to analyze the difference between living and deceased 
donor kidney transplantation populations. Kaplan-Meier analysis was performed 
with HLA mismatches and donor type (deceased vs. living). Univariable and 
multivariable Cox proportional hazard analyses were performed, including all 
variables mentioned in Table 1 and donor type. In Results, we only describe the 
results of multivariable analysis in which backward elimination was used to 
exclude variables with nonsignificant influence. Four models were tested with 
HLA mismatches included in four different ways: as a continuous covariate, as a 
categorical covariate with seven categories, as a binary covariate with zero 
versus nonzero HLA mismatches, and as three categorical covariates; HLA-A, -B, 
and -DR mismatches. We used the Akaike information criterion to compare the 
goodness-of-fit between the four models with the four different HLA definitions 
(11). The proportional hazards assumption was tested for donor type and HLA 
mismatches with log-minus-log plots. All analyses were performed using 
Statistical Package for the Social Sciences (SPSS) 20.0.0.1 (IBM, Armonk, NY). 
P<0.05 was considered significant. Cases with missing values were excluded 
from the analyses.
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(10). From 1990 to 2000, HLA-A, -B, and -DR typing was performed 
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recipient HLA typing was used. HLA mismatches were calculated on the serologic 
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A28, B14, and DR3 (n=218) in accordance with Eurotransplant practice. In 53 
other cases, only broad antigens were available. These cases were excluded 
from the analyses. In living donor transplantation, a high number of HLA 
mismatches are not an exclusion criterion when the crossmatch is negative. 
However, in deceased donor transplantation, HLA matching is an allocation 
criterion in Eurotransplant, aiming at a low number of mismatches.
Statistical analysis
Graft failure censored for death was studied in this retrospective cohort study. 
Observation was until August 2012 or until graft failure, death, or lost to follow-
up. We performed two-tailed independent-samples t test, chi-square test, and 
Mann-Whitney U test to analyze the difference between living and deceased 
donor kidney transplantation populations. Kaplan-Meier analysis was performed 
with HLA mismatches and donor type (deceased vs. living). Univariable and 
multivariable Cox proportional hazard analyses were performed, including all 
variables mentioned in Table 1 and donor type. In Results, we only describe the 
results of multivariable analysis in which backward elimination was used to 
exclude variables with nonsignificant influence. Four models were tested with 
HLA mismatches included in four different ways: as a continuous covariate, as a 
categorical covariate with seven categories, as a binary covariate with zero 
versus nonzero HLA mismatches, and as three categorical covariates; HLA-A, -B, 
and -DR mismatches. We used the Akaike information criterion to compare the 
goodness-of-fit between the four models with the four different HLA definitions 
(11). The proportional hazards assumption was tested for donor type and HLA 
mismatches with log-minus-log plots. All analyses were performed using 
Statistical Package for the Social Sciences (SPSS) 20.0.0.1 (IBM, Armonk, NY). 
P<0.05 was considered significant. Cases with missing values were excluded 
from the analyses.
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Table 1. Transplantation characteristics for deceased donor (DD) and living donor (LD) kidney 
transplantations.
DD N=991 LD N=1007 P
Recipient age (years), mean (SD) 49.9 (13.6) 46.6 (14.9) <0.001a
Recipient gender (male), % 62 63 0.579b
Maximum PRA, median (%>5%) 8 (56) 4 (27) <0.001c
Current PRA, median (%>5%) 0 (23) 0 (10) <0.001c
Transplant year, median (IQR) 2000 (1995-2005) 2006 (2001-2008) <0.001c
Previous transplants, % <0.001b
   0 76 85
   1 18 12
   2+ 6 3
Pretreatment, % <0.001b
   Dialysis 97.1 69.1
   No pretreatment 2.5 28.3
   Transplantation 0.4 2.6
HLA mismatches, mean (SD) 2.7 (1.5) 3.0 (1.7) <0.001a
HLA mismatches, % <0.001b
   0 10 10
   1 11 7
   2 22 19
   3 30 28
   4 18 13
   5 7 16
   6 3 8
HLA zero mismatches, % 10 10 0.942b
HLA-A mismatches, % 0.153b
   0 31 28
   1 49 54
   2 19 19
HLA-B mismatches, % 0.003b
   0 22 18
   1 53 51
   2 25 32
HLA-DR mismatches, % <0.001b
   0 38 24
   1 50 53
   2 12 23
Donor age (years), mean (SD) 46.1 (16.2) 50.0 (12.9) <0.001a
Donor gender (male), % 54 43 <0.001b
CNI as initial immunosuppression, % 97 96 0.394b
Induction therapy, % 21 23 0.207b
mTOR inhibitor, % 3 9 <0.001b
MMF, % 60 77 <0.001b
Prednisone, % 97 97 0.750b
Other immunosuppression, % 5 10 <0.001b
a Independent-samples t test to test significance between DD and LD.
b Chi-square test to test significance between DD and LD.
c Mann-Whitney U test to test significance between DD and LD.
CNI, calcineurin inhibitor; IQR, interquartile range; MMF, mycofenolate mofetil; mTOR, mammalian 
target of rapamycin inhibitor; PRA, panel reactive antibodies; SD, standard deviation.
Results
Of 1998 transplant recipients, 991 patients received a deceased donor kidney 
and 1007 received a living donor kidney. Thirteen deceased donor kidney 
recipients and 14 living donor kidney recipients were lost to follow-up with a 
median (range) time after transplantation of 24 (0-160) and 33.5 (0-110) 
months, respectively. Observation of these patients was until they were lost to 
follow-up. Fifty-three cases were excluded from survival analyses because only 
broad antigens were available. There were missing values in 4 (0.2%) cases. 
Cox proportional hazards analyses were therefore performed with 1941 
transplantations. In Table 1, transplantation characteristics are shown. Mean 
HLA mismatches were significantly higher in the living donor transplantation 
population. A high number of HLA mismatches were more prevalent in living 
donor-recipient pairs (Figure 1).
Figure 1. HLA mismatch distribution in deceased and living donor kidney transplantation. The 
difference in total number of HLA-A, -B, and –DR mismatches between deceased and living donor 
transplantation was significant (P<0.001).
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transplantations.
DD N=991 LD N=1007 P
Recipient age (years), mean (SD) 49.9 (13.6) 46.6 (14.9) <0.001a
Recipient gender (male), % 62 63 0.579b
Maximum PRA, median (%>5%) 8 (56) 4 (27) <0.001c
Current PRA, median (%>5%) 0 (23) 0 (10) <0.001c
Transplant year, median (IQR) 2000 (1995-2005) 2006 (2001-2008) <0.001c
Previous transplants, % <0.001b
   0 76 85
   1 18 12
   2+ 6 3
Pretreatment, % <0.001b
   Dialysis 97.1 69.1
   No pretreatment 2.5 28.3
   Transplantation 0.4 2.6
HLA mismatches, mean (SD) 2.7 (1.5) 3.0 (1.7) <0.001a
HLA mismatches, % <0.001b
   0 10 10
   1 11 7
   2 22 19
   3 30 28
   4 18 13
   5 7 16
   6 3 8
HLA zero mismatches, % 10 10 0.942b
HLA-A mismatches, % 0.153b
   0 31 28
   1 49 54
   2 19 19
HLA-B mismatches, % 0.003b
   0 22 18
   1 53 51
   2 25 32
HLA-DR mismatches, % <0.001b
   0 38 24
   1 50 53
   2 12 23
Donor age (years), mean (SD) 46.1 (16.2) 50.0 (12.9) <0.001a
Donor gender (male), % 54 43 <0.001b
CNI as initial immunosuppression, % 97 96 0.394b
Induction therapy, % 21 23 0.207b
mTOR inhibitor, % 3 9 <0.001b
MMF, % 60 77 <0.001b
Prednisone, % 97 97 0.750b
Other immunosuppression, % 5 10 <0.001b
a Independent-samples t test to test significance between DD and LD.
b Chi-square test to test significance between DD and LD.
c Mann-Whitney U test to test significance between DD and LD.
CNI, calcineurin inhibitor; IQR, interquartile range; MMF, mycofenolate mofetil; mTOR, mammalian 
target of rapamycin inhibitor; PRA, panel reactive antibodies; SD, standard deviation.
Results
Of 1998 transplant recipients, 991 patients received a deceased donor kidney 
and 1007 received a living donor kidney. Thirteen deceased donor kidney 
recipients and 14 living donor kidney recipients were lost to follow-up with a 
median (range) time after transplantation of 24 (0-160) and 33.5 (0-110) 
months, respectively. Observation of these patients was until they were lost to 
follow-up. Fifty-three cases were excluded from survival analyses because only 
broad antigens were available. There were missing values in 4 (0.2%) cases. 
Cox proportional hazards analyses were therefore performed with 1941 
transplantations. In Table 1, transplantation characteristics are shown. Mean 
HLA mismatches were significantly higher in the living donor transplantation 
population. A high number of HLA mismatches were more prevalent in living 
donor-recipient pairs (Figure 1).
Figure 1. HLA mismatch distribution in deceased and living donor kidney transplantation. The 
difference in total number of HLA-A, -B, and –DR mismatches between deceased and living donor 
transplantation was significant (P<0.001).
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There was no difference between living and deceased donor transplantation 
populations in prevalence of zero versus nonzero HLA and HLA-A mismatches. 
Recipients of living donor kidneys had significantly higher numbers of HLA-B and 
-DR mismatches compared to recipients of deceased donor kidneys. Besides, 
there were significant differences between the living and deceased donor 
transplantation populations concerning recipient age, maximum and current 
panel-reactive antibodies (PRA), transplant year, previous transplants, 
pretreatment, donor age, donor gender, mammalian target of rapamycin 
inhibitor treatment, MMF treatment, and other immunosuppressive treatment 
(Table 1). There was no significant difference in recipient gender, calcineurin 
inhibitor (CNI) treatment, induction therapy, and prednisone treatment.
There were 510 graft failures; 335 in recipients of deceased donor kidneys and 
175 in recipients of living donor kidneys. In Kaplan-Meier analysis, the difference 
in graft survival, censored for death between HLA mismatch categories, was 
significant in deceased donor transplantation but not in living donor 
transplantation (Figure 2). We tested four multivariable Cox models. In three 
models, the influence of total number of HLA-A, -B, and -DR mismatches 
showed the same trend, whether included as a continuous, categorical, or binary 
variable (all P<0.001). In the model with HLA-A, -B, and -DR mismatches 
included as three categorical covariates, the influence of HLA-A mismatches was 
significant (P=0.001). The influence of HLA-B and -DR was not significant. 
Because the sum of HLA-A, -B, and -DR mismatches provides a better fit of the 
model, the total number of HLA mismatches was used in the final multivariable 
Cox model. According to the Akaike information criterion (11), the goodness-of-
fit of the model was best when total number of HLA mismatches was included as 
categorical variable, followed by total number of HLA mismatches as continuous 
variable, and eventually total number of HLA mismatches as binary variable. The 
number of degrees of freedom of HLA mismatches was 6 in the first model and 1 
in both other models. Recipient age, current PRA, transplant year, total number 
of HLA mismatches, donor age, CNI treatment, and donor type were found to 
have a significant influence on the risk of graft failure, censored for death (Table 
2). As shown before, donor age had a quadratic influence on the risk of graft 
failure (12). The influence of donor gender was not significant. The interaction 
terms between HLA mismatches and recipient age, transplant year, donor age, 
treatment with CNI, and donor type were not significant. There was no 
interaction between transplant year and donor type. The proportional hazards 
assumption was neither violated for HLA mismatches nor for donor type. Figure 
3 shows the results of two different models: one with total number of HLA 
mismatches as categorical variable (dots) and the other with total number of 
HLA mismatches as continuous variable (lines). In both models, the same 
variables were present in the final model. The combined influence of HLA 
mismatches and donor type is shown on the calculated relative risk of graft 
failure censored for death, corrected for the other variables in the final 
multivariable Cox model. The relative risk increases with increasing total number 
of HLA mismatches, so that the risk of a zero mismatched deceased donor 
kidney transplantation is comparable with that of a five or six mismatched living 
donor kidney transplantation.
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Figure 2. (a) Kaplan-Meier curve comparing death-censored graft survival after deceased donor kidney 
transplantation (P=0.017). The difference was significant between 0 and each of the following HLA 
mismatches: 2, 3, 4, 5, and 6. (b) Kaplan-Meier curve comparing death-censored graft survival after 
living donor kidney transplantation. The difference between HLA mismatches was not significant 
(P=0.232).
Number at risk
HLA mismatches
0 98 80 66 56 40 30 24 16
1 100 76 64 48 43 29 21 15
2 208 147 120 95 69 51 30 21
3 285 205 148 120 84 63 50 39
4 173 118 92 65 51 35 25 13
5 65 48 36 20 14 7 4 2
6 24 16 9 5 3 2 1 1
(a)
Number at risk
HLA mismatches
0 103 88 66 52 45 36 30 20
1 65 59 43 37 29 20 13 6
2 189 172 118 86 62 40 25 18
3 275 229 165 122 76 48 32 21
4 128 99 62 30 17 11 5 1
5 154 122 81 53 29 16 4 1
6 78 65 40 23 7 4 1 1
(b)
Table 2. Results of the multivariable Cox proportional hazards analysis with HLA mismatches analyzed
as (a) categorical and (b) continuous covariate. Event is graft failure censored for death.
N=1941, 510 events
Variable (reference) Exp(B) 95% CI P
(a) Categorical covariate
   Recipient age (per year) 0.982 0.975 - 0.989 <0.001
   Current PRA (per %) 1.010 1.006 - 1.014 <0.001
   Transplant year (per year) 0.974 0.956 - 0.992 0.005
   HLA mismatches (0) <0.001
      1 1.506 0.974 - 2.330 0.066
      2 1.871 1.288 - 2.719 0.001
      3 2.062 1.439 - 2.955 <0.001
      4 1.790 1.192 - 2.688 0.005
      5 2.117 1.344 - 3.335 0.001
      6 3.279 1.936 - 5.555 <0.001
   Donor age (per year) 0.982 0.954 - 1.011 0.212
   Donor age2 (per year2) 1.000 1.000 - 1.001 0.010
   Donor gender (male) 1.150 0.964 - 1.372 0.120
   CNI as initial immunosuppression (no) 0.298 0.211 - 0.420 <0.001
   Donor type (deceased) 0.483 0.394 - 0.593 <0.001
(b) Continuous covariate
   Recipient age (per year) 0.981 0.975 - 0.988 <0.001
   Current PRA (per %) 1.010 1.006 - 1.014 <0.001
   Transplant year (per year) 0.973 0.955 - 0.991 0.003
   HLA mismatches (per HLA mismatch) 1.139 1.071 - 1.211 <0.001
   Donor age (per year) 0.981 0.953 - 1.009 0.186
   Donor age2 (per year2) 1.000 1.000 - 1.001 0.008
   Donor gender (male) 1.169 0.981 - 1.394 0.081
   CNI as initial immunosuppression (no) 0.302 0.214 - 0.425 <0.001
   Donor type (deceased) 0.486 0.397 - 0.594 <0.001
CNI, calcineurin inhibitor; PRA, panel reactive antibodies.
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Figure 3. Calculated relative risk (RR) of graft failure censored for death with increasing numbers of 
HLA mismatches for deceased donor (DD) and living donor (LD) kidney transplantation based on the 
final multivariable Cox proportional hazards model with total number of HLA mismatches included as 
continuous variable (cont; lines) and as categorical variable (cat; dots). The reference value is a 0-0-0
mismatched deceased donor transplantation.
Discussion
Over the past decades, kidney transplantation results have improved 
considerably; however, the contribution of improved HLA matching has not 
always been clear. In some studies, in deceased donor kidney transplantation, 
HLA matching was found to be important (1, 2), whereas others primarily 
showed a benefit for completely HLA-matched donor kidneys (3, 5). The 
combined effect of HLA mismatches and time was debated as well (6, 7). In our 
study, we did not find an interaction between HLA mismatches and transplant 
year. In our study, the influence of HLA mismatches is independent of time.
In all abovementioned studies, HLA mismatches were included as a categorical 
parameter, but interpretation is hampered, as not all studies agreed on the 
definition of HLA mismatches. In these studies, HLA mismatches has been 
defined as total number of HLA-A plus HLA-B (2); total number of HLA-DR plus
HLA-B (1); HLA-A, -B, and -DR separately (4); total number of HLA-A, -B, and -
DR together (3, 6, 7); and HLA-A, -B, and -DR identical or not (5).
In living donor kidney transplantation, the influence of HLA matching as a 
categorical variable has been described in a small number of studies. Among 
other factors, four HLA-A and -B mismatches was shown to be a risk factor for 
long-term graft failure in living donor renal transplantation, whereas HLA-DR 
mismatches appeared not to be of influence (13). In a British population, in 
contrast to the expectations, the degree of HLA-A, -B, and -DR mismatch did not 
influence graft survival (14). In this study, HLA mismatches on A, B, and DR 
were included as three separate categorical variables. Two mismatches for A, B, 
or DR hardly prevailed, which means that a total number of six mismatches was 
very scarce in this population. Recently, Rizzari et al. described a population of 
1632 patients with HLA mismatches defined as 0, 1-2, 3-4, and 5-6. A 
significant effect of HLA mismatches on the risk of graft failure was found in the 
highest category mismatches (15).
There is only one small study evaluating the influence of HLA mismatches in 
both deceased and living donor kidney transplantation (16). Although HLA 
mismatches 3-6 were associated with a significantly increased risk for antibody-
mediated rejection and cell-mediated rejection compared with HLA mismatches 
0-2, HLA mismatches did not influence the risk of graft failure censored for 
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death in this population. In this study, donor type was found not to influence 
rejection and graft failure.
In the present study, HLA mismatches turned out to be an important factor 
influencing graft survival independent of donor type. However, the risk of failure 
in deceased donor kidney transplantation is larger than in living donor 
transplantation, so that the risk of a completely mismatched living donor kidney 
is only slightly higher than that of a HLA-A, -B, and -DR identical deceased 
donor kidney (Figure 3). Although the risk of a high number of HLA mismatches 
in living donor transplantation is comparable with that of completely HLA-A, -B, 
and -DR matched deceased donor transplantation, it should be kept in mind that 
an important disadvantage of a high number of HLA mismatches is that it might 
lead to sensitization, consequently decreasing chances for a potential 
subsequent transplant (17). When available, a low number of HLA mismatches 
should always be preferred, even in living donor kidney transplantation. 
Nevertheless, when a living donor with a high number of HLA mismatches is 
available, better-matched deceased donor kidney transplantation in the future 
should not be awaited, as the effect of HLA mismatches is corrected for by the 
living donation procedure.
Kaplan-Meier analysis did not show an influence of HLA mismatches on graft 
survival, censored for death in living donor kidney transplantation. However, 
Kaplan-Meier analysis only shows what occurred in the population studied. 
Populations with high and low numbers of HLA mismatches are compared 
irrespective of the influence of other variables. This means that the effect found 
could either be the result of HLA mismatches, or of other factors, as recipient 
condition. Moreover, we showed that our populations of deceased and living 
donor kidney transplant recipients differ in many respects (Table 1) and 
therefore cannot be compared with Kaplan-Meier analysis. The Cox proportional 
hazards analysis, on the contrary, does account and correct for the effect of 
other variables. A risk analysis can be made for a kidney transplant patient with 
known variables.
As the definition of HLA mismatches has been variable in the different studies 
mentioned, we decided to compare the influence of the definition of HLA 
mismatches in four different models in the same population. The fit of the model 
was worse with HLA-A, -B, and -DR mismatches included as three separate 
variables and best with HLA-A, -B, and -DR mismatches added up to one total 
number of HLA mismatches in one categorical variable. The fit of the model was 
intermediate with HLA-A, -B, and -DR mismatches added up to one total number 
of HLA mismatches in one continuous variable and when included as a binary 
variable. The strength of this study is that the three different analyses including 
total number of HLA-A, -B, and -DR mismatches defined in three different ways 
led to the same outcome. Figure 3 shows that the influence of total number of 
HLA mismatches whether defined as a continuous or categorical variable is 
comparable. This shows that the influence of HLA mismatches could be analyzed 
as continuous covariate in future research.
A limitation of our study is that 11% of splits were not available. This could have 
caused underestimation of HLA mismatches. Disregarding A28, B14, and DR3 
splits is Eurotransplant policy. The policy not to determine these splits not only 
exists in our center but also holds true for the whole Eurotransplant area.
Our results show that HLA-A, -B, and -DR matching improves outcomes, even in 
living donor kidney transplantation. However, we also showed that disregarding 
a living donor kidney with a high number of HLA mismatches to await a 
deceased donor kidney with a better match does not improve graft survival.
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Abstract
Background. Currently, potential kidney transplant patients more often suffer 
from comorbidities. The Charlson Comorbidity Index (CCI) was developed in 
1987 and is the most used comorbidity score. We questioned to what extent 
number and severity of comorbidities interfere with graft and patient survival. 
Besides, we wondered whether the CCI was best to study the influence of 
comorbidity in kidney transplant patients.
Methods. In our center, 1728 transplants were performed between 2000 and 
2013. There were 0.8% cases with missing values. Nine pretransplant 
comorbidity covariates were defined: cardiovascular disease, cerebrovascular 
accident, peripheral vascular disease, diabetes mellitus, liver disease, lung 
disease, malignancy, other organ transplantation, and human immunodeficiency 
virus positivity. The CCI used was unadjusted for recipient age. The Rotterdam 
Comorbidity in Kidney Transplantation (RoCKeT) score was developed, and its 
influence was compared to the CCI. Kaplan-Meier analysis and multivariable Cox 
proportional hazards analysis, corrected for variables with a known significant 
influence, were performed.
Results. We noted 325 graft failures and 215 deaths. The only comorbidity 
covariate that significantly influenced graft failure censored for death was 
peripheral vascular disease. Patient death was significantly influenced by
cardiovascular disease, other organ transplantation, and the total comorbidity 
scores. Model fit was best with the Rotterdam Comorbidity in Kidney 
Transplantation score compared to separate comorbidity covariates and the CCI. 
In the population with the highest comorbidity score, 50% survived more than 
10 years.
Conclusions. Despite the negative influence of comorbidity, patient survival 
after transplantation is remarkably good. This means that even patients with 
extensive comorbidity should be considered for transplantation.
Introduction
Acceptance criteria for kidney transplantation are continuously eased; for 
example, currently, even patients in their 80s are considered and accepted for 
transplantation. A less well-defined criterion that has been eased is the presence 
of comorbidity. The Charlson Comorbidity Index (CCI) is widely used to express 
the gradation of comorbidity (1). This score was developed in 1987 in a cohort 
of patients admitted to a medical service and validated in a population of breast 
cancer patients. It takes into account both the number and the seriousness of 
comorbid diseases.
In patients on renal replacement therapy (RRT), the CCI was shown to have a 
significant influence on mortality (2-6). Survival rates were strongly influenced 
by age as in these studies the CCI was age adjusted. Other comorbidity indices 
were also shown to have a significant influence on mortality of RRT patients (7-
10).
In most studies on the influence of the CCI on mortality in kidney transplant 
recipients, a significant effect was found (11-15). In these studies, the most 
commonly used CCI was unadjusted for age with a high 5-year patient survival, 
ranging from 90% to 98% in the lowest CCI groups and from 70% to 88% in the 
highest CCI groups. Graft survival censored for death was not influenced by the 
CCI (11-13).
Apart from the CCI, a number of other comorbidity measures were found to 
have a significant influence on graft or patient survival. These were 
cardiovascular disease, peripheral vascular disease (PVD), history of diabetes, 
hepatitis C virus infection, human immunodeficiency virus (HIV) positivity, the 
recipient risk score, and multiple separate comorbidities (16-23).
In all studies, the presence of an increasing burden of comorbidity predicted a 
lower patient survival. However, the highest comorbidity score was not 
necessarily the same in all studies as acceptance criteria and definitions of 
comorbidity were adapted to current knowledge and experience. In potential 
kidney transplant recipients, not all conditions used in the CCI are present. More 
serious conditions, for example, metastatic malignancy or untreated acquired 
immune deficiency syndrome (AIDS) are not present as those conditions 
preclude transplantation. It can be questioned whether the CCI is applicable to 
kidney transplant recipients: Are comorbidities of equal influence in kidney 
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transplant patients, with their predisposition for vascular disease and 
immunosuppressive treatment, as they are in the general population? Besides, 
the importance of comorbidities changed since 1987, for example, peptic ulcer 
disease was no longer considered an important health threat since the 
introduction of proton pump inhibitors in 1985 (24). For AIDS, highly active 
antiretroviral therapy is available since 1996, adding HIV-positive patients to the 
kidney transplant candidate pool (25). In the CCI, cardiovascular interventions 
are not taken into account though their introduction led to an increase in the 
number of potential recipients with cardiovascular disease. Extra points are 
added to the CCI for congestive heart failure, whereas in patients on RRT, this 
may be the result of cardiovascular disease or overhydration. The subdivision of 
both diabetes mellitus and liver disease in more or less severe disease 
unnecessarily complicates the CCI score.
Since the start of our transplantation program in 1971, our center has been very 
liberal concerning acceptance of patients with comorbidity. Therefore, the 
comorbidity scores and the number of patients with the highest comorbidity 
scores in our center are relatively high. Is there a limitation to the number and 
extent of comorbidities that is acceptable for transplantation? In our population 
of kidney transplant recipients, we studied to what extent severity and number 
of comorbidities interfere with graft and patient survival. We tested the 
individual comorbidity covariates separately, in the CCI, and computed a new 
comorbidity index with low complexity and high utility, adapted to recent norms 
and definitions: the Rotterdam Comorbidity in Kidney Transplantation (RoCKeT) 
score.
Materials and methods
Patients
In our center, 1728 transplants were performed between January 1, 2000, and 
December 31, 2012. Most patients were from the Rotterdam region, and also 
patients from other regions in the Netherlands were referred to our center 
because of medical complexity and decline by other university hospitals.
A relative cardiovascular contraindication for kidney transplantation was the 
presence of inducible ischemia on nuclear myocardial perfusion studies or 
dobutamine stress echocardiography. Unless there were contraindications, a 
coronary angiography (CAG) was performed. When CAG showed stenoses, 
treatment was performed before transplantation. When CAG showed 
abnormalities without treatment options, transplantation was reconsidered. An 
ejection fraction below 30% was accepted for transplantation when reversibility 
was expected. Neither the number of myocardial infarctions, coronary stents or 
bypasses per se, nor the presence of fixed defects were exclusion criteria. 
Aortoiliac bypasses or stents were not exclusion criteria. Symptomatic PVD was 
an exclusion criterion for transplantation if there were no options for 
anastomosis due to severe stenosis (>70%) or circular calcification of all iliac 
internal and external vessels. Malignancy per se was not an exclusion criterion 
for kidney transplantation, but depended on type, staging, and time of disease-
free follow-up. In general, a remission period of at least 2 years was accepted. 
For some cancers, such as renal cell and prostate cancer, shorter time intervals 
were accepted and guided by the histopathological examination of the resected 
specimen and approval of the treating physician.
All deceased and living donor kidney transplant recipients in the study period 
were included in this retrospective cohort study. The standard 
immunosuppressive regimen was triple therapy. Most patients (88%) were 
initially given prednisone, tacrolimus, and mycophenolate mofetil. Prednisone 
was tapered and discontinued at 4 months after transplantation. Other 
immunosuppressants administered were induction therapy, other 
immunosuppressives, or study medication. The screening procedure of potential 
living kidney donors has been described previously (26).
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Individual comorbidity covariates
Nine pretransplant comorbidity covariates were defined. Cardiovascular disease
includes myocardial infarction, coronary artery disease, coronary bypass, 
coronary stent, congestive heart failure, and heart transplantation. 
Cerebrovascular accident (CVA) includes CVA and transient ischemic attack. 
Peripheral vascular disease includes symptomatic PVD, amputation, 
radiologically proven PVD, stent placement, or bypass. Diabetes mellitus
includes type 1 and type 2. Liver disease includes cirrhosis, fibrosis, 
decompensated liver, portal hypertension, Child-Pugh A or higher, primary 
sclerosing cholangitis, liver transplantation, and active or chronic hepatitis B or 
C. Lung disease includes pulmonary hypertension, (asthmatic) bronchitis, 
bronchiectasis, chronic obstructive pulmonary disease, emphysema, extrinsic 
allergic alveolitis, and lung transplantation. Malignancies in the study population 
were Grawitz, hematologic, bladder, breast, prostate, testis/seminoma, thyroid 
gland, cervix, colon, melanoma, larynx, lung, ovary, adrenal gland, chorion, 
leiomyosarcoma, and ear-nose-throat tumors. Meningioma was also included 
because of its highly malignant behavior. Skin tumors other than melanoma 
were not included. Other organ transplants were heart, liver, and lung. The HIV-
positive patients had no detectible HIV load at transplantation.
Comorbidity scores
Two comorbidity scores were computed for each patient. Transplantation of 
other organs was not included in the comorbidity scores, but was analyzed as a 
separate variable.
The first comorbidity score was the CCI (1). Limitations of the CCI in the 
transplant population have been handled according to Jassal et al. (14). For 
example, no differentiation was made between diabetes and diabetes with end 
organ damage, and between mild and moderate liver disease. Ulcer disease, 
dementia, and hemiplegia were not recorded. The influence of connective tissue 
disease was included in primary renal disease. In contrast to Jassal et al., 
congestive heart failure with cardiac cause was scored as cardiovascular disease. 
It was not scored when it was caused by mere fluid overload without an 
underlying cardiac disease. Because no patients with severe liver disease, 
metastatic solid tumor, or AIDS were transplanted, 3 or 6 points were not 
attached to our patients. Human immunodeficiency virus was not mentioned in 
the CCI, but we arbitrarily assigned 1 point. In Table 1, the points assigned to 
the comorbidity covariates composing the CCI are shown. The minimal CCI score 
of our patients was 2 (as 2 points were added for renal insufficiency). The CCI 
was unadjusted for age.
The second comorbidity score was the RoCKeT score that was computed for this 
study. It was developed according to Charlson et al.'s method (1). The score 
was based on the influence of the comorbidity covariates in multivariable 
analysis in the presence of all other comorbid diseases. Charlson et al. described 
2 methods for point assignment to comorbidities. In the first method, points 
were assigned when the influence on the risk of patient death was significant. In 
the second method, points were assigned when the relative risk (RR) was 1.3 or 
higher. No extra points were added for moderate or severe renal disease 
because all patients had end-stage renal disease. In the Results section, the 
composition of the RoCKeT score is described.
Table 1. Points assigned to the comorbidity covariates in the RoCKeT score and the CCI
Comorbidity covariates RoCKeT score CCIa
Cardiovascular disease 3 1
CVA 2 1
PVD 2 1
Diabetes mellitus 2 1
Liver disease 2 1
Lung disease 2 1
Malignancy 1 2
HIV 1 1
Renal disease - 2
a CCI as it was applied to the study population. Excluded from the original CCI (similarly to Jassal et al. 
(14)): dementia, connective tissue disease (included in primary renal disease), ulcer disease, severe 
liver disease, metastatic solid tumor, and AIDS.
CCI, Charlson comorbidity index; CVA, cerebrovascular accident; PVD, peripheral vascular disease; 
RoCKeT score, Rotterdam Comorbidity in Kidney Transplantation score.
103
Comorbidity should not be a contraindication for kidney transplantation
Individual comorbidity covariates
Nine pretransplant comorbidity covariates were defined. Cardiovascular disease
includes myocardial infarction, coronary artery disease, coronary bypass, 
coronary stent, congestive heart failure, and heart transplantation. 
Cerebrovascular accident (CVA) includes CVA and transient ischemic attack. 
Peripheral vascular disease includes symptomatic PVD, amputation, 
radiologically proven PVD, stent placement, or bypass. Diabetes mellitus
includes type 1 and type 2. Liver disease includes cirrhosis, fibrosis, 
decompensated liver, portal hypertension, Child-Pugh A or higher, primary 
sclerosing cholangitis, liver transplantation, and active or chronic hepatitis B or 
C. Lung disease includes pulmonary hypertension, (asthmatic) bronchitis, 
bronchiectasis, chronic obstructive pulmonary disease, emphysema, extrinsic 
allergic alveolitis, and lung transplantation. Malignancies in the study population 
were Grawitz, hematologic, bladder, breast, prostate, testis/seminoma, thyroid 
gland, cervix, colon, melanoma, larynx, lung, ovary, adrenal gland, chorion, 
leiomyosarcoma, and ear-nose-throat tumors. Meningioma was also included 
because of its highly malignant behavior. Skin tumors other than melanoma 
were not included. Other organ transplants were heart, liver, and lung. The HIV-
positive patients had no detectible HIV load at transplantation.
Comorbidity scores
Two comorbidity scores were computed for each patient. Transplantation of 
other organs was not included in the comorbidity scores, but was analyzed as a 
separate variable.
The first comorbidity score was the CCI (1). Limitations of the CCI in the 
transplant population have been handled according to Jassal et al. (14). For 
example, no differentiation was made between diabetes and diabetes with end 
organ damage, and between mild and moderate liver disease. Ulcer disease, 
dementia, and hemiplegia were not recorded. The influence of connective tissue 
disease was included in primary renal disease. In contrast to Jassal et al., 
congestive heart failure with cardiac cause was scored as cardiovascular disease. 
It was not scored when it was caused by mere fluid overload without an 
underlying cardiac disease. Because no patients with severe liver disease, 
metastatic solid tumor, or AIDS were transplanted, 3 or 6 points were not 
attached to our patients. Human immunodeficiency virus was not mentioned in 
the CCI, but we arbitrarily assigned 1 point. In Table 1, the points assigned to 
the comorbidity covariates composing the CCI are shown. The minimal CCI score 
of our patients was 2 (as 2 points were added for renal insufficiency). The CCI 
was unadjusted for age.
The second comorbidity score was the RoCKeT score that was computed for this 
study. It was developed according to Charlson et al.'s method (1). The score 
was based on the influence of the comorbidity covariates in multivariable 
analysis in the presence of all other comorbid diseases. Charlson et al. described 
2 methods for point assignment to comorbidities. In the first method, points 
were assigned when the influence on the risk of patient death was significant. In 
the second method, points were assigned when the relative risk (RR) was 1.3 or 
higher. No extra points were added for moderate or severe renal disease 
because all patients had end-stage renal disease. In the Results section, the 
composition of the RoCKeT score is described.
Table 1. Points assigned to the comorbidity covariates in the RoCKeT score and the CCI
Comorbidity covariates RoCKeT score CCIa
Cardiovascular disease 3 1
CVA 2 1
PVD 2 1
Diabetes mellitus 2 1
Liver disease 2 1
Lung disease 2 1
Malignancy 1 2
HIV 1 1
Renal disease - 2
a CCI as it was applied to the study population. Excluded from the original CCI (similarly to Jassal et al. 
(14)): dementia, connective tissue disease (included in primary renal disease), ulcer disease, severe 
liver disease, metastatic solid tumor, and AIDS.
CCI, Charlson comorbidity index; CVA, cerebrovascular accident; PVD, peripheral vascular disease; 
RoCKeT score, Rotterdam Comorbidity in Kidney Transplantation score.
104
Chapter 7
Statistical analyses
Graft failure censored for death and patient death were studied. Follow-up was 
until March 2014 or until graft failure, patient death, or loss to follow-up. We 
analyzed differences between patients with and without comorbidity using 2-
tailed independent-samples t WHVWVǒ2 tests, and Mann-Whitney U tests. Kaplan-
Meier analysis was performed to generate survival curves concerning the 
influence of the RoCKeT score. Various multivariable Cox proportional hazards 
analyses were performed to test the independent influence of comorbidity on the 
risk of graft failure censored for death and on the risk of patient death. In the 
first model, the influence of the individual comorbidity covariates was studied; in 
the second model, the CCI; and in the third model, the RoCKeT score. The 
Akaike information criterion was used to select the model with the best fit (27). 
In each model, we corrected for the influence of all variables shown in Table 2 
and primary renal disease. Primary renal disease was divided into diabetes 
mellitus and other. Pretreatment was analyzed as a binary variable: yes 
(hemodialysis, peritoneal dialysis, former transplantation) or no (no RRT). 
Backward elimination was used to select each final model. To determine the 
number of covariates in the initial multivariable model, we computed the square 
root of the number of events (graft failures or deaths). The outcome reflected 
the maximum total number of degrees of freedom in the model. First, covariates
with the lowest P values in univariable analysis were included. In the 
multivariable model, covariates that did not contribute significantly were 
removed using backward elimination. Subsequently, the covariates with higher P
values were included followed by backward elimination. This procedure was 
repeated until all covariates had been included in the model.
All analyses were performed using Statistical Package for the Social Sciences 
21.0.0.1 (IBM Corporation, Armonk, NY). P values less than 0.05 were 
considered significant. The proportional hazards assumption was tested using 
log-minus-log plots. Cases with missing values were excluded from Cox
proportional hazards analyses.
Table 2. Transplantation characteristics of patients with and without comorbidity
No comorbidity 
N=911
Comorbidity 
N=817
P
Recipient age in years, mean (SD) 46.0 (14.2) 56.3 (12.7) <0.001a
Recipient gender (male), % 61 66 0.032b
Ethnicity, % 0.035b
   European 75 69
   African 9 9
   Arabian 3 4
   Asian 9 13
   Turkish 5 5
Maximum PRA, median (% >5%) 4 (33) 4 (27) 0.361c
Current PRA, median (% >5%) 0 (15) 0 (10) 0.061c
Retransplants, % 20 16 0.022b
Pretreatment, % 77 83 0.004b
Time on dialysis in years, median (IQR) 1.2 (0-2.7) 1.7 (0.5-3.2) <0.001c
BMI, median (IQR) 24 (21-27) 25 (22-29) <0.001c
Transplant year, median (IQR) 2007 (2004-2010) 2008 (2005-2011) 0.004c
HLA mismatches, mean (SD) 3.0 (1.6) 3.3 (1.7) 0.001a
Donor type (living donor), % 68 58 <0.001b
Donor age in years, mean (SD) 50.5 (13.4) 51.8 (14.0) 0.053a
Donor gender (male), % 46 47 0.665b
CNI as initial immunosuppression, % 97 97 0.688b
a Independent-samples t test to test significance between patients with and without comorbidity.
b ǒ2 test to test significance between patients with and without comorbidity.
c Mann-Whitney U test to test significance between patients with and without comorbidity.
BMI, body mass index; CNI, calcineurin inhibitor; IQR, interquartile range; PRA, panel reactive 
antibodies; SD, standard deviation.
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Statistical analyses
Graft failure censored for death and patient death were studied. Follow-up was 
until March 2014 or until graft failure, patient death, or loss to follow-up. We 
analyzed differences between patients with and without comorbidity using 2-
tailed independent-samples t WHVWVǒ2 tests, and Mann-Whitney U tests. Kaplan-
Meier analysis was performed to generate survival curves concerning the 
influence of the RoCKeT score. Various multivariable Cox proportional hazards 
analyses were performed to test the independent influence of comorbidity on the 
risk of graft failure censored for death and on the risk of patient death. In the 
first model, the influence of the individual comorbidity covariates was studied; in 
the second model, the CCI; and in the third model, the RoCKeT score. The 
Akaike information criterion was used to select the model with the best fit (27). 
In each model, we corrected for the influence of all variables shown in Table 2 
and primary renal disease. Primary renal disease was divided into diabetes 
mellitus and other. Pretreatment was analyzed as a binary variable: yes 
(hemodialysis, peritoneal dialysis, former transplantation) or no (no RRT). 
Backward elimination was used to select each final model. To determine the 
number of covariates in the initial multivariable model, we computed the square 
root of the number of events (graft failures or deaths). The outcome reflected 
the maximum total number of degrees of freedom in the model. First, covariates
with the lowest P values in univariable analysis were included. In the 
multivariable model, covariates that did not contribute significantly were 
removed using backward elimination. Subsequently, the covariates with higher P
values were included followed by backward elimination. This procedure was 
repeated until all covariates had been included in the model.
All analyses were performed using Statistical Package for the Social Sciences 
21.0.0.1 (IBM Corporation, Armonk, NY). P values less than 0.05 were 
considered significant. The proportional hazards assumption was tested using 
log-minus-log plots. Cases with missing values were excluded from Cox
proportional hazards analyses.
Table 2. Transplantation characteristics of patients with and without comorbidity
No comorbidity 
N=911
Comorbidity 
N=817
P
Recipient age in years, mean (SD) 46.0 (14.2) 56.3 (12.7) <0.001a
Recipient gender (male), % 61 66 0.032b
Ethnicity, % 0.035b
   European 75 69
   African 9 9
   Arabian 3 4
   Asian 9 13
   Turkish 5 5
Maximum PRA, median (% >5%) 4 (33) 4 (27) 0.361c
Current PRA, median (% >5%) 0 (15) 0 (10) 0.061c
Retransplants, % 20 16 0.022b
Pretreatment, % 77 83 0.004b
Time on dialysis in years, median (IQR) 1.2 (0-2.7) 1.7 (0.5-3.2) <0.001c
BMI, median (IQR) 24 (21-27) 25 (22-29) <0.001c
Transplant year, median (IQR) 2007 (2004-2010) 2008 (2005-2011) 0.004c
HLA mismatches, mean (SD) 3.0 (1.6) 3.3 (1.7) 0.001a
Donor type (living donor), % 68 58 <0.001b
Donor age in years, mean (SD) 50.5 (13.4) 51.8 (14.0) 0.053a
Donor gender (male), % 46 47 0.665b
CNI as initial immunosuppression, % 97 97 0.688b
a Independent-samples t test to test significance between patients with and without comorbidity.
b ǒ2 test to test significance between patients with and without comorbidity.
c Mann-Whitney U test to test significance between patients with and without comorbidity.
BMI, body mass index; CNI, calcineurin inhibitor; IQR, interquartile range; PRA, panel reactive 
antibodies; SD, standard deviation.
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Results
In 15% of the 1728 cases, patients had cardiovascular disease before 
transplantation, 9% CVA, 9% PVD, 20% diabetes mellitus, 4% liver disease, 5% 
lung disease, 7% malignancy, 2% received another organ transplant, and 
0.2%was HIV-positive. The mean CCI was 2.8 ± 1.0, and the median (range) 
was 2 (2-7). A total of 817 (47%) patients had comorbidity.
Observation was until March 2014 so that at least 14 months of follow-up could 
be obtained. Median follow-up time was 4 years (range, 0-13 years). In total, 44 
patients were lost to follow-up with a median (range) of 25.5 (0-125) months 
after transplantation. For these patients, follow-up was calculated until the date 
last seen. There were 13 cases (0.8%) with missing values. Consequently, Cox 
proportional hazards analyses were performed in 1715 cases.
Development of the RoCKeT score
In multivariable analysis, the following comorbidities (RR) had a significant 
influence on the risk of patient death and RR of 1.3 or higher: cardiovascular 
disease (2.5), CVA (1.5), PVD (1.6), diabetes (1.5), liver disease (2.1), and lung 
disease (1.9). According to Charlson et al., the RRs were rounded up/off to 
whole points (1). Consequently, cardiovascular disease was given 3 points and 
the other comorbidities 2 points each. The corrected influence of pretransplant 
malignancy and HIV on the risk of patient death was not significant. However, 
the RR of malignancy was 1.4, allowing assignment of 1 point according to 
Charlson et al. Because there were only 4 patients with HIV, the influence of HIV 
was not significant, and RR was below 1.3. Because of the clinical relevance of 
HIV, 1 point was assigned arbitrarily. In Table 1, the points assigned to the 
comorbidity covariates are shown. All points were added up to create the 
RoCKeT score. The range of the RoCKeT score was 0 to 9, 53% of patients had a 
score of 0; no comorbidity. We categorized the RoCKeT score into 0 (N = 911), 
1 to 2 (N = 413), 3 to 4 (N = 246), and 5 to 9 (N = 158) points to create larger 
groups. Of the patients younger than 40 years, 21% had comorbidity compared 
with 74% of patients aged 70 to 79 years (Figure 1). Comorbidity increased with 
time. In 2000, 39% of patients transplanted had comorbidity. This percentage 
gradually increased to 58% in 2012.
 
Figure 1. Distribution and means of the Rotterdam Comorbidity in Kidney Transplantation (RoCKeT) 
score per age group. The difference between the age groups was significant (P < 0.001). Older patients 
have a higher RoCKeT score.
Pretransplant characteristics
Patients without comorbidity had a score of 0 in the RoCKeT score and a score of 
2 in the CCI. There were significant differences in characteristics between 
patients with and without comorbidity (Table 2). Patients with comorbidity were 
significantly older than patients without comorbidity and spent more time on 
dialysis. Moreover, there were significant differences between the populations 
concerning recipient gender, ethnicity, retransplants, pretreatment, body mass 
index, transplant year, HLA mismatches, and donor type. Of the patients with 
comorbidity, 28% had diabetes mellitus as their primary renal disease.
N in age group 33 135 218 352 425 414 151
Mean RoCKeT score 0.48 0.47 0.42 1.12 1.51 2.29 2.48
SD 1.00 1.03 0.86 1.67 1.87 2.20 2.10
35%
26%
17%
17%
49%
61%
79%
79%
79% 9%6%
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Results
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was not significant, and RR was below 1.3. Because of the clinical relevance of 
HIV, 1 point was assigned arbitrarily. In Table 1, the points assigned to the 
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score of 0; no comorbidity. We categorized the RoCKeT score into 0 (N = 911), 
1 to 2 (N = 413), 3 to 4 (N = 246), and 5 to 9 (N = 158) points to create larger 
groups. Of the patients younger than 40 years, 21% had comorbidity compared 
with 74% of patients aged 70 to 79 years (Figure 1). Comorbidity increased with 
time. In 2000, 39% of patients transplanted had comorbidity. This percentage 
gradually increased to 58% in 2012.
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score per age group. The difference between the age groups was significant (P < 0.001). Older patients 
have a higher RoCKeT score.
Pretransplant characteristics
Patients without comorbidity had a score of 0 in the RoCKeT score and a score of 
2 in the CCI. There were significant differences in characteristics between 
patients with and without comorbidity (Table 2). Patients with comorbidity were 
significantly older than patients without comorbidity and spent more time on 
dialysis. Moreover, there were significant differences between the populations 
concerning recipient gender, ethnicity, retransplants, pretreatment, body mass 
index, transplant year, HLA mismatches, and donor type. Of the patients with 
comorbidity, 28% had diabetes mellitus as their primary renal disease.
N in age group 33 135 218 352 425 414 151
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The influence of comorbidity on graft failure
During follow-up, 325 graft failures were noted. Kaplan-Meier analysis showed 
that the difference between the categories of the RoCKeT score was not 
significant for graft survival censored for death (P = 0.962) (Figure 2). In 
multivariable Cox proportional hazards analysis, the influence of the individual 
comorbidity covariates was tested in the first model. The number of covariates 
included in the model was maximum 18 degrees of freedom. The risk of graft 
failure censored for death was significantly influenced by PVD (P = 0.005) but 
not by the other comorbidities (Table 3). In the second and third models, the 
CCI and the RoCKeT score were removed from the model after backward 
elimination and thus did not have a significant influence on graft failure censored 
for death.
Figure 2. Kaplan-Meier survival curve of the influence of the Rotterdam Comorbidity in Kidney 
Transplantation (RoCKeT) score on graft survival censored for death. There was no significant 
difference between the comorbidity categories (P = 0.962).
Number at risk
RoCKeT score
0 911 719 504 348 240 132 53 3
1-2 413 304 196 108 62 34 13 1
3-4 246 164 102 66 37 16 5 1
5-9 158 103 65 39 22 10 1 0
RoCKeT score
Table 3. Results of the multivariable Cox proportional hazards analysis on the risk of graft failure 
censored for death
325 eventsa
Variable (reference category) Exp(B) 95% CI P
Recipient age (per year) 0.980 0.972 - 0.988 <0.001
Maximum PRA (per %) 1.007 1.003 - 1.011 <0.001
Peripheral vascular disease (no) 1.642 1.161 - 2.321 0.005
Transplant year (per year) 0.966 0.932 - 1.001 0.054
HLA mismatches (per HLA mismatch) 1.085 1.008 - 1.168 0.030
Donor type (deceased) 0.505 0.396 - 0.643 <0.001
Donor age (per year) 1.029 1.019 - 1.039 <0.001
CNI as initial immunosuppression (no) 0.360 0.228 - 0.570 <0.001
a Event is graft failure censored for death. Final model after backward elimination of the following 
covariates: recipient gender, ethnicity, primary renal disease, current PRA, retransplants, pretreatment, 
time on dialysis, cardiovascular disease, cerebrovascular accident, diabetes mellitus, liver disease, lung 
disease, malignancy, transplantation of other organ, HIV, BMI, and donor gender.
BMI, body mass index; CNI, calcineurin inhibitor; PRA, panel reactive antibodies.
The influence of comorbidity on mortality
In the study period, there were 215 deaths. In Kaplan-Meier analysis, we found 
a significant difference in patient survival between the RoCKeT score categories 
(P < 0.001) (Figure 3). Patient survival of 50% of the patients in the highest 
comorbidity category was more than 10 years. In the first Cox proportional 
hazards model with maximum 14 degrees of freedom, mortality was significantly 
influenced by cardiovascular disease (P < 0.001) and transplantation of other 
organ (P = 0.001). Diabetes mellitus as primary renal disease had a significant 
influence on patient death as well (P = 0.002). In the second model, the CCI 
had a significant influence (P = 0.005). In the third model, the RoCKeT score 
showed a significant influence (P < 0.001) (Table 4). The influence of donor type 
was significant (P = 0.02). There was no interaction between recipient age and 
comorbidity: the influence of comorbidity is independent of age. Figure 4 shows 
the combined influence of age and comorbidity on patient death. In addition, no 
significant interaction was found between donor type and comorbidity, time on 
dialysis and comorbidity, and ethnicity and comorbidity in these analyses. The 
proportional hazards assumption was not violated.
The Akaike information criterion showed that the model with the RoCKeT score 
had the best fit, followed by the model with comorbidities included separately. 
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The influence of comorbidity on graft failure
During follow-up, 325 graft failures were noted. Kaplan-Meier analysis showed 
that the difference between the categories of the RoCKeT score was not 
significant for graft survival censored for death (P = 0.962) (Figure 2). In 
multivariable Cox proportional hazards analysis, the influence of the individual 
comorbidity covariates was tested in the first model. The number of covariates 
included in the model was maximum 18 degrees of freedom. The risk of graft 
failure censored for death was significantly influenced by PVD (P = 0.005) but 
not by the other comorbidities (Table 3). In the second and third models, the 
CCI and the RoCKeT score were removed from the model after backward 
elimination and thus did not have a significant influence on graft failure censored 
for death.
Figure 2. Kaplan-Meier survival curve of the influence of the Rotterdam Comorbidity in Kidney 
Transplantation (RoCKeT) score on graft survival censored for death. There was no significant 
difference between the comorbidity categories (P = 0.962).
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1-2 413 304 196 108 62 34 13 1
3-4 246 164 102 66 37 16 5 1
5-9 158 103 65 39 22 10 1 0
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Table 3. Results of the multivariable Cox proportional hazards analysis on the risk of graft failure 
censored for death
325 eventsa
Variable (reference category) Exp(B) 95% CI P
Recipient age (per year) 0.980 0.972 - 0.988 <0.001
Maximum PRA (per %) 1.007 1.003 - 1.011 <0.001
Peripheral vascular disease (no) 1.642 1.161 - 2.321 0.005
Transplant year (per year) 0.966 0.932 - 1.001 0.054
HLA mismatches (per HLA mismatch) 1.085 1.008 - 1.168 0.030
Donor type (deceased) 0.505 0.396 - 0.643 <0.001
Donor age (per year) 1.029 1.019 - 1.039 <0.001
CNI as initial immunosuppression (no) 0.360 0.228 - 0.570 <0.001
a Event is graft failure censored for death. Final model after backward elimination of the following 
covariates: recipient gender, ethnicity, primary renal disease, current PRA, retransplants, pretreatment, 
time on dialysis, cardiovascular disease, cerebrovascular accident, diabetes mellitus, liver disease, lung 
disease, malignancy, transplantation of other organ, HIV, BMI, and donor gender.
BMI, body mass index; CNI, calcineurin inhibitor; PRA, panel reactive antibodies.
The influence of comorbidity on mortality
In the study period, there were 215 deaths. In Kaplan-Meier analysis, we found 
a significant difference in patient survival between the RoCKeT score categories 
(P < 0.001) (Figure 3). Patient survival of 50% of the patients in the highest 
comorbidity category was more than 10 years. In the first Cox proportional 
hazards model with maximum 14 degrees of freedom, mortality was significantly 
influenced by cardiovascular disease (P < 0.001) and transplantation of other 
organ (P = 0.001). Diabetes mellitus as primary renal disease had a significant 
influence on patient death as well (P = 0.002). In the second model, the CCI 
had a significant influence (P = 0.005). In the third model, the RoCKeT score 
showed a significant influence (P < 0.001) (Table 4). The influence of donor type 
was significant (P = 0.02). There was no interaction between recipient age and 
comorbidity: the influence of comorbidity is independent of age. Figure 4 shows 
the combined influence of age and comorbidity on patient death. In addition, no 
significant interaction was found between donor type and comorbidity, time on 
dialysis and comorbidity, and ethnicity and comorbidity in these analyses. The 
proportional hazards assumption was not violated.
The Akaike information criterion showed that the model with the RoCKeT score 
had the best fit, followed by the model with comorbidities included separately. 
110
Chapter 7
The fit of the model with the CCI was less good. Both comorbidity indices 
showed the same trend, though significance levels and RRs varied slightly.
Figure 3. Kaplan-Meier survival curve of the influence of the Rotterdam Comorbidity in Kidney 
Transplantation (RoCKeT) score on patient survival. The overall P value was less than 0.001. After 
Bonferroni corUHFWLRQIRUPXOWLSOHFRPSDULVRQVĮ WKHGLIIHUHQFHEHWZHHQDQGWKHRWKHU
comorbidity categories was significant (P < 0.001), as well as the difference between 1-2 and 5-9 (P <
0.001). The differences between 1-2 and 3-4 (P = 0.010) and between 3-4 and 5-9 (P = 0.150) were 
not considered significant. After 10 years, 50% of the patients in the highest comorbidity category are 
still alive.
Number at risk
RoCKeT score
0 911 719 504 348 240 132 53 3
1-2 413 304 196 108 62 34 13 1
3-4 246 164 102 66 37 16 5 1
5-9 158 103 65 39 22 10 1 0
RoCKeT score
Table 4. Results of the multivariable Cox proportional hazards analysis on the risk of patient death
215 eventsa
Variable (reference category) Exp(B) 95% CI P
Recipient age (per year) 1.061 1.047 - 1.076 <0.001
Ethnicity (European) 0.048
   African 0.411 0.201 - 0.840 0.015
   Arabian 0.245 0.060 - 1.002 0.050
   Asian 0.861 0.553 - 1.338 0.505
   Turkish 0.888 0.475 - 1.659 0.710
Time on dialysis (per year) 1.056 0.998 - 1.117 0.058
RoCKeT score (0) <0.001
   1-2 1.685 1.165 - 2.437 0.006
   3-4 2.129 1.444 - 3.138 <0.001
   5-9 2.700 1.774 - 4.110 <0.001
Transplantation of other organ (no) 2.078 1.102 - 3.921 0.024
Transplant year (per year) 0.935 0.894 - 0.978 0.003
Donor type (deceased) 0.698 0.516 - 0.944 0.020
a Event is patient death. Final model after backward elimination of the following covariates: recipient 
gender, primary renal disease, maximum PRA, current PRA, retransplants, pretreatment, BMI, HLA 
mismatches, donor age, donor gender, and CNI as initial immunosuppression.
BMI, body mass index; CNI, calcineurin inhibitor; PRA, panel reactive antibodies; RoCKeT score, 
Rotterdam Comorbidity in Kidney Transplantation score.
Figure 4. The combined influence of recipient age and the Rotterdam Comorbidity in Kidney 
Transplantation (RoCKeT) score on the relative risk (RR) of patient death. The reference value is the 
risk of a 50-year-old patient without comorbidity (RR = 1). Between ages 50 and 80 years, the RR 
increases 6 times. The RR of the highest comorbidity score is 2.7 compared with a comorbidity score of 
0 (see also Table 4).
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The fit of the model with the CCI was less good. Both comorbidity indices 
showed the same trend, though significance levels and RRs varied slightly.
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comorbidity categories was significant (P < 0.001), as well as the difference between 1-2 and 5-9 (P <
0.001). The differences between 1-2 and 3-4 (P = 0.010) and between 3-4 and 5-9 (P = 0.150) were 
not considered significant. After 10 years, 50% of the patients in the highest comorbidity category are 
still alive.
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a Event is patient death. Final model after backward elimination of the following covariates: recipient 
gender, primary renal disease, maximum PRA, current PRA, retransplants, pretreatment, BMI, HLA 
mismatches, donor age, donor gender, and CNI as initial immunosuppression.
BMI, body mass index; CNI, calcineurin inhibitor; PRA, panel reactive antibodies; RoCKeT score, 
Rotterdam Comorbidity in Kidney Transplantation score.
Figure 4. The combined influence of recipient age and the Rotterdam Comorbidity in Kidney 
Transplantation (RoCKeT) score on the relative risk (RR) of patient death. The reference value is the 
risk of a 50-year-old patient without comorbidity (RR = 1). Between ages 50 and 80 years, the RR 
increases 6 times. The RR of the highest comorbidity score is 2.7 compared with a comorbidity score of 
0 (see also Table 4).
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Discussion
As treatment options for various medical diseases improve over time, end-stage 
renal disease patients with comorbidity are more often referred to transplant 
centers and actually transplanted. There are only a few studies that meticulously 
describe comorbidity and its influence in their renal transplant population. In 
2005, Jassal et al. (14) described comorbidity in their study on 6324 renal 
transplant patients. Mean age was 42 years, and 29% had comorbidity. In the 
population of Wu et al. (12), 45% of 715 patients had comorbidity, and mean 
age was 50 years. In our patient population of 1728 patients, 47% had 
comorbidity, and mean age was 51 years. However, the definition of comorbidity 
was not exactly the same in these studies. These studies are on the influence of 
the presence of multiple comorbidities on patient survival, independent of the 
heterogeneity within each of the comorbid diseases. Though heterogeneity may 
exist, it is questionable whether subjective subdivision of comorbidities in 
multiple categories increases reliability of results. The severity of comorbidities 
cannot always be measured neither will they be available in retrospective 
analysis. Moreover, subdivision of comorbidities into multiple categories 
unnecessarily complicates the score and analysis.
The CCI was previously shown to be a significant predictor of mortality (2-6, 11-
15). However, the population the CCI was developed in is totally different from 
the population of kidney disease patients, questioning its applicability. The 
recipient risk score was designed to improve deceased donor kidney allocation 
and was found to have a better fit in this population than the CCI (21, 28). The 
RoCKeT score had a better fit in kidney transplant recipients than the CCI and 
turned out to be a significant covariate influencing patient survival which 
emphasizes its importance in survival and intervention studies.
The scores we tested were unadjusted for age, because in a previous study, we 
showed that age is an important and independent risk factor for patient death 
(29). Including age in comorbidity scores would contaminate these scores. The 
independent influence of age was recognized by others as well (7, 8, 10).
In the current study, the only comorbidity that influenced graft survival censored 
for death was PVD. This has been described before (17). Difficult anastomoses 
and/or a decreased flow caused by stenoses might play a role. Patient survival 
was influenced by the presence of comorbidities. However, even in the 
population with comorbidity, patient survival after transplantation is very good. 
More than 10 years after transplantation, 50% of the patients with a RoCKeT 
score of 5 to 9 survived, which is far better than the 34% 10-year survival of 
Dutch RRT patients (hemodialysis, peritoneal dialysis, and transplantation) (30). 
Published patient survival data in dialysis populations was 30.5% after 8 years 
and 18.1% after 10 years (31, 32). Despite their good survival after kidney 
transplantation, patients with serious comorbidity were less likely to be 
recommended for kidney transplantation by their nephrologists (33, 34). Unless 
trained or involved in transplantation, nephrologists were less likely to accept 
patients with comorbidity for kidney transplantation. This suggests that gains 
could be made in this respect. Apart from survival gains, transplanting patients 
with comorbidities is more cost-effective than dialysis (35). The survival benefit 
of transplant patients with comorbidity still holds after a waiting time of up to 3 
years (36).
Though survival is far better after transplantation compared with hemodialysis, 
it should be kept in mind that the population selected for transplantation is a 
comparatively healthy hemodialysis population. This is an inevitable limitation of 
our study that causes selection bias. On the other hand, part of this population 
already survived another few years on hemodialysis before they were 
transplanted, and survival is calculated from transplantation onward. Though 
survival of patients with a high comorbidity score is good, this does not imply 
that all patients with a comorbidity score of 9 should be transplanted. The 
RoCKeT score was developed to estimate the risks of different and added 
comorbidities. It is not possible to use the score for the decision to accept or 
reject a potential transplant patient. For each patient, the individual risks and 
potential success rate should be evaluated by an experienced physician taking 
into account all comorbidities and their severity. Our results show that 
meticulous selection of high-risk patients for kidney transplantation can lead to 
successful outcomes. In our center, relatively more living compared to deceased 
donor kidney transplantations are performed. We did not find an interaction 
between comorbidity and donor type, which means that there is no extra profit 
for patients with high comorbidity scores when they receive a living instead of 
deceased donor kidney transplantation compared with any other patient.
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Discussion
As treatment options for various medical diseases improve over time, end-stage 
renal disease patients with comorbidity are more often referred to transplant 
centers and actually transplanted. There are only a few studies that meticulously 
describe comorbidity and its influence in their renal transplant population. In 
2005, Jassal et al. (14) described comorbidity in their study on 6324 renal 
transplant patients. Mean age was 42 years, and 29% had comorbidity. In the 
population of Wu et al. (12), 45% of 715 patients had comorbidity, and mean 
age was 50 years. In our patient population of 1728 patients, 47% had 
comorbidity, and mean age was 51 years. However, the definition of comorbidity 
was not exactly the same in these studies. These studies are on the influence of 
the presence of multiple comorbidities on patient survival, independent of the 
heterogeneity within each of the comorbid diseases. Though heterogeneity may 
exist, it is questionable whether subjective subdivision of comorbidities in 
multiple categories increases reliability of results. The severity of comorbidities 
cannot always be measured neither will they be available in retrospective 
analysis. Moreover, subdivision of comorbidities into multiple categories 
unnecessarily complicates the score and analysis.
The CCI was previously shown to be a significant predictor of mortality (2-6, 11-
15). However, the population the CCI was developed in is totally different from 
the population of kidney disease patients, questioning its applicability. The 
recipient risk score was designed to improve deceased donor kidney allocation 
and was found to have a better fit in this population than the CCI (21, 28). The 
RoCKeT score had a better fit in kidney transplant recipients than the CCI and 
turned out to be a significant covariate influencing patient survival which 
emphasizes its importance in survival and intervention studies.
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(29). Including age in comorbidity scores would contaminate these scores. The 
independent influence of age was recognized by others as well (7, 8, 10).
In the current study, the only comorbidity that influenced graft survival censored 
for death was PVD. This has been described before (17). Difficult anastomoses 
and/or a decreased flow caused by stenoses might play a role. Patient survival 
was influenced by the presence of comorbidities. However, even in the 
population with comorbidity, patient survival after transplantation is very good. 
More than 10 years after transplantation, 50% of the patients with a RoCKeT 
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Dutch RRT patients (hemodialysis, peritoneal dialysis, and transplantation) (30). 
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and 18.1% after 10 years (31, 32). Despite their good survival after kidney 
transplantation, patients with serious comorbidity were less likely to be 
recommended for kidney transplantation by their nephrologists (33, 34). Unless 
trained or involved in transplantation, nephrologists were less likely to accept 
patients with comorbidity for kidney transplantation. This suggests that gains 
could be made in this respect. Apart from survival gains, transplanting patients 
with comorbidities is more cost-effective than dialysis (35). The survival benefit 
of transplant patients with comorbidity still holds after a waiting time of up to 3 
years (36).
Though survival is far better after transplantation compared with hemodialysis, 
it should be kept in mind that the population selected for transplantation is a 
comparatively healthy hemodialysis population. This is an inevitable limitation of 
our study that causes selection bias. On the other hand, part of this population 
already survived another few years on hemodialysis before they were 
transplanted, and survival is calculated from transplantation onward. Though 
survival of patients with a high comorbidity score is good, this does not imply 
that all patients with a comorbidity score of 9 should be transplanted. The 
RoCKeT score was developed to estimate the risks of different and added 
comorbidities. It is not possible to use the score for the decision to accept or 
reject a potential transplant patient. For each patient, the individual risks and 
potential success rate should be evaluated by an experienced physician taking 
into account all comorbidities and their severity. Our results show that 
meticulous selection of high-risk patients for kidney transplantation can lead to 
successful outcomes. In our center, relatively more living compared to deceased 
donor kidney transplantations are performed. We did not find an interaction 
between comorbidity and donor type, which means that there is no extra profit 
for patients with high comorbidity scores when they receive a living instead of 
deceased donor kidney transplantation compared with any other patient.
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Another limitation of this single-center study is the lack of a control group. The
ideal control group would be a population accepted for transplantation with 
comparable baseline characteristics who did not receive a kidney transplant. 
However, on ethical grounds, a randomized controlled trial for kidney 
transplantation or not is unacceptable. The population on the waiting list is not 
comparable to the population transplanted concerning baseline characteristics. 
The population of patients rejected for kidney transplantation is not appropriate, 
because in this population, selection bias also plays a major role with the 
opposite effect. Besides, data are incomplete because rejection may occur in any 
stage of the process. Some elderly patients or those with comorbidity have not 
even been referred to a transplant center. The hemodialysis population is a 
heterogeneous group of patients accepted or rejected for transplantation or 
unwilling to receive a transplant. Moreover, regional dialysis populations should 
be included as our transplant population origins from these centers. 
Unfortunately, these data are not available.
With the intention of generalizing our findings, the RoCKeT score should be 
validated in other kidney transplant populations. Until now, we did not find 
another transplant population with information available to test the RoCKeT
score. For proper validation, it is important that there is unanimity on the 
definitions of all different comorbidities.
In conclusion, patient survival is influenced by comorbidity. Compared with the 
CCI, the RoCKeT score was shown to have a better fit in kidney transplant 
population. The most important finding of this study is that after transplantation, 
patient survival is very good for patients with a high burden of comorbidity, 
compared with published survival data of hemodialysis patients. This means
that, despite severe comorbidity, these patients should be considered for kidney 
transplantation.
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Discussion
Over the years, kidney transplantation has become the treatment of preference 
for end stage renal disease patients. In this thesis, we describe our studies on 
clinical, demographic and socioeconomic factors that influence access to living or 
deceased donor kidney transplantation. Furthermore, we studied the relative 
influence of these factors on graft and patient survival.
Access to kidney transplantation
Because the medical healthcare system in The Netherlands assures equal care 
for all inhabitants, it might be expected that access to kidney transplantation is 
equally available for all end stage renal disease patients. However, it is 
remarkable that there is a preponderance of elderly and non-European patients 
in the hemodialysis population. One reason might be that this represents the 
residue of patients deemed unfit for transplantation. This doctor’s assessment is 
subjective and is based on an estimation of both physical or non-physical 
condition.
Nevertheless, increasing numbers of elderly with or without comorbidity are 
being referred for transplantation. In chapter 2 we describe the influence of age 
on outflow once patients have been placed on the waiting list for transplantation. 
The results showed that the younger the patient the higher the chance that 
shortly after wait-listing or onset of dialysis the patient will receive a living donor 
kidney transplantation. In contrast, with increasing age more time is spent 
waiting for a deceased donor kidney transplantation. A possible explanation for 
the reduced access of older patients to living donor kidney transplantation may 
be their difficulties in finding a suitable living donor. Their smaller social network 
or the reduced health of their peer group compared with that of younger 
patients may be the cause of this difference. Because of their shorter life 
expectancy older patients may feel reluctant to accept a kidney from a healthy 
person, for instance their child. However, the burden of dialysis on top of higher 
age causes premature aging, loss of condition, and eventually people may 
become unfit for transplantation or even die without a transplantation. Our study 
shows that approximately half of the patients above 55 years will never be 
transplanted when they have to wait for a deceased donor organ. They simply 
do not survive waiting time for a deceased donor organ in a condition fit enough 
119
Discussion
Over the years, kidney transplantation has become the treatment of preference 
for end stage renal disease patients. In this thesis, we describe our studies on 
clinical, demographic and socioeconomic factors that influence access to living or 
deceased donor kidney transplantation. Furthermore, we studied the relative 
influence of these factors on graft and patient survival.
Access to kidney transplantation
Because the medical healthcare system in The Netherlands assures equal care 
for all inhabitants, it might be expected that access to kidney transplantation is 
equally available for all end stage renal disease patients. However, it is 
remarkable that there is a preponderance of elderly and non-European patients 
in the hemodialysis population. One reason might be that this represents the 
residue of patients deemed unfit for transplantation. This doctor’s assessment is 
subjective and is based on an estimation of both physical or non-physical 
condition.
Nevertheless, increasing numbers of elderly with or without comorbidity are 
being referred for transplantation. In chapter 2 we describe the influence of age 
on outflow once patients have been placed on the waiting list for transplantation. 
The results showed that the younger the patient the higher the chance that 
shortly after wait-listing or onset of dialysis the patient will receive a living donor 
kidney transplantation. In contrast, with increasing age more time is spent 
waiting for a deceased donor kidney transplantation. A possible explanation for 
the reduced access of older patients to living donor kidney transplantation may 
be their difficulties in finding a suitable living donor. Their smaller social network 
or the reduced health of their peer group compared with that of younger 
patients may be the cause of this difference. Because of their shorter life 
expectancy older patients may feel reluctant to accept a kidney from a healthy 
person, for instance their child. However, the burden of dialysis on top of higher 
age causes premature aging, loss of condition, and eventually people may 
become unfit for transplantation or even die without a transplantation. Our study 
shows that approximately half of the patients above 55 years will never be 
transplanted when they have to wait for a deceased donor organ. They simply 
do not survive waiting time for a deceased donor organ in a condition fit enough 
120
Chapter 8
to undergo transplantation. Especially this population could benefit from early 
living donor kidney transplantation.
When observing the transplant recipient population, it is striking that the 
composition of the population of recipients of living versus deceased donor 
kidney transplantations is very different. In chapter 3 we studied our transplant 
population in order to find out what clinical and socioeconomic factors determine 
the composition of these populations. Compared to recipients of a living donor 
kidney, recipients of a deceased donor kidney more often are non-European, 
they more often are diabetics, less often preemptively transplanted and more 
often on hemodialysis before transplantation and they also more often are highly 
sensitized. Regarding socioeconomic factors, recipients of a deceased donor 
kidney more often live in cheaper houses, in an area with a high percentage of 
non-Europeans, they mostly live in town, and have lower incomes than 
recipients of a living donor kidney. When comparing European versus non-
European recipients of a kidney transplant, non-Europeans less often received a 
living donor transplantation. All differences mentioned above between recipients 
of a living versus deceased donor kidney also hold true for European versus non-
European recipients. Unfavorable factors prevail in both the recipient population 
of a deceased donor kidney and in the non-European recipient population. To 
analyze whether these factors had an independent influence on the chance of 
receiving a living donor kidney transplantation we performed a multivariable 
binary logistic regression analysis. In accordance with our findings in chapter 2, 
we found that increasing age led to a decrease in access to living donor kidney 
transplantation. A known problem we confirmed is that patients with ABO blood 
type O have a smaller chance than patients with blood type A. We also found 
that non-Europeans only have a 50% chance of undergoing living donor kidney 
transplantation compared with Europeans. Regarding socioeconomic factors 
potential recipients living in an area with a high percentage of non-Europeans 
have a smaller chance. This also applies to living in an area with a low housing 
value. An interesting finding was that the regression analysis revealed that the 
chance of receiving a living donor kidney was higher for patients living in a 
highly urbanized area than in rural area, while the percentage recipients living in 
the most urbanized area was lower for the recipient population of a living donor 
kidney than for the recipient population of a deceased donor kidney. This means 
that the factors that were corrected for accounted for a large part of the 
influence of urbanization on the access to living donor kidney transplantation. 
Moreover, the majority of recipients of both populations lived in town.
It is not easy to influence the factors that determine access to transplantation. 
Clinical factors cannot always be influenced and although socioeconomic factors 
could change over time, one cannot always control them. Non-Europeans that 
immigrated a longer time ago are better integrated and have a better social 
position than non-Europeans that arrived more recently. The next generation 
climbs on the social ladder and socioeconomic factors usually are more favorable 
for subsequent generations. Unfavorable factors are rather a matter of time than 
a factor that can be influenced individually. Newcomers are facing the same 
problems.
To summarize, access to transplantation was influenced by age. Besides, access 
to living donor kidney transplantation was influenced by clinical and 
socioeconomic factors. This was the reason to start home based education for 
patients without a living donor. Patients and their social network (family and 
friends) were educated in their own home on the various options of renal 
replacement therapy. Misconceptions about religious objections against organ 
donation were relieved. This method turned out to have a positive influence on 
participation of these patients and their network in living donor kidney 
transplantation programs. We expect that education will help other patients 
groups, such as elderly, as well. Recently home based education was added to 
our standard care for all potential recipients that present without a living donor. 
However, the problem of non-referral will not be solved by home based patient 
education. Professionals should learn to be more liberal in referring patients for 
transplantation as well.
Survival after kidney transplantation
Although the advantage of kidney transplantation over remaining on the waiting 
list was not explicitly tested in this thesis, the literature shows that survival on 
dialysis is worse compared to our survival data. However, (graft) survival after 
transplantation is not equal for all patients or patient groups. We studied the 
influence of ethnicity and socioeconomic factors on graft and patient survival in 
chapter 4. Socioeconomic factors that were studied were urbanization level, 
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transplantation. A known problem we confirmed is that patients with ABO blood 
type O have a smaller chance than patients with blood type A. We also found 
that non-Europeans only have a 50% chance of undergoing living donor kidney 
transplantation compared with Europeans. Regarding socioeconomic factors 
potential recipients living in an area with a high percentage of non-Europeans 
have a smaller chance. This also applies to living in an area with a low housing 
value. An interesting finding was that the regression analysis revealed that the 
chance of receiving a living donor kidney was higher for patients living in a 
highly urbanized area than in rural area, while the percentage recipients living in 
the most urbanized area was lower for the recipient population of a living donor 
kidney than for the recipient population of a deceased donor kidney. This means 
that the factors that were corrected for accounted for a large part of the 
influence of urbanization on the access to living donor kidney transplantation. 
Moreover, the majority of recipients of both populations lived in town.
It is not easy to influence the factors that determine access to transplantation. 
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could change over time, one cannot always control them. Non-Europeans that 
immigrated a longer time ago are better integrated and have a better social 
position than non-Europeans that arrived more recently. The next generation 
climbs on the social ladder and socioeconomic factors usually are more favorable 
for subsequent generations. Unfavorable factors are rather a matter of time than 
a factor that can be influenced individually. Newcomers are facing the same 
problems.
To summarize, access to transplantation was influenced by age. Besides, access 
to living donor kidney transplantation was influenced by clinical and 
socioeconomic factors. This was the reason to start home based education for 
patients without a living donor. Patients and their social network (family and 
friends) were educated in their own home on the various options of renal 
replacement therapy. Misconceptions about religious objections against organ 
donation were relieved. This method turned out to have a positive influence on 
participation of these patients and their network in living donor kidney 
transplantation programs. We expect that education will help other patients 
groups, such as elderly, as well. Recently home based education was added to 
our standard care for all potential recipients that present without a living donor. 
However, the problem of non-referral will not be solved by home based patient 
education. Professionals should learn to be more liberal in referring patients for 
transplantation as well.
Survival after kidney transplantation
Although the advantage of kidney transplantation over remaining on the waiting 
list was not explicitly tested in this thesis, the literature shows that survival on 
dialysis is worse compared to our survival data. However, (graft) survival after 
transplantation is not equal for all patients or patient groups. We studied the 
influence of ethnicity and socioeconomic factors on graft and patient survival in 
chapter 4. Socioeconomic factors that were studied were urbanization level, 
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housing value, percentage non-Europeans, and income. Although all these 
factors, apart from income, were found to influence access to living donor kidney 
transplantation, they neither had an influence on graft survival censored for 
death nor on patient survival. Apparently the effect of socioeconomic factors is 
overruled by the success of transplantation. This could be the result of the 
excellent medical healthcare system in The Netherlands. This assumption is 
supported by the fact that socioeconomic factors have been found to influence 
survival in countries with restrictive healthcare systems, i.e. the USA.
Nephrologists and pediatricians are reluctant to accept older living donors as 
they suppose that renal capacity of an older organ is less. They rather wait for a 
younger deceased donor kidney. In chapter 5 we studied the effect of donor age 
on graft and patient survival. We found that the influence of donor age on graft 
survival followed a J-shaped curve. The best results were found for patients 
transplanted with a kidney from donors aged 20-40 years. The risk of graft 
failure was higher for donor ages under 20 years and over 40 years. The shape 
of the curve is equal for transplants from deceased and living donors, hence 
independent of donor type. However, the individual risk for each donor is 
influenced by donor type so that the risk for a 60-year-old deceased donor 
kidney is much higher than that of a 60-year-old living donor kidney. When 
taking donor type (deceased versus living), into account, part of the unfavorable 
effect of high age can be compensated for by a living donor. For instance, the 
risk of graft failure of a 60-year-old living donor kidney is as low as the risk of a 
20-year old deceased donor kidney. This means that it pays to accept a living 
donor kidney instead of waiting for a young deceased donor kidney. Concerning 
recipients’ graft and patient survival, donor age is not a contraindication for 
donation in otherwise healthy elderly persons and living donor kidney should be 
preferred over any deceased donor kidney, independent of donor age.
The same reluctance that is seen for donor age, is also true for HLA matching. 
Completely mismatched donor-recipient combinations are less easily accepted. 
As expected, a completely matched kidney leads to the best transplant results 
(chapter 6). However, an ideally HLA-matched deceased or living donor will not 
become available for all patients. Participation in alternative donation programs, 
such as the kidney exchange program, or a long waiting time do not guarantee a 
better match. Besides, not all patients can afford waiting for a perfect kidney. 
The difference in risk of graft failure is highest between 0 and 6 HLA 
mismatches. In between, there is a gradual increase in risk. The shape of the 
curves of the failure risk of deceased and living donor kidneys is the same and 
independent of donor type. However, the risk of the individual kidney depends 
on donor type so that the risk of graft failure of a totally HLA-mismatched 
deceased donor kidney is much higher than that of a completely mismatched 
living donor kidney. In agreement with donor age, part of the unfavorable effect 
of HLA mismatches can be compensated for by choosing for a living instead of a 
deceased donor. This puts into perspective the concept of a good match, 
especially when waiting for a deceased donor kidney, as we showed that the risk 
of survival of a highly mismatched living donor kidney is lower than that of any 
deceased donor kidney. This means that any living donor, independent of HLA 
matching should be preferred over a deceased donor kidney. However, the 
advantage of a highly mismatched living donor kidney over a 0-mismatched 
deceased donor kidney counts primarily for the current transplant. In the short 
term survival is better with a living donor kidney with a high number of HLA 
mismatches than with a better matched deceased donor kidney. Nevertheless,
keeping HLA mismatches as low as possible is favorable for future transplants, 
as a high number of HLA mismatches may lead to sensitization. The unbalanced 
donor kidney exchange program may be a solution for compatible donor-
recipient pairs with a high number of HLA mismatches. If no match is found once 
kidney function of the potential recipient becomes critical, it can be decided to 
perform the directed transplantation after all.
In the past decades, characteristics of potential recipients have changed. Older 
patients are considered for transplantation, as well as patients with extensive 
comorbidity. In the seventies, 66% of potential recipients were younger than 41 
years. In the last years, only 17% of potential recipients were younger than 41 
years, while 59% were between 41 and 65 years old and 24% were above 65 
years. Also in the seventies 94% did not have cardiovascular disease whereas 
only 58% is without overt cardiovascular disease in more recent years. In 
chapter 7 we describe the influence of comorbidity on graft and patient survival. 
The conditions supposed to influence survival that we included are 
cardiovascular disease, cerebrovascular accident, peripheral vascular disease, 
diabetes mellitus, liver disease, lung disease, malignancy, other organ
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transplantation, and human immunodeficiency virus positivity. In addition to 
including all conditions separately, the gradation of comorbidity can also be 
expressed by calculated comorbidity scores. Existing comorbidity scores have 
been developed in the general population in the seventies and have not been 
validated in the renal transplant population. Besides, they are outdated, using 
diseases that no longer are a threat for survival like AIDS and stomach ulcers. A 
new total comorbidity score, the Rotterdam Comorbidity in Kidney 
Transplantation (RoCKeT) score was developed based on the presence of all 
aforementioned conditions. Our score turned out to be the best predictor of 
patient survival. In order to be generally used, the RoCKeT score should be 
validated in other kidney transplant populations. Although the risk of death 
increases with increasing comorbidity, patients experience advantages of 
transplantation. Survival of transplanted patients with a high comorbidity score 
is surprisingly good compared to patients that remain hemodialysis dependent. 
For patients with comorbidity, it is important to be transplanted before dialysis 
starts in order to prevent their condition to worsen, resulting in even more 
comorbidity. As patient survival of kidney transplant recipients with extensive 
comorbidity is better than the reported survival results of hemodialysis patients 
in the literature, comorbidity should not be a contraindication for 
transplantation.
Conclusion and comment of recommendation
All studies showed an advantage of living over deceased donor kidney 
transplantation. We clearly demonstrated the importance of the compensatory 
effect of donor type in relation to other factors, such as donor age and HLA 
mismatches. Moreover, by means of living donor kidney transplantation dialysis 
can be prevented. Pre-emptive transplantation prevents unnecessary 
deterioration of the physical condition of patients during hemodialysis. Still, 
access to kidney transplantation is not open for all end stage renal disease 
patients. There is too much focus on reasons why patients should not be 
referred for transplantation, while the focus should be on reasons why patients 
can indeed be transplanted. Our study showed that kidney transplantation is 
favorable for most patients, even for patients with extensive comorbidity and for 
elderly patients. Until now, comorbidity and age were reasons for non-referral, 
as were inadequate mastering of the language, low intelligence, nonadherence, 
and poor or precarious social conditions. Also, potential living donors sometimes 
are rejected because of high age or a high number of HLA mismatches, while our 
studies showed that these factors should not be contraindications for donation. 
We believe that a large part of the inequality in access to transplantation can be 
reduced through increasing awareness about living kidney donation. This does 
not only apply to patients themselves, but also to their social network and to 
their nephrologists. Occasionally, patients are referred only several years after
hemodialysis has started as they are supposed to have to wait for a kidney offer 
for a long time. We recommend that nephrologists refer patients to the pre-
transplant outpatient clinic at the same time they refer them for hemodialysis 
preparation. Also patients without a potential living donor should be referred 
early, as participation in the home based education program may help them find 
a living donor after all. This prevents them from years of unnecessary waiting 
for a deceased donor kidney while on dialysis.
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Summary
For patients that require renal replacement therapy, kidney transplantation is 
the best option in terms of outcomes and quality of life. However, not all 
patients have equal access to transplantation, as for various reasons some are 
not even referred for transplantation. Though not always obvious, a spectrum of 
reasons may be responsible for non-referral, e.g. insufficient condition to 
undergo surgery or inadequate mastering of the language to understand and 
communicate the transplantation process. Other patients are highly sensitized 
which complicates finding a match. Once transplanted, graft survival may be 
hampered by various factors causing a fall back on less favorable options for 
renal replacement therapy.
The aims of this thesis were to investigate what factors influence access to living 
or deceased donor kidney transplantation and what factors influence graft and 
patient survival once transplantation is carried out.
In chapter 1 a general introduction to the topic of kidney disease and 
transplantation is given. In chapter 2 the chances to receive either a living or 
deceased donor kidney transplant for patients approved for transplantation are 
described. The most important finding is the difference in outflow patterns 
between age groups. Whereas the majority of younger patients had received 
primarily living donor kidney transplants within 2 years, a large proportion of 
older patients had died or been delisted at that time. Half of patients above 55
years without a living donor, i.e. who are dependent on the waiting list, will not 
stay in adequate condition to survive waiting time for a deceased donor kidney 
transplantation.
Chapter 3 contains the description of a retrospective cohort study on the
influence of clinical and socioeconomic factors on access to living versus 
deceased donor kidney transplantation. Apart from known clinical factors, 
demographic and socio-economic factors also turned out to be determining 
factors influencing the chance of receiving a living donor kidney transplantation. 
Non-European ethnicity, percentage non-Europeans living in the area, and low 
housing value were found to have a negative influence on the chance to receive 
a living donor kidney. The influence of urbanization level was also significant: 
living in the countryside decreased chances compared to living in town.
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In chapter 4 we investigated whether the factors found in chapter 3 had an 
influence on graft and patient survival once transplantation was performed. 
While various clinical factors were found to influence graft and patient survival, 
socioeconomic factors did not influence survival.
In chapter 5 the influence of donor age on graft survival after living donor 
kidney transplantation compared with deceased donor kidney transplantation 
was studied. The influence of donor age on the risk of graft failure showed a J-
shaped curve. The risk was lowest for donors between ages 20-40 but was 
higher at younger and older ages. The combined influence of donor age and 
donor type showed that the risk of graft failure of a recipient of a 60-year-old 
living donor kidney is comparable to the risk of a recipient of a 20-year-old 
deceased donor kidney.
In chapter 6 the relative influence of HLA mismatches on the risk of graft 
failure was studied in a multivariable model in the presence of important clinical 
factors. The influence of HLA mismatches was studied using 4 different 
definitions. Both in living and in deceased donor kidney transplantation graft 
survival is negatively influenced by higher numbers of HLA mismatches. 
However, the relative risk of death-censored graft failure of a 2-2-2 HLA 
mismatched living donor kidney is comparable with that of a 0-0-0 HLA 
mismatched deceased donor kidney.
Transplantation has become an everyday process that nowadays attracts even 
people with extensive comorbidities. In chapter 7 we describe the influence of 
comorbidities on patient and graft survival. We developed a new comorbidity 
score, the Rotterdam Comorbidity in Kidney Transplantation (RoCKeT) score, for 
testing this influence. Though a higher comorbidity score did influence patient 
survival, patient survival after transplantation was still remarkably good. This 
means that even patients with extensive comorbidity should be considered for 
transplantation.
In the general discussion (chapter 8) the results of all studies are integrated in 
order to give a main conclusion. The main conclusion is that survival after living 
donor kidney transplantation is superior to deceased donor kidney 
transplantation. Living donor kidney transplantation should be accessible for all 
patients, also for elderly patients with extensive comorbidity and for patients 
with unfavorable socioeconomic factors. They should be referred for 
transplantation as early as possible to prevent dialysis, even when they present 
without a potential living donor. As home based education was added to our 
standard care for these patients, their chance to become transplanted increases.
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Nederlandse samenvatting
Met betrekking tot overleving en kwaliteit van leven is niertransplantatie de 
beste behandeling voor patiënten met eindstadium nierziekte. Niet alle patiënten 
hebben echter gelijke toegang tot transplantatie. Om verschillende redenen, 
worden sommige patiënten niet verwezen voor transplantatie. Er is een scala 
aan mogelijke redenen waarom patiënten niet worden verwezen. Hoge leeftijd, 
veel comorbiditeit (overige ziekten), onvoldoende conditie om een operatie te 
ondergaan of onvoldoende beheersing van de taal om het transplantatieproces 
goed te begrijpen zijn veel genoemde argumenten. Andere patiënten worden wel 
verwezen maar zijn hoog gesensibiliseerd wat het vinden van een geschikte 
donor bemoeilijkt. Eenmaal getransplanteerd is de transplantaatoverleving 
afhankelijk van verschillende al dan niet beïnvloedbare factoren. Na 
transplantaat falen kan weer worden teruggevallen op minder gunstige opties 
voor nierfunctie vervangende therapie zoals hemodialyse of buikspoeling. 
Het doel van dit proefschrift was om te onderzoeken welke factoren invloed 
hebben op de toegang tot levende of postmortale (overleden) donor 
niertransplantatie en welke factoren de transplantaat- en patiëntoverleving na 
niertransplantatie beïnvloeden. 
In hoofdstuk 1 wordt een algemene inleiding over nierziekte en transplantatie 
gegeven. De kansen voor het ontvangen van zowel een levende als postmortale 
donor niertransplantatie voor patiënten die zijn goedgekeurd voor transplantatie 
worden in hoofdstuk 2 beschreven. De belangrijkste bevinding is het verschil in 
uitstroom patronen tussen de leeftijdsgroepen. Hoewel de meerderheid van de 
jongere patiënten al binnen 2 jaar een, voornamelijk levende, donor nier had 
ontvangen, was een groot aantal oudere patiënten op dat moment al overleden 
of van de wachtlijst afgehaald zonder transplantaat. Van de helft van de 
patiënten boven 55 jaar die zonder een levende donor zijn aangewezen op de 
postmortale donor wachtlijst, zal de conditie niet goed genoeg blijven om de 
wachttijd voor een postmortale donor niertransplantatie te overleven. Zij zullen 
dus nooit worden getransplanteerd. 
Hoofdstuk 3 bevat de omschrijving van een retrospectieve cohortstudie naar de 
invloed van klinische en socio-economische factoren op de toegang tot levende 
versus postmortale donor niertransplantatie. Naast bekende klinische factoren, 
bleken ook demografische en socio-economische factoren de kans op het krijgen 
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niertransplantatie beïnvloeden. 
In hoofdstuk 1 wordt een algemene inleiding over nierziekte en transplantatie 
gegeven. De kansen voor het ontvangen van zowel een levende als postmortale 
donor niertransplantatie voor patiënten die zijn goedgekeurd voor transplantatie 
worden in hoofdstuk 2 beschreven. De belangrijkste bevinding is het verschil in 
uitstroom patronen tussen de leeftijdsgroepen. Hoewel de meerderheid van de 
jongere patiënten al binnen 2 jaar een, voornamelijk levende, donor nier had 
ontvangen, was een groot aantal oudere patiënten op dat moment al overleden 
of van de wachtlijst afgehaald zonder transplantaat. Van de helft van de 
patiënten boven 55 jaar die zonder een levende donor zijn aangewezen op de 
postmortale donor wachtlijst, zal de conditie niet goed genoeg blijven om de 
wachttijd voor een postmortale donor niertransplantatie te overleven. Zij zullen 
dus nooit worden getransplanteerd. 
Hoofdstuk 3 bevat de omschrijving van een retrospectieve cohortstudie naar de 
invloed van klinische en socio-economische factoren op de toegang tot levende 
versus postmortale donor niertransplantatie. Naast bekende klinische factoren, 
bleken ook demografische en socio-economische factoren de kans op het krijgen 
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van een levende donor niertransplantatie te beïnvloeden. Niet-Europese 
etniciteit, percentage niet-Europeanen die in de omgeving wonen en een lage 
woningwaarde bleken een negatieve invloed te hebben op de kans op het 
ontvangen van een levende donor niertransplantatie. De invloed van 
stedelijkheid was ook significant: wonen op het platteland geeft lagere kansen 
op een levende donor nier transplantatie in vergelijking met wonen in de stad. 
Socio-economische factoren spelen blijkbaar een rol in de mate waarin levende 
donoren uit het eigen netwerk zich aanbieden. 
In hoofdstuk 4 hebben we onderzocht of de factoren die we hebben gevonden 
in hoofdstuk 3 ook invloed hadden op de transplantaat- en patiëntoverleving na 
niertransplantatie. Terwijl verschillende klinische factoren de transplantaat- en 
patiëntoverleving van de patiënt bleken te beïnvloeden, hadden socio-
economische factoren hier geen invloed op. Het Nederlandse 
gezondheidssysteem garandeert dus goede zorg onafhankelijk van het socio-
economische milieu. 
In hoofdstuk 5 werd de invloed van donorleeftijd op de transplantaatoverleving 
bestudeerd waarbij de resultaten van levende en postmortale donor 
niertransplantatie werden vergeleken. De invloed van donorleeftijd op het risico 
op transplantaat falen volgde een J-vormige curve. Het risico was het laagst 
voor donoren tussen de 20 en 40 jaar, maar was hoger voor jongere en oudere 
donoren. Uit de gecombineerde invloed van donorleeftijd en donortype is 
gebleken dat het risico op transplantaat falen van een ontvanger van een 60-
jarige levende donor nier vergelijkbaar is met het risico van een ontvanger van 
een 20-jarige postmortale donor nier. De resultaten van levende donor nier 
transplantatie zijn dus altijd beter dan die van een postmortale donor nier 
onafhankelijk van de leeftijd van de levende donor.
In hoofdstuk 6 werd de relatieve invloed van HLA mismatches op het risico op 
transplantaat falen bestudeerd. In het multivariabele model werd gecorrigeerd 
voor de aanwezigheid van belangrijke klinische factoren. De invloed van HLA 
mismatches werd bestudeerd met 4 verschillende definities van HLA 
mismatches. Zowel na levende als postmortale donor niertransplantatie wordt de 
transplantaatoverleving negatief beïnvloed door een toenemend aantal HLA 
mismatches. Het relatieve risico op transplantaat falen gecensureerd voor 
overlijden van een levende donor nier met 2-2-2 HLA A-B-DR mismatches is 
echter vergelijkbaar met dat van een postmortale donor nier met 0-0-0 HLA A-
B-DR mismatches. De resultaten van levende donor nier transplantatie zijn dus 
altijd beter dan die van een postmortale donor nier onafhankelijk van het aantal 
HLA mismatches met de levende donor. 
Dankzij het succes van niertransplantatie zijn de selectiecriteria voor potentiële 
ontvangers in de loop der jaren steeds verder versoepeld. Inmiddels worden ook 
potentiële ontvangers met uitgebreide comorbiditeit voor beoordeling voor 
niertransplantatie verwezen. In hoofdstuk 7 wordt de invloed van comorbiditeit 
op transplantaat- en patiëntoverleving beschreven. Om de invloed van 
comorbiditeit op de transplantaat- en patiëntoverleving te kunnen beoordelen 
werd een nieuwe comorbiditeit score ontwikkeld: de Rotterdam Comorbidity in 
Kidney Transplantation score (RoCKeT score). Hoewel een hogere comorbiditeit 
score een negatieve invloed heeft op de patiëntoverleving, was de 
patiëntoverleving na transplantatie nog steeds opmerkelijk goed. Dit betekent 
dat zelfs patiënten met uitgebreide comorbiditeit groot voordeel kunnen hebben 
van transplantatie en dus in aanmerking zouden moeten komen voor 
beoordeling voor geschiktheid voor transplantatie. Van alle comorbiditeiten en 
comorbiditeit scores was perifeer vaatlijden de enige met een significante en 
negatieve invloed op de transplantaatoverleving. 
In de algemene discussie (hoofdstuk 8) zijn de resultaten van alle studies 
geïntegreerd tot een hoofdconclusie. De belangrijkste conclusie is dat overleving 
na levende donor niertransplantatie superieur is aan dat na postmortale donor 
niertransplantatie. Levende donor niertransplantatie zou voor alle patiënten 
beter toegankelijk moeten worden gemaakt. Ook voor oudere patiënten, voor 
patiënten met uitgebreide comorbiditeit en voor patiënten met ongunstige socio-
economische factoren zou de toegankelijkheid van levende donor nier 
transplantatie moeten worden vergroot. Om te voorkomen dat patiënten 
onnodig moeten gaan dialyseren, zouden zij in een vroeg stadium moeten 
worden verwezen voor beoordeling van de transplantatie mogelijkheid. Een goed 
moment voor verwijzing naar de pre-transplantatie polikliniek is bijvoorbeeld het 
moment waarop patiënten van de algemene nefrologie poli naar de pre-dialyse 
poli worden verwezen. Zelfs wanneer patiënten geen potentiële levende donor 
lijken te hebben is verwijzing zinvol. Voor deze patiënten werd thuisvoorlichting 
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Dankwoord
Hoera, mijn boekje is er! Na vele jaren data verzamelen, analyseren, denken en 
schrijven is hier het eindresultaat. Ik ben er erg trots op. Ik had het echter niet 
alleen kunnen doen en daarom wil ik een aantal mensen bedanken.
Mijn promotor, prof. dr. Willem Weimar, bedankt voor de kans om als 
psycholoog op een medisch onderwerp te promoveren, voor de goede ideeën, 
het voor me opkomen en voor het nuttige commentaar op mijn artikelen. Ze 
werden er elke keer weer beter van.
Mijn co-promotor, dr. Joke Roodnat. Bedankt dat je mijn co-promotor wilde zijn. 
Ik ben er trots op jouw eerste promovendus te zijn. Doordat we beiden een 
tikkeltje perfectionistisch zijn, ging het niet altijd even snel, maar werd het wel 
goed. Ik heb heel veel van je geleerd over de Cox, artikelen schrijven en het 
uitpluizen van medische dossiers. Met jouw enthousiasme en gedrevenheid 
stimuleerde je mij om door te zetten, ook na tegenslagen.
De leden van de kleine promotiecommissie, prof. dr. Andries Hoitsma, prof. dr. 
Bob Zietse en prof. dr. Jan van Saase. Bedankt voor het beoordelen van mijn 
proefschrift.
De leden van de grote promotiecommissie, prof. dr. Frans Claas, prof. dr. 
Frederike Bemelman, prof. dr. Jan IJzermans en dr. Stefan Berger. Hartelijk 
dank voor het zitting nemen in de commissie.
De co-auteurs van mijn artikelen, Emma Massey, Frans Claas, Geert Haasnoot, 
Jacqueline van de Wetering, Jan IJzermans, Joke Roodnat, Judith Kal-van 
Gestel, Marcia Kho, Michiel Betjes en Willem Weimar, bedankt voor jullie 
waardevolle inbreng.
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Chapter 10
Mijn collega datamanagers en paranimfen Judith en Tessa. Judith, je hebt me op 
zoveel manieren geholpen; survivaldata, meedenken, meeschrijven, voor me 
presenteren. En hoewel je, naar eigen zeggen, niet zo empathisch bent, ken ik 
weinig mensen die zo attent zijn als jij. Tessa, zonder jou was ik hier zeer 
waarschijnlijk nooit terecht gekomen. Des te leuker was het dat jij hier ook 
kwam werken. Ons Nashville avontuur, je gezelligheid, humor, in jezelf praten 
en zingen, ik zou het niet willen missen.
Willij Zuidema, dank voor je steun en geloof in mij. En voor het aansporen om 
abstracts te schrijven voor congressen. Ik heb er veel inspiratie en leuke reisjes 
aan overgehouden.
Mijn grote voorbeelden Marry, Lotte en Mirjam. Bedankt voor jullie gevraagde én 
ongevraagde adviezen als ervaringsdeskundigen.
Mijn collega’s Brigitte, Cheetah, Denise, Emma, Frederike, Ingrid, Ivana, Karin, 
Kasia, Linda, Louise, Marian, Marieken, Marleen, Monique, Nelly, Saïda, Sandra 
en Willeke en natuurlijk ook al mijn oud-collega’s en oud-kamergenoten. 
Overige collega’s van de sectie Nefrologie en Transplantatie, zoals de 
nefrologen, poli, dialyse en het lab, maar uiteraard ook van de Heelkunde, en 
natuurlijk patiënten en donoren. Zonder jullie geen transplantaties, geen data en 
geen proefschrift. Daarnaast dank aan de Nederlandse Transplantatie Stichting 
en Eurotransplant voor aanvullende data.
Mijn (schoon)familie en vrienden, bedankt voor jullie steun, op welke manier 
dan ook. Met name oma Ger voor uw interesse in mijn onderzoek en Nienke 
voor alle praktische tips en voor het zijn van mijn beste vriendin.
Mijn ouders, broer Marco en zusje Michelle, bedankt voor de onbezorgde jeugd 
die jullie me hebben gegeven en voor alle ondersteuning en aanmoediging. Door 
de stabiele basis voelt het altijd vertrouwd om bij jullie te zijn.
Jürgen, zonder jou zou mijn leven er heel anders uitzien. We zijn heel
verschillend en vullen elkaar daardoor goed aan. Daarnaast delen we een hoop 
interesses. Zo’n beetje het enige dat daar niet onder valt, is werk, behalve dan 
dat we allebei computernerds zijn. Toch heb je me enorm gesteund dan wel 
ontzien en daar ben ik je ontzettend dankbaar voor.
Luna, je krijgt er nu nog weinig van mee, maar je bent gek op boeken (nu nog 
“boe”), dus misschien lees ik wel een keer een stukje uit eigen werk voor. Ik 
geniet elke dag van je.
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